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ABSTRACT 
The Effect of In Utero Exposure to Beta-2 Adrenergic Receptor Agonists and Selective 
Serotonin Reuptake Inhibitors on the Risk for Autism Spectrum Disorders 
Nicole B. Gidaya 
Craig J. Newschaffer, Ph.D. 
 
Objective: This dissertation explored associations between two specific classes of drug 
exposures, beta-2 adrenergic receptor (B2AR) agonists and selective serotonin reuptake 
inhibitors (SSRIs) and the risk for ASD. 
Study Design: This project had two components: 1) a case-control study focused on 
estimation of exposure main effects from Denmark’s population-registers and 2) a 
candidate gene-environment interaction analysis using both exposure and genotype data 
from a large ongoing US autism case-control study.   
Methods: From the Danish registers, one case per ten controls was individually matched 
on birth month and year. Conditional logistic regression was used to estimate unadjusted 
and adjusted drug exposure odds ratios (OR) and 95% confidence intervals (CI).  
Estimates were calculated in each drug class for any exposure, any exposure by 
preconception or trimester, dose, and duration.  Special attention was paid to confounding 
by indication, as well as a sensitivity analysis for exposure and indicating condition 
misclassification.  The gene-environment interaction analysis was based on unmatched 
case-control data and explored whether effects of in utero B2AR agonist drugs used 
during pregnancy are modified by polymorphisms in the ADRB2 gene (Gly16 and Glu27 
polymorphisms).  Logistic regression was used to estimate adjusted ORs and 95% CI.   
	   	   x 
Results:  In parental age and child sex adjusted models we observed an increased risk for 
ASD associated with any in utero B2AR agonist drugs exposure (OR 1.3, 95% CI: 1.1-
1.5).  Similarly, any exposure to SSRIs during pregnancy was associated with ASD (OR 
2.0 [95% CI, 2.0 [1.6-2.6]) compared to the unexposed reference group.  Lastly, for the 
gene-environment interaction analysis we found some suggestion that the ASD risk 
associated with prenatal B2AR exposure may be modified by ADRB2 genotype; 
although estimates were imprecise.      
Conclusion: The combination of low exposure prevalence during pregnancy and modest 
odds ratios we had observed for these two classes of drugs implies that the population 
attributable risks associated with both exposures will be fairly small. The possible 
increase in ASD risk from exposure to these medications must be weighed against effects 
of uncontrolled indications during pregnancy and the growing concern over the potential 
risk for the developing fetus and the mother as well as benefits of medication to mother 
and fetus despite possible ASD risk.  
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CHAPTER 1: OVERVIEW 
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OVERVIEW 
Introduction 
Autism spectrum disorders (ASD) are a group of developmental disabilities 
characterized by core deficits in three domains: social interaction, communication, and 
repetitive or stereotypic behavior [1].  Prenatal pharmacologic exposures are one of the 
few known environmental risks factors for ASD [2]. Specifically, three prescription 
medications have been identified as potential prenatal environmental risk factors for this 
neurodevelopmental disorder –thalidomide [3], antiepileptic drugs [4], and misoprostol 
[5].  Although these drugs are now rarely prescribed during pregnancy they provide proof 
of principal for associations between prenatal pharmacologic exposures and ASD.   The 
fact that the teratogenic risks, especially with respect to neurodevelopmental outcomes, 
of many other drugs is still undetermined, it is important to consider further prenatal 
maternal prescription drug use as ASD risk factors.  For women with certain chronic 
medical conditions such as epilepsy, diabetes, psoriasis, inflammatory bowel disease and 
asthma, the use of drugs is an important part of standard care [6].   However, since 
clinical trials during drug development commonly exclude pregnant women due to 
ethical reasons, there are often many open questions regarding the effects of drugs 
commonly used for chronic conditions on the developing human fetus even as these 
medications come into use in populations of pregnant women [7].  For example, a 
number of observational studies have found associations between medications that 
became commonly prescribed during pregnancy and birth defects [8-10].    
Further, the potential for exposure to pregnant women is substantial.  Data from 
the Baltimore-Washington Infant Group Study suggest that 68% of women used at least 
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one prescription or non-prescription drug during pregnancy [11].  The mean number of 
drugs reported is 1.2; however evidence suggest that this might be underestimated due to 
exclusion of some drug categories [11].  Two studies conducted in European populations 
raise concerns regarding the potential harm in some prescription drugs given to pregnant 
women.  Olesen et al found from 1991 to 1996, 18% of pregnant women in Denmark 
reported receiving at least one drug during pregnancy with “proven or anticipated 
harmful fetal effects” [12].   A study in southwest France reported that 59% of the 
women had a prescription for a drug that demonstrated fetal risk[13].   
In this dissertation, two classes of drugs that have been commonly used over the 
last two decades, beta-2-adrenergic receptor (B2AR) agonist drugs and selective 
serotonin reuptake inhibitors (SSRIs), were investigated to explore a potential association 
with ASD.  Long-acting B2AR agonist drugs such as salmeterol and formoterol are used 
to reduce asthma exacerbations and provide asthma control in adults [14].  Estimates of 
the prevalence of B2AR agonist drug exposure during pregnancy range from 4%-20% 
[15, 16] in the U.S. and 1.9-7.5% in Denmark [17, 18].  B2AR agonist drugs are thought 
to have the potential to impact the fetal brain because they cross the placenta [19]  and 
have been shown in animal and in vitro studies to disrupt either replication or 
differentiation of the developing neurons [20].  Selective serotonin reuptake inhibitors are 
among the most commonly used medications, with the prevalence of prenatal prescription 
use ranging from 3.8-5% in the US and Denmark [21-23].  SSRIs also can cross the 
placenta [24].  Serotonin is known to play an important role in human brain development 
by regulating both, serotonergic outgrowth and maturation of target regions [25, 26].  
Data from animal models suggest early exposure to SSRIs can disrupt the normal 
	   	   4 
maturation of the serotonin system however it is not known whether this effect of SSRIs 
is paralleled in humans [27].   
 
  AIMS OF THIS DISSERTATION 
 The aims of this dissertation are to evaluate the associations between two drugs 
commonly prescribed during pregnancy and ASD risk.  In addition, for one of the drugs, 
an interaction between a known susceptibility genotype and the drug exposure-ASD risk 
relationship will be explored.   
Aim 1. Estimate the main effects of two medications commonly used during the 
prenatal period on autism risk in a large population-based cohort 
Aim 1a. Estimate the effects of prenatal B2AR agonist exposure on ASD 
risk for any exposure and for exposure by trimester, dose and duration  
Aim 1b. Estimate the effects of prenatal SSRI exposure on ASD risk for 
any exposure and for exposure by trimester, dose and duration 
Aim2. Explore whether effect of exposure to B2AR is modified by maternal 
susceptibility genotypes in the ADRB2 gene. 
 
ORGANIZATION OF THE DISSERTATION 
 This dissertation is comprised of a total of six chapters.  Following the brief 
overview provided in this chapter is a more comprehensive review of the relevant 
literature in Chapter 2. Chapter 3 describes a large population based case-control study 
capitalizing on environmental data in a large epidemiological sample from Denmark’s 
health registers to provide detailed information regarding prescription drugs used during 
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pregnancy and autism diagnosis, as well as health and socioeconomic status by linking 
individuals’ unique civil-register number.  The chapter investigates the association 
between maternal B2AR agonist drug use and ASD risk.   This is then followed by 
Chapter 4, which uses the same study sample described in Chapter 3, to estimate the 
effect of prenatal SSRI use and risk associated with ASD.  Chapter 5 investigates the 
possibility of gene-environment interaction between maternal B2AR agonist drug use 
during pregnancy and single nucleotide polymorphisms in the ADRB2 gene using a 
different sample from the US. The Study to Explore Early Development (SEED), a 
multisite investigation case-control study aimed at addressing knowledge gaps in autism 
phenotype and etiology.  The sixth Chapter is a summary and discussion of the findings.   
The dissertation was designed to investigate associations between two common 
classes of drug exposures still prescribed during pregnancy and the risk for ASD.  It took 
advantage of the existence of both population based genetic and environmental data from 
two different epidemiological samples to investigate their effect on this developmental 
disorder.  Results from this dissertation add to the limited amount of epidemiologic 
evidence on pharmacologic ASD risk factors, particularly exposures during pregnancy.  It 
will help targer further research on maternal pharmacological exposures as well as 
susceptibility genotypes.       
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CHAPTER 2: A REVIEW OF THE LITERATURE 
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Autism Spectrum Disorders 
Autism spectrum disorders (ASD) are a group of developmental disabilities 
characterized by core deficits in three domains: social interaction, communication, and 
repetitive or stereotypic behavior [1].  There is variability in level of disability among 
individuals with ASD, and it is a much more common disorder than previously believed.  
The disorder is largely of unknown cause, and there is variability of impairment among 
individuals with ASD [2].  Currently, ASD has a US prevalence of 11.3 cases per 1,000, 
and a prevalence of seven cases per 1,000 in Denmark [3-5].  There has been strong 
evidence of a heritable component in ASD etiology however no definitive gene has been 
identified [6-10].  Molecular genetics of ASD are complicated by a combination of 
phenotypic heterogeneity [11], the possibility of multiple interacting loci [12] and gene-
environment interaction [13].  Initial early linkage studies found only a few genes 
associated with ASD, but with technical advancements such as the development of DNA 
microarrays to measure the expression levels of large numbers of genes simultaneously 
and cytogenetics, more recent studies have focused on genome wide association (GWA) 
and copy number variation (CNV). In addition, studies using micro-array-based 
comparative genomic hybridization (array-CGH) have showed that the genomes of 
unrelated healthy individuals vary significantly with respect to the number of copies an 
individual has of each DNA segment [14].  Small cytogenetic abnormalities and overall 
rate of copy number variants (deletion, insertion, duplication or a complex multisite 
variant that can be inherited or may arise de novo on a paternally or maternally inherited 
chromosome) are increased in individuals with ASD compared to controls [15].   
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In addition to the complexities in identifying the genetic influence of ASD, 
identifying environmental risk factors are also largely unknown.  Prenatal pharmacologic 
exposures are one of the few known environmental risks factors for ASD [16].  
Specifically, three prescription medications have been identified as potential prenatal 
environmental risk factors for ASD -thalidomide, antiepileptic drugs, and misoprostol.  
Synthesized in the 1950s, thalidomide was used as a potent sedative which was 
withdrawn from the market in 1961 after it was learned that children were being born 
with serious malformations associated with prenatal exposure [17]. A study of 100 
Swedish thalidomide embryopathy cases, found at least four cases that met full criteria 
for DSMIII-R autistic disorder and ICD-10 childhood autism, indicating that there was a 
possible association of thalidomide embryopathy with ASD [17].  Antiepileptic drugs 
such as carbamazepine monotherapy, valproate monotherapy, phenytoin monotherapy, 
and polytherapy used during pregnancy have also been suggested as ASD risk factors 
[18-21].  Mothers taking antiepileptic drugs are also more likely to have a child with 
developmental delays than in children of epileptic mothers who were unexposed [22].  
Lastly, misoprostol has been used in the treatment of gastric ulcers and also used in 
abortions since it causes uterine contractions.  In a case series study of 23 patients with 
Möbius sequence, five children met criteria for autism, three of which had a positive 
history of misoprostol exposure during the first trimester of pregnancy [23].   
Although the above mentioned drugs are now considered a rare prenatal exposure, 
given the suggested association between prenatal pharmacologic exposures with ASD 
and the fact that the teratogenic risks of most other drugs is still undetermined, especially 
with respect to neurodevelopmental outcomes [24], it is important to consider further 
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prescription drug use as ASD risk factors.  For women with certain chronic medical 
conditions such as epilepsy, diabetes, inflammatory bowel disease and asthma, the use of 
drugs is essential, and it is commonly believed that the benefits for mother and child will 
outweigh risks, and exposure to a range of medications in pregnancy continues today.  
Since clinical trials during drug development commonly exclude pregnant women due to 
ethical reasons, there have been many questions regarding the effects of the drug on the 
developing human fetus.  Several observational studies have found associations between 
many commonly used prescription drugs and birth defects [25-27].   Two classes of drug 
exposures that have been commonly used over the last two decades, B2AR agonists and 
SSRIs, were investigated in this dissertation to explore a potential association with ASD.  
The table below described the three epidemiological findings thus far. 
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Table 1: Epidemiological studies of B2AR agonist drugs and SSRIs and ASD Risk 
Epidemiological Studies of B2AR agonists and SSRIs and ASD Risk 
Data Source Study Design N 
Exposure Outcome 
Results 
Connors, S.L., 
et al. (2005)  
Twin 
study 
37 non-identical 
multiple births  
 
Medical record 
review for B2AR 
agonist drug 
exposure 
 
Expert record 
review according 
to DSM-IV, ADOS, 
and ADI-R 
-Increased 
concordance 
for ASD in DZ 
twins with 
terbutaline 
exposure 
-Increase in 
the risk for 
male twins  
Croen, L.A., et 
al., (2011) 
Case-
control 
291 = Cases 
284 = Controls 
Prenatal medical 
records and 
health plan 
databases for 
B2AR agonist 
drug exposure 
Kaiser 
Permanente of 
Northern 
California 
outpatient clinical 
database from 
ICD-9 codes 
-No 
association 
between 
prenatal 
exposure to 
B2AR agonist 
and ASD, 
except 
terbutaline. 
-Exposure for 
>2 days 
associated 
with ASD  
Croen, L.A., et 
al. (2011) 
Case-
control 
298 = Cases 
1507 = Controls  
Prenatal medical 
records and 
health plan 
databases for 
SSRI exposure 
Kaiser 
Permanente of 
Northern 
California 
outpatient clinical 
database from 
ICD-9 codes 
2-fold 
increased risk 
of ASD 
associated 
with prenatal 
SSRIs  
-Strongest 
effect 
associated 
with 3rd  
trimester  
 
 
 
Beta-2-adrenergic receptor agonist 
The prevalence of asthma among pregnant and all childbearing-aged women from 
the US national health surveys indicate that it is currently between 3.7% -8.4% [28].  In 
Denmark the prevalence of asthma increased from 5.3% in 1986 to 11.7% in 2001 [29].  
Long-acting B2AR agonist drugs such as terbutaline have been used to reduce asthma 
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exacerbations and provide asthma control in adults [30].  In addition, these drugs have 
been also commonly used off-label as a tocolytic agent since they appear to have an 
immediate and comparable profound effect on uterine activity in term labor to stop early 
contractions [31]. The prevalence of terbutaline exposure during pregnancy in the US is 
estimated to be between 4%-20% [32, 33].  In Denmark, 1.9-7.5% of women received 
prescriptions for asthma medication during pregnancy [34, 35]. 
Beta-2 adrenergic receptors play an important role in the pathophysiology of 
asthma. In regards to the treatment of asthma, beta-2 adrenergic receptor agonist drugs 
relax the muscles surrounding the airways to relieve symptoms. In mature adults, these 
receptors are important for pulmonary and cardiovascular physiology and are activated 
by hormones such as adrenaline and noradrenaline [36].  The binding of these hormones 
to the receptor plays a critical role in the sympathetic nervous system, resulting in the 
fight or flight response [36].  Once the hormones bind to the receptor, a downstream 
signaling molecular response leads to the various stress responses such as accelerated 
heart rate, inhibition of stomach and upper-intestinal action, constriction of blood vessels 
in many parts of the body, dilation of blood vessels for muscles, and dilation of pupil 
(mydriasis) to name a few [37].  In the developing fetus, these receptors have a much 
different role, since they are involved in tissue differentiation and axonal growth [38].  
Transcription, which is the first step leading to gene expression, is down regulated for 
beta 2 adrenergic receptors, preventing cells from being over stimulated and maintaining 
the balance between sympathetic and parasympathetic nervous system [38].  
Since B2AR agonist drugs, such as tocolytics like terbutaline and asthma 
medications mentioned previously can cross the placenta, they have the potential to 
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impact the fetal brain by reaching and directly binding to fetal beta 2 adrenergic 
receptors.  This can result in the disruption of either replication or differentiation of the 
developing neurons [39].  Therefore, aberrations within this system could result in an 
imbalance of natural cell proliferation and differentiation during gestation when the brain 
is developing [40].  Exposures during pregnancy that increase beta 2 adrenergic receptor 
signaling or over stimulate the receptor could have wide spread effects in light of the 
function of these receptors during pre- and postnatal life [41].  However, the observed 
main effects are subtle in pregnancies exposed to B2AR agonist drugs, which indicate the 
possibility for gene-environment interaction effects. 
 
Animal studies 
Animal models have been developed to understand the neurodevelopmental 
effects of B2AR agonist drugs and results from this work appear relevant to ASD 
pathogenesis [42, 43].  It has been shown that during gestation, overstimulation of the 
beta 2- adrenergic receptors from an exogenous source during the development of the 
nervous system may have harmful effects on the development of the brain and the 
peripheral nervous system [42, 44].  The mechanisms within the mature beta 2- 
adrenergic receptors protect against over-stimulation; however, fetal receptors do not 
have the ability to regulate any imbalance and may in fact become sensitized [45].  Early 
research has shown that B2AR agonist drugs administered to pregnant rats during the 
second trimester of gestation alters neural cell replication and differentiation, 
synaptogenesis, and expression of synaptic proteins involved in neurotransmission [45].  
These animal model experiments also found abnormalities within the central and 
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peripheral nervous system and a decrease in the cell numbers in the fetal brain and liver 
of rats that were exposed prenatally [42].  The effect on the rats is gender selective with 
males experiencing more abnormalities, which is analogous to the male predominance of 
ASD in humans [42]. 
 
Human studies of B2AR agonist drugs and autism risk 
Human studies of B2AR agonist drugs and ASD or other neurodevelopmental 
disorders are limited.  In a study investigating the effects of prenatal overestimation of 
the beta 2 adrenergic receptors in dizygotic twins who were exposed to terbutaline to treat 
premature labor, there was an increased concordance for ASD in dizygotic twins than 
among similar unexposed twins [43].  In addition, this study found a further increase in 
the risk for male twins with no other affected siblings [43].  A recent, study looking at the 
association between maternal exposure to B2AR agonist drugs during pregnancy and 
ASD risk using 291 cases and 284 controls found that exposure for more than two days 
during the third trimester was associated with a six fold increased risk for ASD 
independent of the indication (adjusted odds ratio (OR) = 6.01, 95% confidence interval 
(CI) 1.05-34.28), although the confidence intervals were wide [46].  Along with 
considering B2AR agonist drugs as a tocolytic agent, this study also considered B2AR 
agonist drugs prescribed for other purposes (e.g., asthma control) and B2AR- mimics 
which also impact cellular cAMP levels (e.g., inhaled steroids, steroids administered 
through other routes, theophylline and the tocolytic magnesium sulfate).  The analysis 
including all agonists and mimics showed exposure in the 30 days before conception to 
be associated with three times higher ASD risk (adjusted OR 2.98, 95% CI 1.01-8.83) 
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[47].   B2AR mimics were defined as drugs that impact cellular cAMP levels, including 
inhaled steroids, steroids administered through other routes, theophylline and the 
tocolytic magnesium sulfate [46].  As mentioned, the effect estimates for specific 
exposure windows and doses in this investigation were statistically imprecise and the 
mechanism behind the pre-conception exposure has not been described.  
 
Effect of indicating condition (asthma) on autism risk 
Among mothers who are severe asthmatics, avoidance of asthma treatment during 
pregnancy has been linked to birth complications including preterm birth, low birth 
weight, preeclampsia, and neonatal death [28, 48].  Since uncontrolled asthma has been 
associated with poor birth outcomes, mothers are often still recommended to continue 
asthma medication [32, 49].  However, there is a high frequency of preterm labor and 
intrauterine growth restriction in corticosteroid-dependent asthmatic patients [49-51].  
Infants with a gestational age at birth that is less than 35 weeks have shown to have more 
than two-fold increase risk for ASD [52]. Only one study has reported an association 
between maternal asthma and autism risk showing a more than a two-fold elevated risk of 
ASD associated with maternal asthma during the first (OR=2.8; 95% CI, 1.3-6.10) and 
second (OR=2.2; 95% CI, 1.1-4.2) trimester of pregnancy [53].  However, this study was 
not able to explore the independent role of indicating condition and medication exposure. 
 
Genetic susceptibility 
Polymorphisms in the beta 2-adrenergic receptor gene (ADBR2) have been shown 
to influence beta 2-adrenergic receptor sensitivity and consequently may enhance 
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susceptibility to the neurodevelopment effects of B2AR agonist drug exposure [54].  The 
mechanism of the genetic susceptibility that over stimulate the beta 2-adrenergic receptor 
may increase the risk for neurodevelopment impairment [42].  Located on chromosome 
5q31-32, there are three polymorphisms, Arg16Gly, Gln27Glu, and Thr164Ile, which are 
common in the general population and influence receptor function [54]. In vivo studies to 
determine the responsiveness of the receptor have been investigated through forearm 
blood flow and hand vein dilation [55].  Muscle vasodilatation during mental stress and 
exercise appear to be higher in women who were homozygous Gly(16)/Glu(27) of the 
beta 2-adrenergic receptors [56].   Therefore, presence of these alleles indicates that there 
may be an increase in responsiveness and sensitivity of the beta 2-adrenergic receptor.  A 
study using of 331 autism case parent trios from the Autism Genetic Resource Exchange 
(AGRE) found a Glu27 homozygous genotype to be associate with increased autism risk, 
while Gly16 did not reach statistical significance [57].  Exogenous B2AR agonist drug 
exposure in conjunction with the presence of the genetic polymorphisms may increase 
beta 2-adrenergic receptor activity and affect neurodevelopment.  
 
Selective serotonin reuptake inhibitors 
Selective serotonin reuptake inhibitors (SSRIs), such as many antidepressants, are 
among the most commonly used medications, with a prescription frequency of 5-13% in 
pregnant women in the US [58, 59]. In Denmark 10-12.3% of pregnant women received 
at least one prescription for an SSRI a year before delivery [60].  The extent of use of 
SSRIs before and during pregnancy and its trend over the years in the Netherlands 
indicated that the prescription rate for SSRIs was highest in the trimester before 
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conception, decreased in the first trimester and further in the second trimester, which was 
comparable to the third trimester [60].  SSRIs can potentially influence the intrauterine 
environment because it is known to cross the placenta [61].  
There have been inconsistencies in early reports of SSRI treatment during 
pregnancy [62], however in 2005 the Food and Drug Administration (FDA) issued an 
advisory indicating that early exposure to paroxetine may increase the risk for cardiac 
defects (http://www.fda.gov/CDER/Drug/advisory/paroxetine200512.htm).  Moreover, 
several studies have looked at the possible association between exposures to SSRIs in late 
pregnancy, and have reported an increased risk of persistent pulmonary hypertension in 
the newborns [63].  These resulted in either inconsistent findings ranging from no 
association to a six-fold increased risk [26, 64].  In a recent prospective study to 
determine the exposure prevalence of SSRI treatment in pregnant women found that over 
20% of the pregnant women with major depressive disorder who were using SSRIs 
delivered a preterm infant [65]. There were 5% of women who had depression during 
their pregnancy and did not receive an SSRI [65].  Preterm labor has been known as a 
potential risk factor for ASD [52].  In addition, a recent study reports an odds ratio of 2.0 
(95% CI, 1.3-3.2) for preterm birth in the women exposed to SSRIs compared with 
women with no history of psychiatric illness [66].  This suggests that the preterm birth 
rate appears to be significantly higher in SSRIs exposed pregnancy.   
There is also growing concern over the potential risk for relapsed depression after 
discontinuing antidepressant medication during pregnancy.  A recent study found that 
68% of the women who discontinued antidepressant treatment during pregnancy relapsed 
in depression, with 50% experiencing recurrence of depression in the first trimester of 
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pregnancy and 90% by the end of the second trimester [67]. Weighing the risk-benefit 
decision for women with major depression who are treated with antidepressants such as 
SSRIs is vital.  Concerns about prenatal exposure to these medications range from risk of 
malformations [68], obstetrical and peri-natal complications [69].  Mothers must also 
consider a relapse in depression during pregnancy [67], and the effect of untreated 
depression on the fetus.   
 
SSRIs and autism risk 
Abnormalities in serotonin metabolism are one of the few consistent biological 
findings that are thought to be a potential biomarker for ASD [70]. Elevated levels of 
serotonin in the blood (5-hydroxytryptamine, 5-HT) have been reported in patients with 
ASD [71].  Other studies have shown that more than 99% of whole blood serotonin is 
contained in platelets, which accounts for the elevated serotonin levels in found in autism 
[72].  Several lines of evidence suggest that alterations in the serotonergic 
neurotransmitter system might represent one of the biological pathways of ASD.  
Serotonin has been shown to play an important role in brain development by regulating 
both, serotonergic outgrowth and maturation of target regions [71, 73].  However, the 
mechanisms behind differences in circulating serotonin levels seen in individuals with 
ASD are not fully understood and whether this in anyway reflects neurodevelopmentally 
relevant pathology remains unclear.   
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Animal Studies 
Animal models have shown that higher prenatal levels of serotonin produce 
adverse neurodevelopment such as a reduction in the number of β -adrenergic and 
serotonin receptors as well as cause abnormal brain serotonin receptor binding in the 
cerebral cortex [74].  Chronic neonatal exposure to SSRIs in male offspring of timed-
pregnant rats resulted in reduced serotonin expression that persists into adulthood, which 
produces changes in the normal maturation of the serotonin system [75].  Rats exposed to 
SSRIs during the prenatal period have resulted in neuroautomic alterations in 
somatosensory structures [76], as well as serotonin content and receptor binding sites 
[77].  Interestingly, following in utero exposure to serotonergic drugs significantly 
impacted the number of serotonin receptors expressed in the brains of rats [78].  Data 
from animal models indicate that early exposure to SSRIs can disrupt development of the 
serotonin system and alter serotonin-dependent neural processes, however it however it is 
not known whether this effect of SSRIs is paralleled in humans. 
 
Human studies of health effects of prenatal SSRI exposure 
Data on the relationship of birth defects and SSRI exposure are inconsistent; 
however, Louki et al found a significant association between the use of SSRIs and the 
occurrence of omphaloceles and septal defects [79].  In a more recent study of 298 cases 
and 1507 controls the investigators reported a two-fold increase of ASD associated with 
maternal SSRI use a year before delivery (adjusted OR 2.2 [95% CI, 1.2-4.3]), with the 
largest effect estimate found in the first trimester (adjusted OR 3.8 [95% CI, 1.8-7.8]) 
[80].  However, the small sample size and low exposure prevalence in the study 
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population should be considered when interpreting results.  There have been several 
studies looking at neonatal outcomes following exposure to SSRIs, particularly affecting 
the respiratory, gastrointestinal and neurological systems, however the findings were also 
inconsistent [81].  A small retrospective case study has linked maternal SSRI exposure in 
the latter half of pregnancy with risk for persistent pulmonary hypertension, but these 
findings have yet to be replicated in a prospective study [82].   Other studies report a 
greater association of ‘withdrawal symptoms’ with SSRIs such a paroxetine and 
fluoxetine in children who were exposed to these drugs late in pregnancy however one of 
the issues of making the interpretation of these studies is the lack of definition of the term 
‘withdrawal symptoms’ [83].   The inconsistency in the literature, as well as some 
fundamental methodological limitations across many studies, including lack of control 
for independent effect of maternal depression, has made it difficult to interpret findings. 
 
Effect of indicating condition on autism risk 
Diagnosis for psychiatric disorders before the birth of the child have been more 
commonly reported among parents of children with ASD than parents of children without 
a diagnosis of ASD, with the condition-specific ORs for depression stronger for mothers 
than fathers [84].  In addition, elevated rates of clinical psychiatric disorders, distinct 
from autism, including schizophrenia, anxiety, depression, and social phobias, have been 
reported among the relatives of individuals with autism, [85].  A case-control study 
explored the association between peri-natal factors and risk of autism reported an OR of 
3.44 (95% CI, 2.21-5.58) for parental psychiatric history of affective disorder [85].  
Associations between maternal depression and developmental psychopathology in early 
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children have been widely reported; however, it is difficult to determine whether these 
effects are due to a genetic predisposition, intrauterine environment, maternal 
prescription drug use, or the effects of parenting. Inconsistencies in the literature are 
perhaps mainly due to reporting bias since one would need to examine parents’ 
psychiatric diagnoses not only after their child had received an ASD diagnosis, but also 
before the child’s birth [86].  Researchers must often struggle with whether parents who 
report depression display more difficulties compared to the general population. These 
difficulties are more pronounced when investigating parents of children with ASD, 
primarily due to determining whether or not the depression is a symptom of having a 
child on the spectrum.  Although a number of studies have looked at the possible 
association between ASD and parental depression, the biological mechanism and causal 
pathway are still unknown. 
 
Conclusion 
Exposures during the pregnancy period have been a focus of several 
epidemiological studies [16, 41, 87-90].  As autism research moves closer to identifying 
risk factors and risk biomarkers during the pre-, peri- and neonatal periods, large 
population-based cohort designs can be used understand the etiology of this disorder.  
Emphasis on the pregnancy period is supported by a recently reported higher rate of 
concordance in dizygotic twins [13], which was substantially larger than the non-twin 
sibling recurrence risk (18.7%) [91].  This implicates a shared environment, such as in 
utero, as a critical time period for development and suggests the need to explore potential 
environmental triggers or causes during pregnancy, which could lead to autism.  
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A current review of the literature, which is summarized in Table 1 above, reveal 
that there are only two epidemiological studies that have investigated prenatal exposure 
to B2AR agonist and risk for ASD, and one observational study on SSRIs and risk for 
ASD.  Although these studies were all population based, they had a relatively small 
sample size and may not have enough statistical power to adequately untangle the effects 
of the indicating condition and risk for ASD.  Further research is needed to replicate the 
findings thus far and utilize various statistical techniques to address confounding by 
indication such as restriction methods along with various correction techniques for 
exposure and outcome misclassification.  Given the evidence supporting the associations 
between the indications for both these medications and risk for ASD, as mentioned 
above, statistical methods to parse out the effects are needed to fully understand the 
possible causal pathways.    
These medications are known to cross the placenta and have deleterious effects 
from studies using animal models, and the biological mechanism and causal pathways 
remain unclear.   As described previously, asthma exacerbations, maternal stress, and 
relapse of depression have the potential to be dangerous for the fetus and mother, 
therefore to recommend avoidance of all medications during pregnancy is unrealistic.  
About 8% of pregnant women need permanent drug treatment due to their chronic 
diseases [92].  Thus, there is increasing need to understand the etiology of 
neurodevelopmental disorders such as autism, identify critical time periods of 
development for the fetus, and adequately balance the risks and benefits of medication 
use during pregnancy. 
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CHAPTER 3: IN UTERO EXPOSURE TO BETA-2-ADRENERGIC RECEPTOR 
AGONIST DRUGS AND RISK FOR AUTISM SPECTRUM DISORDERS  
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Abstract 
Objectives: The purpose of this study was to investigate associations between use of 
beta-2-adrenergic receptor (B2AR) agonist drugs during pregnancy and risk for autism 
spectrum disorders (ASD).  
Methods: The matched case-control study sample consisted of children born in Denmark 
between 1997 and 2006.  Health register data provided detailed information regarding 
maternal indications and prescription drug use, ASD diagnoses, and socioeconomic 
status.  Conditional logistic regression models were used to estimate odds ratios (OR) and 
confidence intervals (CI) for any B2AR agonist drug exposure during pregnancy, 
preconception and by trimester.  
Results:  In models adjusted for parental age, sex of the child, maternal asthma, and 
family socioeconomic status, increased risk for ASD was associated with any exposure to 
B2AR agonist drugs during pregnancy (OR: 1.3, 95% CI: 1.1-1.5) with similar effect size 
across all other exposure periods of interest.  These estimates remained robust to various 
sensitivity analyses. 
Conclusion: Our results indicate that B2AR agonist drug exposure during pregnancy 
may be associated with an increased risk for ASD.  While this association is biologically 
plausible, epidemiologic associations should be replicated in additional populations.  
Further research is needed to determine underlying biological mechanisms, and if this 
relationship is real, pregnant women must balance their treatment decisions against 
benefits of indicated medication use.  
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Introduction 
Autism spectrum disorders (ASD) are a group of developmental disabilities 
characterized by core deficits in three domains: social interaction, communication, and 
repetitive or stereotypic behavior [1] and currently has a US prevalence of 11.3 per 1,000 
[2].  Although ASD has moderate to high heritability [3] several reviews of autism 
genetics have suggested the possibility for an interaction between genetic mechanisms 
and environmental exposures in autism etiology [4, 5].  A large population-based twin 
study recently conducted by Hallmayer et al, found a dizygotic twin concordance higher 
than previously reported [6], which was substantially larger than the non-twin sibling 
recurrence risk (18.7%) [7].  This implicates a shared experience between twin 
individuals, such as the prenatal environment, as a critical period of life with respect to 
environmental influences.   
In utero exposures such as obstetric complications, maternal illness, and prenatal 
stress may be etiologically relevant[8-10].   Prenatal pharmacologic exposures have also 
been implicated as potential risk factors for ASD [11-13].  In particular, concerns have 
been expressed that exposure to terbutaline, a beta-2 adrenergic receptor (B2AR) agonist 
drug, used as indicated throughout pregnancy to reduce asthma exacerbations and provide 
asthma control [19] and used off-label later in pregnancy as a tocolytic agent [14], may 
increase the risk for neurodevelopmental disorders in offspring [15-17].  A study of in 
utero B2AR agonist drug exposure in a small series of dizygotic twin pairs suggested an 
increased risk associated with ASD[18].  A more recent case-control study of 291 cases 
and 284 controls found that exposure for more than two days during the third trimester 
was associated with increased risk for ASD, although estimates were imprecise (adjusted 
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odds ratio (OR) 6.01, 95% confidence interval (CI) 1.05-34.28) [19].  B2AR agonist drug 
utilization will be strongly associated with indicating conditions.   Croen et al 2005 
observed autism was associated with women with a diagnoses of asthma or allergies 
during the second trimester, which suggest that disease severity may be more strongly 
correlated with fetal neuropathologic conditions or that a critical period for dysregulation 
in neurodevelopment occurs in mid-pregnancy [8].  However, only one study has thus far 
reported an association between maternal asthma and autism, reporting a more than a 
two-fold increased risk of ASD associated with maternal asthma during the first (OR, 2.8; 
95% CI, 1.3-6.10) and second (OR, 2.2; 95% CI, 1.1-4.2) trimesters of pregnancy [8].   
However, that study was not able to explore the independent role of indicating condition 
and medication exposure.  
Beta-2 adrenergic receptors within the catecholamine system are present in 
normal nervous system development and for the function of both neural and non-neural 
tissues in adults [20].  If used during pregnancy, these drugs can impact the fetal brain by 
crossing the placenta, resulting in the disruption of either replication or differentiation of 
the developing neurons [21].   However, because uncontrolled asthma has been 
associated with poor birth outcomes, mothers are often still recommended to continue 
asthma medication [22, 23].  Given the biological plausibility and limited knowledge 
regarding risks of prenatal pharmacological exposures, which need to be balanced against 
the benefits of indicated medication use by pregnant mothers, we conducted a large 
population-based case-control study to determine the associations of maternal exposure to 
outpatient B2AR agonist drugs used during preconception and pregnancy and risk 
associated with delivering a child who goes on to develop ASD.  
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Methods 
Participants 
All children (n = 749,755) born in Denmark in the period from January 1, 1997 to 
December 31, 2006 were identified through the Danish Civil Register System (DCRS).  
The study population was then drawn from all biological singletons and one child 
randomly selected from multiple births.   Children were also excluded if they could not 
be linked to their biological mother (n = 1,139), if their mother was not living in 
Denmark a year before delivery (n = 10,806), or if they were born extremely preterm or 
post-term (gestational ages less than 23 weeks or greater than 43 weeks, n = 1,774).  
There were a total of 628,408 live births in the study population.   
Cases were identified from the Danish Psychiatric Central Register (DPCR) with 
an International Classification of Diseases code (ICD-10) for ASD diagnoses identified 
using records up to March 31, 2011. ICD-10 codes for childhood autism, atypical autism, 
Asperger’s syndrome and pervasive developmental disorder-unspecified using ICD-10 
codes F840, F841, F845, F848, and F849, respectively.  Controls were defined as never 
receiving an ASD diagnosis.  Ten controls per case were individually matched on birth 
month and year to assure that controls have the same length of follow-up time as a case, 
and thus the same opportunity to acquire an ASD diagnosis and be entered in the 
registers.   Matching on birth month also controlled for birth seasonality. The Institutional 
Review Board of Drexel University and the University of Copenhagen, Danish Data 
Protection Agency (Record No. 2010-41-4861) approved this study. 
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Outcome 
As mentioned above, outcome was based on the ICD-10 codes from both the 
Danish National Hospital Register (DNHR) and DCPR.  Data from both the DNHR and 
DCPR includes information on all inpatient and outpatient care from psychiatric hospitals 
and psychiatric wards in general hospitals in Denmark.  General practitioners or school 
psychologists refer children who are suspected of having ASD to a child psychiatric ward 
where they can receive a diagnosis and both inpatient and outpatient treatment.  A recent 
study was able to measure the validity of the reported ASD diagnosis in the register.  This 
validation study evaluated the concordance of reported diagnosis of childhood autism in 
the DPCR with a record review method developed at the Centers for Disease Control and 
Prevention (CDC) for population-based surveillance of ASDs in the United States and 
adopted by CDC’s Autism and Developmental Disabilities Monitoring (ADDM) 
Network.  The investigators concluded that the diagnosis of childhood autism was 
confirmed in 94% of cases with childhood autism in the DPCR. As many as 486 cases 
(97%) fell within the autism spectrum and only five cases were found not to have an ASD 
diagnosis [24].   
 
Exposure 
Pharmacologic information was drawn from the Danish Drug Prescription 
Register (DDPR) which contains information regarding unique personal identification 
number, dispense date, drug code using the WHO Anatomical Therapeutic Chemical 
classification system (ATC), name of drug, number of units in the container, number of 
packets dispensed, strength of the medication, form, and defined daily dosage (DDD) on 
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all dispensed medication from any pharmacy, except hospital dispensaries, in Denmark 
(see Table A in the Appendix for medication codes).  Therefore, we did not have 
information on in-hospital use of B2AR agonist drugs, which limits our ability to study 
maternal B2AR agonist drugs used as a tocolytic, since inpatient prescription of this is 
common.  The drug codes included in the analysis are listed in (see Table A in the 
Appendix for medication codes under ß2 adrenergic receptor agonist).   The DDPR 
includes ATC and the DDD for the expressed purpose of facilitating drug utilization 
research [25] and these coding schemes have been employed in a variety of studies [26-
29].  
The Danish Medical Birth Register (DMBR) contains information estimated date 
of conception (EDC) which is calculated from mother’s self-reported last menstrual 
period, and corrected with an early ultrasound estimate if the woman reported 
contraceptive use in the four months prior to conception, had irregular periods or an 
abnormal last menstrual period. The exposure windows were defined as preconception 
(90 days prior to the EDC), first trimester (within 90 days after the EDC), second 
trimester (within 90-180 days after EDC), and third trimester (180 days after the EDC to 
delivery date).  A child was considered exposed if the dispense date fell within the 
specified exposure period or the days supplied overlapped any portion of the exposure 
period or interest.  Children born to women who did not fill a prescription for B2AR 
agonist drugs for the entire period from 90 days before EDC through the date of delivery 
were considered unexposed.   
To calculate the cumulative dose dispensed during a particular exposure window, 
we first calculated the prescribed dose by multiplying the strength of the medication by 
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the number of units in the container to give the total dose in the package.   The prescribed 
dose was then calculated by dividing the total package dose by the number of DDD in the 
package.  Cumulative dose over each exposure period of interest was divided into 
quartiles (low, medium, medium-high, and high) based on the distribution of the exposed 
controls.     
To calculate duration of use for each prescription, the number of packets 
dispensed was multiplied by the DDD in the package.  Duration was dichotomized into 
two categories representing use for more or less than half (0-45 days and ≥45 days) in 
each exposure window.   The reference group for determining the risk of dose and 
duration of use was no exposure during any period of interest.   
 
Covariates  
Candidate covariates include parental age, sex of the child, gestational age, birth 
weight, history of parental autoimmune disease, history of parental psychiatric disorder, 
maternal infection during pregnancy, number of live births, obstetric complications, and 
family socioeconomic status (a combination of parental income and highest level of 
education).  These covariates were identified from available data in the Danish Fertility 
Database, DMBR, DCPR and DNHR.  Covariates were selected based on prior literature 
suggesting them as potential risk factors for ASD [10, 30-36].  Parental psychiatric 
history was categorized as either absent or falling into one of four severity categories 
following the algorithm of a prior study [34] developed by Larrson et al in 2005.  A 
parent was defined as having a psychiatric history if a psychiatric diagnosis had been 
recorded before the date of birth of the child.  Diagnosis considered in the severity score 
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included schizophrenia-like psychosis followed by affective disorder in the second most 
severe category.   Diagnoses were ranked by Larrson et al 2005 according to severity and 
each parent with a psychiatric history received a score equal to the highest ranked 
condition.  The score of the parent with the highest-ranking diagnosis determined the 
specific category assigned. 
Candidate covariates such maternal illness and obstetric complications were 
identified from available data in the Danish Fertility Database, DMBR, and DNHR.  
These covariates were selected based on prior literature suggesting these as potential risk 
factors for ASD and the exposure[37].  Maternal illness such as autoimmune disease was 
identified using ICD-8 and ICD-10 codes present in the register prior to the delivery of 
the child. Maternal infection during pregnancy and other obstetric complications were 
identified also using ICD-8 and ICD-10 codes if they were present a year before delivery 
and by trimester. 
History of maternal asthma before the birth of the child was included as a 
covariate because of concerns over potential confounding by indication - when 
confounding is introduced because a known or perceived indication (or contraindication) 
for the treatment under study and is also a risk factor for an outcome [38].    Inpatient and 
outpatient information on maternal asthma was obtained from the DNHR using ICD-8 
and ICD-10 codes.  Data on maternal asthma were extracted as far back as 1973 for all 
mothers.  Presence of both primary and secondary diagnoses of asthma anytime before 
delivery was used.  From 1973-1993 ICD-8 codes were used in Denmark’s national 
registers, and were replaced after 1993 by ICD-10 code. 
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Analytic method 
Conditional logistic regression analysis was conducted to estimate crude and 
adjusted associations with no exposure during any period of interest as the reference 
group.   Parental age and gender were forced in all adjusted models as covariates.  Other 
covariates were included only if they resulted in a 10% or greater change in unadjusted 
log odds ratios when added individually. To guard against joint confounding, any 
excluded covariate was added back to the adjusted model and retained if the log odds 
ratios changed by 10%.   Additional adjustment for maternal asthma was conducted to 
control for confounding by indication.  To further consider confounding by indication we 
also examined the effect of the exposure in a sample restricted to mothers with an asthma 
diagnosis history.   
 
Sensitivity analyses 
A number of sensitivity analyses were also conducted.  Since outpatient data were 
added to the DCPR in 1993, we wanted to ensure that our estimates were not influenced 
by this change.  Consequently, we re-analyzed data limited to the birth cohort born 
between 1998 and 2002 whose outcome status would be based on both inpatient and 
outpatient data.  Because some time was likely needed for any impact of the inclusion of 
outpatient data to be felt, we chose to restrict the birth cohort at 1998 rather than 1993.  
We also compared effect estimates based on different criteria for considering an 
individual exposed during a specific window.  For example, exposure within a window 
(e.g., first trimester) was first defined as any maternal B2AR agonist drug use during that 
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window regardless of whether B2AR agonist drugs were also used in other windows. The 
alternate definition considered only individuals exclusively exposed during that window. 
We also explored the potential effect of maternal B2AR agonist drug exposure 
misclassification.  In our data the observed maternal B2AR agonist drug use prevalence 
was 3%, while data from national health registers in other Nordic countries such as 
Finland report exposure prevalence to 4% [39].  Although the exposure prevalence that 
we observed only differs slightly from what is reported in the literature, any exposure 
misclassification could lead to bias effect estimates [40].  A Monte Carlo simulation of 
maternal B2AR agonist drug use and ASD effect estimates was conducted after re-
classifying exposure status according to published prevalence estimates [41].   To 
stimulate increased the prevalence of maternal B2AR agonist drug exposure, we used 
1,000 simulated datasets and randomly assigned an unexposed mother to being exposed 
from a normal distribution.  From each of the 1,000 simulated datasets we obtained the 
OR and then took 1,000 samples from each OR normal distribution.  We then took the 
median effect estimate from these 1,000,000 samples as the OR and the 2.5% and 97.5% 
percentile to estimate the 95% confidence interval.  We assumed under-reporting was 
non-differential with respect to outcome by keeping sensitivity and specificity equal in 
case and control groups.   Specificity was assumed to be 100%, because it is unlikely a 
prescription for a B2AR agonist drug would be documented in the register when none 
was given, and sensitivity was assumed to be 73% because that corresponds to a true 
B2AR agonist drug use prevalence of 4%. 
In addition, we also examined the impact of misclassification of asthma, which 
would lead to incomplete control for confounding by indication using the same Monte 
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Carlo simulation approach described above. Our simulation adjusted asthma prevalence 
from the observed prevalence in the Denmark register data of 1.3% to a prevalence of 
2%, which is the prevalence indicated from another national health register [41] assuming 
that this misclassification was also non-differential with respect to outcome.   Specificity 
was assumed to be 100%; in other words, all mothers truly without a history of maternal 
asthma where assumed to be correctly classified as without asthma in the register, and 
sensitivity was set to 66% to reflect the under-reporting needed where the true asthma 
prevalence of 2%.    
   In both Monte Carlo simulations (correcting for misclassification of maternal 
B2AR agonist drug use and for misclassification of asthma) we also considered the 
maternal B2AR agonist drug use effect in the overall dataset and in the data stratified by 
maternal asthma status.   
 
Results 
Description of study sample 
Over the entire pregnancy period, children with ASD (n = 5,200) were more 
likely than controls (n=52,000) to be male, have a higher parental age and have a mother 
with an asthma diagnosis prior to the birth of the child (Table 1).  For each of the 
exposure periods examined, similar patterns were observed (as compared with over the 
entire pregnancy period).  In the source population, which consisted of all live births from 
January 1996 to December 2006 the frequency of any ASD was 0.86%. 
The frequency of exposure to maternal B2AR agonist drugs use throughout each 
exposure period was higher in children with ASD compared to controls.  In the 
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preconception period, 2.0% (n = 102) of cases and 1.6% (n = 816) of controls were 
exposed. For the pregnancy exposure period 3.7% (n = 190) of cases and 2.9% (n = 
1,489) of controls were exposed to B2AR agonist drugs in utero. 
 
Associations of any B2AR agonist use with ASD 
Table 2 shows unadjusted and adjusted estimates of the association of maternal 
B2AR agonist use with ASD.   Since no additional covariates resulted in a 10% change in 
the log odds ratios, we show estimates from one adjusted model including parental age 
and sex of the child and a second adjusted model adding the maternal asthma history 
variable.   In conditional regression models controlling for child birth year and month, 
sex of the child, and parental age we found an increased risk for any ASD diagnosis 
associated with exposure to B2AR agonist drugs during pregnancy (OR, 1.3 [95% CI, 
1.1-1.5]).  The largest effect estimate was found for exposure in the second trimester 
(adjusted OR, 1.4 [95% CI, 1.1-1.7]) compared to those who are unexposed, although 
confidence limits of this estimate overlap with point estimates for the maternal B2AR 
agonist drug use effect in other trimesters.  For exposure during the preconception period 
the adjusted OR was 1.3 (95% CI, 1.0-1.5) for ASD compared to those who were 
unexposed.  
 
Analyses of B2AR agonist dose and duration of use      
The mean cumulative dose over the whole pregnancy period for cases was slightly 
higher than controls (205.3 mg versus 198.0 mg) for any ASD (Table 3).  Median 
cumulative dose was the same (50 mg) for any ASD and controls throughout pregnancy.  
Across each trimester, the median cumulative dose did not vary substantively, however 
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the highest dosage among cases and controls occurred during in the second trimester.   
Results as displayed in Table 4 do not consistently suggest dose response. 
Overall, the mean and median duration of use was similar between cases and 
controls within each period of interest (Table 5).  For example the mean duration for the 
pregnancy period was 62.2 days vs 63.9 days and median duration of maternal B2AR 
agonist drug use during the pregnancy period was 50 days for both cases and controls. In 
conditional logistic regression results (Table 6), the point estimates for the longer 
duration exposure category (>45 days) tended to be slightly larger than that for the 
shorter duration exposure category (1-45 days) during the preconception and first and 
second trimesters periods; however the confidence limits for longer duration exposure 
effects overlapped substantively with those for shorter duration exposure.    
Additional statistical adjustment for maternal asthma did not substantively change 
effect estimates as seen by comparing Adjusted Model 2 and Adjusted Model 1 findings 
in Tables 2, 4, and 6.  Statistical adjustment for maternal asthma resulted in consistently 
elevated estimates (adjusted OR, 1.3 [95% CI, 1.1-1.5]) for any exposure during 
pregnancy, adjusting for parental age, sex of the child and risk for any ASD diagnosis 
compared to the unexposed group.  Analyses restricting to only mothers with asthma 
(Table 7; n = 863) resulted in estimates suggesting elevated effect estimates, although the 
95% confidence interval around the odds ratio included the null (adjusted OR, 1.3 [95% 
CI, 0.8-2.1]). 
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Sensitivity Analyses 
Effect estimates in analyses restricting the birth cohort to those born between 
1998-2002, a cohort where all members classified with ASD in the Psychiatric Register 
would have been entered after outpatient data were included, were comparable to 
estimates we had observed using our entire sample population (Table 8).  In the second 
sensitivity analysis where we contrasted trimester-specific effects under alternative 
approaches for defining exposure status our estimates were reasonably close, with 
overlapping confidence intervals (data not shown).  In these analyses we were comparing 
the estimates obtained when we defined exposure during that period but not limited to 
other exposure time periods verses exposure in a single trimester only.  For example, 
exposure during the first trimester only had a crude OR of 1.6 (95% CI 0.6-3.7) compared 
to exposure during the first trimester, but not limited to other exposure periods (crude OR 
2.3 [95% CI 1.8-3.0]).   
Table 9 and 10 present the analysis results that reflect the impact of potential 
misclassification of any maternal B2AR agonist drug exposure in pregnancy and 
maternal asthma, respectively.  In the full sample analysis, maternal B2AR agonist drug 
exposure misclassification (Table 9) did not appear to lead to any change in point or 
confidence bound estimates.  The sensitivity analysis of misclassification of the 
indication condition (asthma) (Table 10) also suggested minimal impact of this potential 
misclassification on the effect estimate.  Table 9 and 10 also show observed and 
simulation analysis effect estimates stratified by maternal asthma status and suggest that 
the finding mentioned above, where B2AR effects persists when looking only at mothers 
with the indicating condition, persists after considering misclassification of covariates. 
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Discussion 
 The present study examined maternal preconception and prenatal use of B2AR 
agonist drugs and subsequent ASD risk in an offspring in a large population-based 
register.  To our knowledge this is the largest study to-date to look at this drug class and 
risk associated with ASD, as well as the first study to look at both dose and duration.  
Results suggest that exposure during the prenatal period was associated with modest 
association for ASD compared to those who were unexposed in utero.  Adjustment for 
covariates considered did not appreciable change results.    Specific exposure window 
effect estimates were higher in the second and third trimesters.  However, trimester-
specific effect estimates had confidence intervals with substantial overlap, indicating that 
results do not provide strong evidence suggesting a particular critical exposure window.  
Furthermore, we observed an association between exposure during the preconception 
period and ASD. 
 These findings are consistent with other epidemiological evidence regarding in 
utero exposure to B2AR agonist drugs and risk for ASD in that a modest increase effect 
estimates for ASD were also reported [18, 19].  Connors et al 2005 reported an increased 
concordance for ASD in dizygotic twins exposed to terbutaline [18].  In a more recent 
study, the findings from Croen et al 2010 also suggest a modest association for ASD, 
(adjusted OR 1.39 and 95% CI 0.87-2.22) for exposure to maternal B2AR agonist drug 
use or mimics and time during pregnancy.  These estimates were similar to what we 
report, especially with regards to the second trimester effect estimates.  Exposure to 
maternal B2AR agonist drugs or mimics during the second trimester and risk for any 
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ASD, Croen et al 2010 report an adjusted OR of 1.50 95% CI (0.69-3.25).  However this 
same study found that exposure to maternal B2AR agonist drugs or mimics in the 30 days 
before conception to be associated with three times higher ASD risk (adjust OR 2.98, 
95% CI 1.01-8.83) [43].  The effect estimates for specific exposure windows and doses in 
the study conducted by Croen et al 2010 as well as this present study were statistically 
imprecise and the mechanism behind the pre-conception exposure has not been described.  
The preconception effect sizes that were observed may be the result of induced persistent 
changes in the intracellular signals, although there has been no evidence of 
bioaccumulation of B2AR agonist drugs in the body, or can be due to uncontrolled 
confounding by indication. 
 This is the first study to look at both dose and duration of prenatal use of B2AR 
agonist drugs and risk for ASD.  Epidemiological studies thus far have only looked at 
duration of use and report the highest risk with prolonged use (>2 days) [19], which is 
also consistent with our findings.  In a study investigating the effects of prenatal 
overestimation of the B2AR receptors in dizygotic twins who were exposed to terbutaline 
to treat premature labor, the investigators were able to assess duration. However, they 
defined duration in their exposed group only as two weeks of continuous treatment with 
terbutaline in utero.  In this present study, we defined duration in preconception and in 
each trimester into two categories, 1-45 days and more than 45 days of use, and included 
all B2AR agonist drugs.  Although we had defined duration differently from Connor et al 
2005, both results agree that increased length of duration is associated with ASD. 
In regards to dose for any ASD diagnosis, the second trimester was the only 
exposure window where the largest dose quartile had the highest risk associated with 
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ASD, which was higher than the lowest dose quartile, suggesting a possible dose 
response mechanism for the second trimester.  All confidence intervals overlapped each 
effect estimates, which remained elevated throughout each dose category.  However, this 
evidence does not suggest any particular cumulative dose range or trimester specific 
exposure for dose.   
Although we cannot definitively implicate any specific exposure window, our 
results do raise concerns around the second trimester exposure period.  Croen et al 2010 
found associations between B2AR agonist drugs and mimics and increased ASD risk 
associated with exposure around the time of preconception and in the third trimester, and 
did not find an associate for the second trimester use.   However, our analyses were able 
to detect the highest effect estimate in the second trimester, which is also supported by 
animal models [42, 43].  It has been shown that during gestation, overstimulation of the 
beta-2- adrenergic receptors from an exogenous source during the development of the 
nervous system may have harmful effects on the development of the brain and the 
peripheral nervous system [44, 45].  The mechanisms within the mature beta-2- 
adrenergic receptors protect against over-stimulation; however, fetal receptors do not 
have the ability to regulate any imbalance and may in fact become sensitized [43].  Early 
research has shown that B2AR agonist drugs administered to pregnant rats during the 
second trimester of gestation alters neural cell replication and differentiation, 
synaptogenesis, and expression of synaptic proteins involved in neurotransmission [43].  
This was evidence for chemical and structural damage to the cerebellum, hippocampus, 
and somatosensory cortex [44, 45], as well as deficiencies in the cerebellar Purkinje cell 
numbers [45].  These animal models also found abnormalities within the central and 
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peripheral nervous system and a decrease in the cell numbers in the fetal brain and liver 
of rats that were exposed prenatally [44].  The effect on the rats is gender selective with 
males experiencing more abnormalities, which is analogous to the male predominance of 
autism in humans [44]. 
 Although animal models shed some insight on the possible biological mechanisms 
that could lead to ASD, there has been evidence linking the indication for B2AR agonist 
drugs, maternal asthma, to ASD.  Only one study has reported an association between 
maternal asthma and autism risk showing a more than a two-fold elevated risk of ASD 
associated with maternal asthma during the first (OR, 2.8; 95% CI, 1.3-6.10) and second 
(OR 2.2; 95% CI, 1.1-4.2) trimester of pregnancy [8].  However, that study was not able 
to explore the independent role of indicating condition and medication exposure. 
 Our analyses suggest that maternal B2AR agonist drug use, independent of 
indication, was associated with increased ASD.  Both analytical techniques used to 
address confounding by indication, restriction and statistical adjustment, remained 
elevated.  These methods have also been used by Croen et al 2010 in order to control for 
the indication, which also suggest an increased risk associated with ASD for exposure to 
B2AR agonist drugs during pregnancy.   Among mothers who are severe asthmatics, 
avoidance of asthma treatment during pregnancy, has been linked to birth complications 
including preterm birth, low birth weight, preeclampsia, and neonatal death [46, 47].  
Since uncontrolled asthma has been associated with poor birth outcomes, mothers are 
often still recommended to continue asthma medication[22, 23, 48].  A high frequency of 
preterm labor and intrauterine growth restriction in corticosteroid-dependent asthmatic 
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patients has been reported [22, 49, 50].  Infants with a gestational age at birth that is less 
than 35 weeks have shown to have more than two-fold increase risk for ASD [34].  
Although this study had advantages compared to past work in terms of available 
sample size and ability to assess dose and duration, our study has several potential 
limitations.  As a register-based study, data on outcome and exposure were limited to 
information available in the databases.  Outcome misclassification is one potential 
concern; however, the quality of ASD classification in the DPCR has been previously 
investigated using expert review of a subset of children’s medical records [24].  Our 
additional sensitivity analysis restricting the birth cohort indicated that our findings were 
not due to the addition of outpatient data into the register after 1994. 
There was a possibility for exposure misclassification.  We were able to assess the 
impact of exposure misclassification by conducting a simulation-based sensitivity 
increasing the prevalence of exposure that to a rate similar to what is observed in the 
literature, specifically that of other Nordic countries [39].  In these sensitivity analysis we 
increased the prevalence of B2AR agonist use in register from 3% to 4% non-differential 
with respect to exposure status by reclassifying 1.38% unexposed cases and 1.07% 
unexposed controls as being exposed.  In addition, since we believed that the possible 
misclassification was non-differential, we fixed the sensitivity among cases and controls 
to be 0.73, and assumed perfect specificity.  In this sensitivity analysis, we did not 
observe any changes in the effect estimates.  However, we have assumed that the mothers 
consumed all of the medication.  It was, however, also possible that portions of 
prescriptions during the study period where unused or that subjects used B2AR agonist 
drugs during the study period that were prescribed outside the study period.   
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Overestimation of the exposure could lead to an underestimate of effect estimate however 
we would expect this to be consistent throughout each exposure window.  Any resulting 
exposure misclassification would be non-differential with respect to outcome, and any 
bias in exposure effects would tend to be toward the null.   
Our exposure data was also restricted to outpatient prescriptions.   Although most 
prescriptions for B2AR agonist drugs, including those used for asthma indications are 
obtained in an outpatient setting, they are also prescribed as a tocolytic for in-hospital 
use. B2AR agonist drug exposure due to tocolytic use would most likely occur in the 
third trimester.  Therefore, third trimester exposure may have been underestimated since 
drugs prescribed during hospital admission are not included.  Therefore, if terbutaline 
administered as a tocolytic does in fact increase ASD risk as previously reported [19] our 
estimates of third trimester associations may in fact underestimate the true association.   
Croen et al 2010 was able to isolate the effect of terbutaline, which was used to prevent 
preterm labor and accounted for the majority of third trimester exposures for both cases 
and controls [19].  Our findings were consistent with Croen et al 2010 in that we also 
observed an association for maternal B2AR agonist drug use and ASD in the third 
trimester [19].  Both Croen et al 2010 and our results provide evidence to further 
investigate the indication for using B2AR agonist drugs, as a tocolytic.  
Finally, as with most observational epidemiology, the unmeasured covariates 
were also a limitation. However, we were able to consider a number of potential 
covariates available in the Danish register.   Unmeasured covariates that were not 
represented in the register include in-home environmental exposures and pollutants, 
which may potentially be associated with ASD [51].  One covariate of potential interest 
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that was unavailable in the register was maternal smoking which has been suggested as 
an ASD risk factor and, since it is linked to maternal asthma exacerbation [52], may be 
associated with maternal B2AR agonist drug use.   However, the relationship between 
maternal smoking and ASD is not proven [53].    
This case-control analysis benefits from a large study population and prospective 
documentation of pharmacologic utilization through the DNPR.  As registers are 
population-based, selection bias is not anticipated to be a large problem in these analyses 
because all information from Danish citizens are intended to be included in the register.  
Because of the large sample size, even with relatively small exposure prevalence, the 
study was powered to detect modest effects.    The combination of low exposure 
prevalence and modest effect size implies that population attributable risks associated 
with this exposure will be small.   Prevalence of asthma drugs used during pregnancy in 
our study was 2.9% and we observed a 1.3 odds ratio associated with exposure and 
delivering a child with ASD, the population attributable risk was 0.9%. If the effect is in 
fact real, this still suggests that a small proportion of autism cases in the population could 
be prevented if they were not exposed to B2AR agonist drugs during pregnancy.   
Given the clinical and suspected etiologic heterogeneity of the ASDs, it is likely 
that attributable risks associated with implicated exposures will be quite small.  
Consideration of the biological mechanisms underlying exposure effects as they emerge 
might lead to an understanding of common etiologic pathways in ASD.   As mentioned, 
animal models have been developed to understand the neurodevelopmental effects of 
maternal B2AR agonist drug use in conjunction with the results from this work appear 
relevant to ASD pathogenesis [18, 44].  Exposures during pregnancy that modify beta-2 
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adrenergic receptor signaling could have wide spread effects during critical periods of 
development [15]. It is also possible that downstream signaling abnormalities including 
the dysregulated cAMP generation could be a pathway in the development of this 
disorder[15, 18].   
Results from this study add to the limited knowledge on prenatal pharmacological 
exposures as potential ASD risk factors.  Specifically, three prescription medications 
have been already been identified as potential prenatal environmental risk factors for 
ASD [12, 13, 54].  Although the effect sizes that we have observed for maternal B2AR 
agonist drug use during the prenatal period are modest and exposure carries a small 
population attributable risk, given the fact that the neurodevelopmental consequences of 
many medications used in pregnancy is still undetermined [55, 56] there is a need to 
continue to carefully explore prenatal prescription drug use as ASD risk factors.  At the 
same time, while it is important to detect any such associations and consider their 
etiologic implications, the public health implications may not be straightforward.   With 
respect to maternal B2AR agonist drug use, uncontrolled asthma in pregnancy has been 
associated with poor birth outcomes [23, 50].   During an asthma exacerbation in 
pregnancy, prenatal maternal stress response may be elevated, especially before 32 weeks 
of gestation, when the fetal limbic system is considered to be the most vulnerable to such 
a stress response [9].   Consequently, any ASD risk associated with maternal B2AR 
agonist drug use needs to be balanced against the benefits of indicated medication use by 
pregnant mothers.  Additional studies need to replicate the present study before the 
implications of prenatal B2AR agonist drug exposure through maternal use of these 
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agents for asthma control on ASD risk be considered when making individual decisions 
about asthma control in pregnancy. 
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TABLES 
Table 1. Study demographics for B2AR analysis 
 Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls 
 Pregnancy Preconception 1st Trimester 2nd Trimester 3rd Trimester 
No. (%) 5200 (9.1) 52000 (90.9) 5112 (9.1) 51120 (90.9) 5096 (9.1) 50960 (90.9) 5116 (9.1) 51196 (90.9) 5117 (9.1) 51170 (90.9) 
Maternal age           
≤25 years 814 (15.7) 7461 (14.4) 805 (15.8) 7302 (14.3) 798 (15.7) 7169 (14.1) 799 (15.6) 7189 (14.0) 805 (15.7) 7261 (14.2) 
26-30 1747 (33.6) 18763 (36.1) 1715 (33.6) 18398 (36.0) 1709 (33.5) 18256 (36.0) 1718 (33.6) 18670 (36.5) 1716 (33.5) 18330 (35.8) 
31-35 1738  (33.4) 17886 (34.4) 1713 (33.5) 17764 (34.8) 1708 (33.5) 17791 (35.0) 1717 (33.5) 17601 (34.4) 1714 (33.5) 17812 (34.9) 
≥36 901 (17.3) 7790 (15.2) 879 (17.2) 7656 (15.0) 881 (17.3) 7744 (15.2) 882 (17.2) 7700 (15.1) 882 (17.2) 7767 (15.2) 
Paternal age           
≤29 years 1269 (24.4) 13089 (25.2) 1247 (24.4) 12623 (24.7) 1242 (24.3) 12682 (25.0) 1246 (24.4) 12895 (25.2) 1248 (24.4) 12714 (24.9) 
29-39 2666 (51.3) 27925 (53.8) 2618 (51.2) 27643 (54.1) 2610 (51.2) 27587 (54.2) 2622 (51.3) 27598 (54.0) 2624 (51.3) 27686 (54.0) 
40-49 532 (10.2) 4276 (8.2) 525 (10.3) 4294 (8.4) 527 (10.3) 4251 (8.3) 524 (10.3) 4147 (8.1) 522 (10.2) 4153 (8.1) 
50-54 36 (0.7) 284 (0.6) 37 (0.7) 247 (0.5) 36 (0.7) 243 (0.5) 36 (0.7) 258 (0.5) 36 (0.7) 224 (0.4) 
≥ 55  20 (0.4) 118 (0.2) 20 (0.4) 126 (0.3) 20 (0.4) 112 (0.2) 20 (0.4) 119 (0.2) 20 (0.4) 105 (0.2) 
Missing 677 (13.0) 6308 (12.2) 665 (13.0) 6187 (12.1) 661 (13.0) 6065 (11.9) 668 (13.1) 6143 (12.0) 667 (13.0) 6274 (12.3) 
Child sex           
Boys 4267 (82.1) 26406 (50.7) 4196 (82.1) 25944 (50.8) 4184 (82.1) 25980 (51.0) 4198 (82.0) 26274 (51.4) 4194 (82.0) 25979 (50.8) 
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Table 1 (continued). Study demographics for B2AR analysis (continued) 
 Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls 
 Pregnancy Preconception 1st Trimester 2nd Trimester 3rd Trimester 
No. (%) 5200 (9.1) 52000 (90.9) 5112 (9.1) 51120 (90.9) 5096 (9.1) 50960 (90.9) 5116 (9.1) 51196 (90.9) 5117 (9.1) 51170 (90.9) 
Maternal 
Asthma 
          
Yes 83 (1.6) 673 (1.3) 66 (1.3) 588 (1.2) 70 (1.4) 545 (1.1) 69 (1.4) 559 (1.1) 73 (1.4) 608 (1.2) 
Paternal 
history of 
psychiatric 
disorder  
          
Rank 1 24 (0.5) 137 (0.3) 24 (0.5) 143 (0.3) 23 (0.5) 112 (0.2) 22 (0.4) 139 (0.3) 24 (0.5) 119 (0.2) 
Rank 2 22 (0.4) 161 (0.3) 22 (0.4) 157 (0.3) 22 (0.4) 163 (0.3) 22 (0.4) 161 (0.3) 22 (0.4) 167 (0.3) 
Rank 3 25 (0.5) 187 (0.4) 25 (0.5) 193 (0.4) 24 (0.5) 198 (0.4) 25 (0.5) 192 (0.4) 24 (0.5) 172 (0.4) 
Rank 4 143 (2.8) 799 (1.5) 140 (2.7) 777 (1.5) 140 (2.8) 746 (1.5) 140 (2.7) 804 (1.6) 143 (2.8) 808 (1.6) 
No disorder 4986 (95.9) 50716 (97.6) 4901 (95.9) 49850 (97.5) 4887 (95.9) 49741 (97.6) 4907 (95.9) 49864 (97.5) 4904 (95.8) 49904 (97.5) 
Maternal 
history of 
psychiatric 
disorder  
          
Rank 1 13 (0.3) 82 (0.2) 15 (0.3) 60 (0.1) 13 (0.3) 73 (0.1) 13 (0.3) 63 (0.1) 13 (0.3) 75 (0.1) 
Rank 2 22 (0.4) 102 (0.2) 22 (0.4) 100 (0.2) 21 (0.3) 104 (0.2) 20 (0.4) 96 (0.2) 21 (0.4) 93 (0.2) 
Rank 3 12 (0.2) 74 (0.1) 13 (0.3) 73 (0.1) 12 (0.2) 77 (0.2) 12 (0.2) 73 (0.1) 12 (0.2) 68 (0.1) 
Rank 4 125 (2.4) 695 (1.3) 121 (2.4) 696 (1.3) 120 (2.4) 657 (1.3) 121 (2.4) 711 (1.4) 123 (2.4) 689 (1.4) 
No disorder 5028 (96.7) 51047 (98.2) 4941 (96.7) 50191 (98.2) 4930 (96.7) 50049 (98.2) 4950 (96.8) 50217 (98.2) 4948 (96.7) 50245 (98.2) 
Family SES           
Low 831 (16.0) 6624 (12.7) 812 (15.9) 6512 (12.7) 808 (15.9) 6525 (12.8) 805 (15.8) 6494 (12.7) 814 (15.9) 6560 (12.8) 
Medium 2712 (52.2) 26298 (51.0) 2676 (52.4) 25671 (50.2) 2668 (52.4) 25652 (50.3) 2672 (52.2) 26001 (50.9) 2668 (52.1) 25554 (49.9) 
High 1657 (31.9) 19066 (36.3) 1624 (31.8) 18932 (37.0) 1620 (31.8) 18772 (36.8) 1639 (32.0) 18656 (36.5) 1635 (32.0) 19051 (37.0) 
Missing 0 (0.0) 12 (0.0) 0 (0.0) 5 (0.0) 0 (0.0) 11 (0.0) 0 (0.0) 9 (0.0) 0 (0.0) 5 (0.0) 
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Table 2. Effect estimates for prenatal B2AR agonist drug exposure and risk for ASD. 
  Exposed No. (%)  
Outcome  # Cases Exposure Period Cases Controls Unadjusted ORa 
(95% CI) 
Adjusted Model 1 
ORb 
(95% CI) 
Adjusted Model 2 
ORc 
(95% CI) 
Any ASD        
 5112 Preconception 102 (2.0) 816 (1.6) *1.3 (1.0-1.5) *1.3  (1.0-1.6) *1.3 (1.0-1.6) 
 5200 Pregnancy 190 (3.7) 1489 (2.9) *1.3 (1.1-1.5) *1.3 (1.1-1.5) *1.3 (1.1-1.5) 
 5096 First Trimester 86 (1.7) 756 (1.5) 1.1 (0.9-1.4) 1.2 (0.9-1.5) 1.1 (0.9-1.4) 
 5116 Second Trimester 106 (2.1) 765 (1.5) *1.4 (1.1-1.7) *1.4 (1.1-1.7) *1.5 (1.1-1.7) 
 5117 Third Trimester 107 (2.1) 805 (1.6) *1.3 (1.1-1.6) *1.4 (1.2-1.8) *1.4 (1.1-1.7) 
Abbreviations: Autism spectrum disorders (ASD); Odds ratio (OR); Confidence Intervals (CI) 
Reference: No exposure during any exposure period 
a. Controls for matching variables of child year and month of birth through conditioning 
b. Odds ratios adjusted for parental age and sex of the child (and conditions on matching variables of child birth month and year) 
c. Odds ratios adjusted for parental age, sex of the child, history of maternal asthma (and conditions on matching variables of child birth month and year) 
*P-value < 0.05 
 
Table 3. Cumulative dose of prenatal exposure to B2AR agonist drugs. 
  Cumulative Dose of Prenatal Exposure to B2AR Agonists (mg) 
 Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls 
 Pregnancy Preconception 1st Trimester 2nd Trimester 3rd Trimester 
Mean 205.3 198.0 97.5 102.9 100.2 92.1 169.9 180.0 167.2 130.0 
Variance 599.7 588.1 174.6 217.8 188.6 154.8 354.3 310.6 340.5 332.4 
Mode 100.0 100.0 100.0 100.0 100.0 100.0 40.0 16.0 100.0 100.0 
Minimum 1.6 0.3 0.1 0.1 0.5 0.1 0.8 0.1 1.6 0.4 
25th percentile 25.0 36.0 18.0 25.0 12.0 20.0 36.1 34.0 25.0 24.8 
Median 100.0 100.0 48.9 60.0 57.0 52.0 83.0 80.0 62.0 70.4 
75th percentile 120.0 120.0 100.0 100.0 100.0 100.0 148.8 174.0 109.7 102.5 
Maximum 6800.0 9438.2 1112.0 3810.0 1256.0 2474.4 3154.0 2810.0 2452.0 6955.0 
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Table 4. Effect Estimates for Any ASD Associated with Cumulative Dose of Prenatal Exposure to B2AR Agonists 
  Models 
Exposure Period Dosea  Crude ORb 
(95% CI) 
Adjusted Model 1 ORc 
(95% CI) 
Adjusted Model 2 ORd 
(95% CI) 
Preconception     
 Quartile 1 (≤25 mg) *1.5 (1.1-2.2) *1.5 (1.0-2.2) *1.5 (1.0-2.2) 
 Quartile 2 (26-60 mg) 1.3 (0.9-2.0) *1.5 (1.0-2.2) 1.4 (0.9-2.1) 
 Quartile 3 (61-100 mg) 1.3 (0.8-2.0) 1.3 (0.9-2.1) 1.3 (0.9-2.1) 
 Quartile 4 (>100 mg) 0.9 (0.6-1.5) 0.8 (0.5-1.3) 0.8 (0.5-1.4) 
Pregnancy     
 Quartile 1 (≤36 mg) 1.5 (1.1-2.0) *1.5 (1.1-2.0) *1.5 (1.1-2.0) 
 Quartile 2 (37-98 mg) 1.0 (0.7-1.5) 0.9 (0.6-1.3) 0.9 (0.6-1.3) 
 Quartile 3 (99-120 mg) 1.3 (1.0-1.7) 0.9 (0.6-1.3) *1.3 (1.0-1.8) 
 Quartile 4 (>120 mg) 1.3 (1.0-1.7) 1.3 (1.0-1.7) 1.2 (1.0-1.7) 
First Trimester     
 Quartile 1 (≤20 mg) *1.7 (1.2-2.6) 1.3 (1.0-1.7) *1.6 (1.0-2.2) 
 Quartile 2 (21-52 mg) 0.7 (0.4-1.3) 0.8 (0.5-1.4) 0.8 (0.4-1.3) 
 Quartile 3 (53-100 mg) 0.7 (0.4-1.3) 1.2 (0.7-1.9) 1.1 (0.6-1.8) 
 Quartile 4 (>100 mg) 1.2 (0.7-1.9) 1.2 (0.7-1.9) 1.1 (0.6-1.8) 
Second Trimester     
 Quartile 1 (≤34 mg) 1.3 (0.9-2.0) 1.2 (0.8-1.8) 1.2 (0.8-1.8) 
 Quartile 2 (35-80 mg) 1.4 (1.0-2.1) 1.4 (0.9-2.1) 1.4 (0.9-2.1) 
 Quartile 3 (81-174 mg) 1.6 (1.1-2.3) *1.7 (1.1-2.5) *1.6 (1.1-2.5) 
 Quartile 4 (>174 mg) 1.3 (0.8-2.0) 1.3 (0.8-2.0) 1.3 (0.8-2.0) 
Third Trimester     
 Quartile 1 (≤25 mg) 1.3 (0.9-2.0) 1.3 (0.9-2.0) 1.3 (0.9-2.0) 
 Quartile 2 (26-70 mg) 1.4 (1.0-2.1) *1.7 (1.1-2.7) *1.7 (1.1-2.7) 
 Quartile 3 (71-102 mg) 1.6 (1.1-2.3) 1.2 (0.8-1.9) 1.2 (0.8-1.9) 
 Quartile 4 (>102 mg) 1.3 (0.8-2.0) 1.5 (1.0-2.2) 1.5 (1.0-2.2) 
The reference group is unexposed 
a. Dose categories were based on the distribution of cumulative dose of exposed controls in the exposure period of interest. 
b. Controls for matching variables of child year and month of birth through conditioning 
c. Odds ratios adjusted for parental age and sex of the child (and conditions on matching variables of child birth month and year) 
d. Odds ratios adjusted for parental age, sex of the child, history of maternal asthma (and conditions on matching variables of child birth month and year) 
*P-value < 0.05 
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Table 5. Duration of prenatal exposure to B2AR agonist drugs. 
Duration of Prenatal Exposure to B2AR Agonists (days) 
 Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls 
 Pregnancy Preconception 1st Trimester 2nd Trimester 3rd Trimester 
Mean 66.2 63.9 38.1 35.4 40.6 37.6 54.4 51.3 42.1 42.3 
Variance 73.6 74.3 28.9 29.3 27.3 28.5 28.4 30.0 31.9 32.2 
Mode 50.0 50.0 90.0 90.0 50.0 90.0 90.0 91.0 50.0 50.0 
Minimum 2.0 1.0 1.0 1.0 2.0 1.0 2.0 1.0 2.0 0.3 
25th percentile 15.0 15.0 10.0 10.0 15.0 13.0 32.0 25.0 15.0 15.0 
Median 50.0 50.0 34.0 27.0 41.5 30.5 54.0 48.0 31.0 34.0 
75th percentile 72.0 65.0 50.0 50.0 51.0 50.0 88.0 86.0 60.0 59.0 
Maximum 296.0 301.0 90.0 90.0 90.0 90.0 90.0 90.0 116.0 121.0 
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Table 6. Effect Estimates for Any ASD Associated with Duration of use of Prenatal Exposure to B2AR Agonists 
  Models  
Exposure Period Unadjusted ORa (95% CI) Adjusted Model 1 ORb (95% CI) Adjusted Model 2 ORc (95% CI)* 
Preconception    
1-45 days 1.2 (0.9-1.5) 1.2 (0.9-1.5) 1.2 (0.9-1.5) 
≥ 45 days *1.4 (1.0-2.0) *1.5 (1.0-2.1) *1.5 (1.1-2.1) 
First Trimester    
1-45 days 1.0 (0.7-1.4) 1.1 (0.8-1.5) 1.1 (0.8-1.5) 
≥ 45 days 1.4 (1.0-1.1) 1.3 (0.9-1.8) 1.2 (0.8-1.7) 
Second Trimester    
1-45 days 1.2 (0.9-1.7) 1.2 (0.9-1.7) 1.2 (0.9-1.6) 
≥ 45 days *1.5 (1.2-2.0) *1.5 (1.2-2.0) *1.5 (1.1-2.0) 
Third Trimester    
1-45 days *1.3 (1.0-1.7) *1.4 (1.1-1.8) *1.4 (1.1-1.8) 
≥ 45 days *1.4 (1.0-1.9) *1.4 (1.1-2.0) *1.4 (1.0-2.0) 
≥ 45 days *1.4 (1.0-1.9) *1.4 (1.1-2.0) *1.4 (1.0-2.0) 
The reference group is unexposed 
The cut point at 45 days was determined since it was median number of days in each 90-day exposure period for preconception and each trimester.  
a. Controls for matching variables of child year and month of birth through conditioning 
b. Odds ratios adjusted for parental age and sex of the child (and conditions on matching variables of child birth month and year) 
c. Odds ratios adjusted for parental age, sex of the child, history of maternal asthma (and conditions on matching variables of child birth month and year) 
*P-value < 0.05 
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Table 7. Effect estimates for any ASD associated with any prenatal exposure to B2AR restricted to mothers with asthma 
 Exposed No. (%) Models 
Exposure Period ASD Cases Controls Unadjusted OR  
(95% CI) 
Adjusted Model 1  
ORa (95% CI) 
Adjusted Model 2  
ORb (95% CI) 
Preconception  25 (37.9) 
n=66 
234 (35.5) 
n=660 
1.1 (0.7-1.9) 
 
1.2 (0.7-2.1) 
 
1.2 (0.7-2.1) 
Pregnancy  42 (50.6) 
n=83 
363 (43.7) 
n=830 
1.3 (0.8-2.1) 1.4 (0.9-2.3) 
 
1.4 (0.9-2.3) 
First Trimester 29 (41.4) 
n=70 
241 (34.4) 
n=700 
1.4 (0.8-2.3) 1.3 (0.8-2.3) 1.3 (0.8-2.2) 
Second Trimester 28 (40.6) 
n=69 
228 (33.0) 
n=690 
1.4 (0.8-2.3) 1.6 (0.9-2.7) 1.6 (0.9-2.7) 
Third Trimester 32 (43.8) 
n=73 
254 (34.8) 
n=730 
1.5 (0.9-2.5) 1.6 (0.9-2.8) 
 
1.7 (1.0-2.9) 
The reference group had no exposure during the exposure period of interest. 
a. Odds ratios were adjusted for parental age and child sex (matching on child birth month and year) 
b. Odds ratios were adjusted for parental age, child sex, maternal asthma (matching on child birth month and year) 
Maternal Asthma: ICD – 10 codes:  J45, J45.0, J45.1, J45.8, J45.9, J46, J46.9 ; ICD – 8 codes: 493.00, 493.01, 493.02, 493.08, 493.09 
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Table 8. Effect estimates for any ASD associated with any prenatal exposure to B2AR restricted to birth cohort (1998-2002) 
Exposed No. (%)    
ASD Cases  
(N = 3252) 
Controls  
(N = 32520) 
Unadjusted OR  
(95% CI) 
Adjusted Model 1  
ORa (95% CI) 
Adjusted Model 2  
ORb (95% CI) 
125 (3.3) 872 (2.7) *1.5 (1.2-1.8) *1.5 (1.2-1.8) *1.5 (1.2-1.8) 
The reference group had no exposure during the exposure period of interest. 
a. Odds ratios were adjusted for parental age and child sex (matching on child birth month and year) 
b. Odds ratios were adjusted for parental age, child sex, maternal asthma (matching on child birth month and year) 
*P-value < 0.05 
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Table 9. Effect estimates from the sensitivity analysis using Monte Carlo simulation to examine the impact of misclassification 
of any B2AR agonist exposurea in pregnancy in the register 
 
Adjusted odds ratiosb (95% confidence intervals) for prenatal exposure to B2ARs and risk for ASD  
Observed Sensitivityc Analysis 
Stratifiedb Stratifiedb Full Samplea 
(n = 57,200) Asthma  
(n=756) 
No Asthma 
(n=56,4444) 
Full Samplea  
(n = 57,200) Asthma  
(ñ=1,176) 
No Asthma 
(ñ=56,444) 
1.3 (1.1-1.5) 1.3 (0.8-2.0) 1.2 (1.1-1.5) 1.3 (1.1-1-5) 1.2 (0.8-1.8) 1.2 (1.0-1.4) 
a. Reference group is no exposure during pregnancy  
b.  Odds ratios adjusted for child birth year and month, parental age, and sex of the child. Models using observed 
data are conditional logistic regressions conditioning on the matching variables (child birth year and month) 
and adjusting for other covariates while models in simulation were unconditional logistic regressions models 
adjusting for all variables as covariates.    
c.  Simulations increase prevalence of B2AR agonist drug use in register from 3% to 4% non differential with 
respect to outcome (1.38% unexposed cases; 1.07% unexposed controls were reclassified being exposed).  
This assumes that overall B2AR agonist sensitivity was 73%, was non-differential across cases and controls, 
and that asthma specificity was 100%. 
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Table 10. Effect estimates from the sensitivity analysis using Monte Carlo simulation to examine the impact of 
misclassification of asthma in the register. 
 
Adjusted odds ratiosb (95% confidence intervals) for prenatal exposure to B2ARs and risk for ASD  
Observed Sensitivityc Analysis 
Stratifiedb Stratifiedb Full Samplea 
(n = 57,200) Asthma  
(n=756) 
No Asthma 
(n=56,4444) 
Full Samplea  
(n = 57,200) Asthma  
(ñ=1,178) 
No Asthma 
(ñ=56,022) 
1.3 (1.1-1.5) 1.3 (0.8-2.0) 1.2 (1.1-1.5) 1.2 (1.1-1.5) 1.2 (0.8-1.8) 1.2 (1.0-1.5) 
a. Reference group is no B2AR agonist exposure during pregnancy  
b.  Odds ratios adjusted for child birth year and month, parental age, and sex of the child. Models using observed 
data are conditional logistic regressions conditioning on the matching variables (child birth year and month) 
and adjusting for other covariates while models in simulation were unconditional logistic regressions models 
adjusting for all variables as covariates.    
c.  Simulations increase prevalence of maternal asthma in register from 1.3% to 2% non differential with respect 
to outcome (1.38% unexposed cases; 1.07% unexposed controls were reclassified being exposed).  This 
assumes that overall asthma sensitivity was 66%, was non-differential across cases and controls, and that 
asthma specificity was 100%. 
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CHAPTER 4: IN UTERO EXPOSURE TO SELECTIVE SEROTONIN 
REUPTAKE INHIBITORS AND RISK FOR AUTISM SPECTRUM DISORDERS 
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Abstract 
Objective: The objective of this study was to investigate associations between a 
commonly used antidepressant, selective serotonin reuptake inhibitors (SSRIs), that is 
prescribed during pregnancy and risk for autism spectrum disorders (ASD).  
Method: We performed a case-control study of children born in Denmark between 1997 
and 2006. Linkages using Denmark’s health and population registers were performed to 
obtain information regarding prescription drugs used, ASD diagnosis and health and 
socioeconomic status. Separate analyses were performed to take into account the 
independent effect of maternal depression and to assess the potential for under-reporting 
in the register.   
Results: Estimates were calculated for any exposure during pregnancy, exposure by 
trimester, and preconception exposure.  In conditional logistic regression models adjusted 
for parental age and sex of the child, any exposure to SSRIs during pregnancy was 
associated with ASD (odds ratio (OR) 2.0 [95% confidence interval CI, 1.6-2.6]) 
compared to the unexposed reference group. Similar estimates were found during other 
specific exposure periods of interest.  Statistical adjustment for maternal depression to 
control for confounding by indication did not substantively change effect estimates 
(adjusted OR for any in pregnancy exposure was 1.9 [95% CI, 1.5-2.5]).   Although 
analyses restricted to only mothers with a history of depression resulted in attenuated 
SSRI effect estimates, when Monte Carlo simulations were used to gauge the impact of 
under-reporting of maternal depression in the register, results suggested that the 
independent SSRI effect persists.  
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Conclusion: We found evidence supporting the hypothesis that in utero exposure to 
SSRIs is associated with a child’s risk for ASD.  Confounding by indication remains a 
concern and, although we attempted to control for this as best as possible.  Additional 
studies should explore this alternative hypothesis further as well as attempt to understand 
the persistence of the association across the preconception and prenatal periods.  Results 
from this study add to the limited knowledge on prenatal pharmacological exposures as 
potential ASD risk factors; yet emerging evidence of this nature needs to be balanced 
against the benefits of indicated medication use by pregnant mothers. 
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Introduction 
Autism spectrum disorders (ASDs) are a complex group of neurodevelopment 
disabilities defined by core deficits in three domains: social interaction, communication, 
and repetitive or stereotypic behavior [1]. This disorder represents a significant public 
health concern, with a current US prevalence of 11.3 per 1,000 [2]. Although ASD has 
moderate to high heritability [3] several reviews of autism genetics have suggested the 
possibility for an interaction between genetic mechanisms and environmental exposures 
in autism etiology [4, 5].  A large population-based twin study recently conducted by 
Hallmayer et al, found a dizygotic twin concordance rate higher than previously reported 
[6] and at a level substantially larger than the non-twin sibling recurrence risk (18.7%) 
[7].  This implicates the prenatal period, when twins’ environments are shared more so 
than those of non-twin siblings, as a critical period of life with respect to environmental 
influences.   
Selective serotonin reuptake inhibitors (SSRIs), such as many antidepressants, are 
among the most commonly used medications in pregnancy, with prescription frequency 
estimates ranging from 5% to 13% in pregnant US women [8-10].   SSRIs cross the 
placenta, thus exposing the developing fetus [11].  There is accumulating evidence that 
mothers treated with SSRIs during pregnancy may experience increased rates of adverse 
reproductive outcomes including atrium septum defects [12, 13] preterm delivery, a low 
Apgar score, and more complications resulting in intensive care unit admissions [14].  
 A recent case-control study conducted within the Kaiser Permanente Medical 
Care Program in Northern California reported an ASD odds ratio (OR) associated with 
any prenatal SSRI use of 2.2 (95% confidence interval (CI) 1.4, 2.3) [15].  The largest 
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effect was due to use in the first trimester, though confidence intervals on trimester-
specific effects were very wide, and an effect was also observed for exposure during the 
preconception period [15].    
Associations between maternal depression, the chief indicating condition for SSRI 
use, and developmental psychopathology in children have been widely reported [16-20].  
Diagnosis for psychiatric disorders before the birth of the child have been more 
commonly reported among parents of children with ASD than parents of children without 
a diagnosis of ASD, with the condition-specific ORs for depression stronger for mothers 
than fathers [21].  Consequently, it may be challenging to separate the effect of SSRI use 
from other effects of maternal depression (e.g., shared genetic predisposition, altered 
intrauterine environment, or downstream effects of parenting).  To address the analytic 
concerns about treatment versus underlying condition for which the treatment was 
prescribed, Croen et al 2011 statistically adjusted for maternal depression and a broader 
range of maternal psychiatric disorders in their models assessing exposure to SSRIs 
during pregnancy and risk for ASD [15].    This resulted in SSRI exposure during the first 
trimester to remain significantly associated with risk of ASD, as was a history of SSRI 
exposure anytime during the year before delivery [15].  In addition, they still observed an 
association after conducting a restriction analysis to a subgroup of women with a history 
of mental health disorder in the year before delivery, although confidence intervals were 
wide (OR, 1.6 [95% CI, 0.6-4.0]) [15].  
To follow-up on this report, we conducted a population register-based case-
control study of maternal prenatal SSRI use and risk of ASD.  The study sample was 
drawn from the Danish national health registers, which allowed for a sufficient numbers 
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of exposed mothers even though prenatal SSRI use may be lower in Nordic countries 
compared to the US [22].  We considered a variety of factors that might be associated 
with either SSRIs or ASD, including the sex of the child, perinatal risk factors for ASD, 
and family factors such as parental education and income, as potential confounders.   In 
addition, several sensitivity analyses were used to address the issues of confounding by 
indication and explore the impact of covariate misclassification. 
 
Methods 
Eligible Participants 
All children (n = 749,755) born in Denmark in the period from January 1, 1997 to 
December 31, 2006 were identified through the Danish Civil Register System (DCRS).  
The study population was then drawn from all biological singletons and one child 
randomly selected from multiple births.   Children were also excluded if they could not 
be linked to their biological mother (n = 1,139), if their mother was not living in 
Denmark a year before delivery (n = 10,806), or if they were born extremely preterm or 
post-term (gestational ages less than 23 weeks or greater than 43 weeks, n = 1,774).  
There were a total of 628,408 in the study population.   
 
Case and control definitions 
ASD diagnoses are based on data from the Danish National Hospital Register 
(DNHR) supplemented by data from the Danish Psychiatric Central Register (DPCR). 
These sources include information on all inpatient and outpatient care from psychiatric 
hospitals and psychiatric wards in general hospitals in Denmark.  General practitioners or 
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school psychologists refer children who are suspected of having ASD to a child 
psychiatric ward where they can receive a diagnosis and both inpatient and outpatient 
treatment.  The quality of the diagnosis of childhood autism in the Denmark registers has 
recently been investigated through a validation study that conducted detailed abstraction 
of the children’s medical records that were reviewed by autism experts.  Register 
diagnosis of childhood autism was confirmed 94% of the time with an additional 3% 
falling within the autism spectrum [23]. 
 Subjects’ DNHR and DCPR record’s from January 1, 1999 to March 31, 2011 
were searched for International Classification of Diseases codes (ICD-10) of: F840, 
F841, F845, F848, and F849 (childhood autism, atypical autism, Asperger’s syndrome 
and pervasive developmental disorder-unspecified, respectively).  Subjects were 
considered a case if any of these codes were present.    
Controls were defined as never having register evidence of any of these ASD 
diagnostic codes.  Ten controls per case were individually matched on birth month and 
year.  Matching on birth month and year assured that controls have the same length of 
follow-up time as a case, and thus the same opportunity to acquire an ASD diagnosis and 
be entered in the register.   Matching on birth month also controlled for birth seasonality, 
though this was not anticipated to be a strong confounder.   
 
Exposure definition 
Pharmacologic exposure information was drawn from the Danish Drug 
Prescription Register (DDPR).  The DDPR contains data on all dispensed medication 
from any pharmacy, except hospitals’ dispensaries, in Denmark.   Information extracted 
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included number of packets dispensed, dispense date, drug code using the WHO 
Anatomical Therapeutic Chemical classification system (ATC), name of drug, number of 
units in the container, strength of the drug, and defined daily dosage (DDD).  The drug 
codes included in the analyses are list in (see Table A in the Appendix for medication 
codes).   The DDPR includes ATC and DDD codes for the expressed purpose of 
facilitating drug utilization research [24] and these coding schemes have been employed 
in a variety of studies [25-28].  
Data for each subject were assembled for the three months prior to estimated-
date-of-conception (EDC) to birth.  EDC was estimated from the Danish Medical Birth 
Register (DMBR), which calculates EDC base on mother’s self-reported last menstrual 
period but corrects with an early ultrasound estimate if the woman reported contraceptive 
use in the four months prior to conception, had irregular periods, or an abnormal last 
menstrual period.   Exposure windows were defined as preconception (90 days prior to 
EDC), first trimester (within 90 days after EDC), second trimester (within 90-180 days 
after EDC), and third trimester (180 days after EDC to delivery date).  A child was 
considered exposed during any window if the dispense date fell within the specified 
exposure period or the number of days supplied overlapped any portion of the time 
period.  
To calculate the cumulative dose dispensed during a particular exposure window, 
we first calculated the prescribed dose by multiplying the strength of the medication by 
the number of units in the container to give the total dose in the package, which was then 
divided by the number of DDD in the package.   The cumulative dose over each exposure 
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period of interest was divided into quartiles (low, medium, medium-high, and high) based 
on the distribution in the exposed controls.  
To calculate duration of use for each prescription, the number of packets 
dispensed was multiplied by the DDD in the package.  Duration was dichotomized into 
two categories representing use for more or less than half (0-45 days and ≥45 days) in 
each exposure window.   The reference group for estimating associations of dose and 
duration of use was no exposure during any period of interest. 
 
Covariates  
Candidate covariates include parental age, parental psychiatric history, gestational 
age, birth weight, parental history of autoimmune disease, maternal infection during 
pregnancy, number of live births, obstetric complications, and family socioeconomic 
status (a combination of parental income and highest level of education).  These were 
identified from available data in Danish Fertility Database, DMBR, and DNHR.  These 
covariates were chosen a priori because they are potential risk factors for ASD [21, 29-
35].  Family socioeconomic status was measured as a sum of father’s educational level, 
mother’s educational level, father income, and mother income. Education for each parent 
was categorized and scored from 1-3 and income from 1-4. Each parent’s socioeconomic 
status was a summation of income and education scores, and family socioeconomic status 
a sum of the mother and father’s scores (score ranges from 1-14).   
Maternal psychiatric history prior to delivery was obtained by searching DCPR 
records (available back through 1973).   Psychiatric conditions that are indicators for 
SSRI use were given special consideration.   One variable was created for history of 
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maternal depression, the principal indication for SSRI use, and another for the presence 
of any other indication, including anxiety, obsessive-compulsive disorder, phobia, 
adjustment disorder and schizophrenia in the register.  DCPR records from 1973-1993 
used ICD-8 codes with ICD-10 codes used thereafter (appendix Table Y lists specific 
codes). 
 
Analytic method 
 Conditional logistic regression analysis was conducted to estimate unadjusted and 
adjusted associations with no SSRI exposure during any period of interest as the 
reference group.   Parental age and sex of the child were forced in all adjusted models as 
covariates.  Other covariates were included only if they resulted in a 10% or greater 
change in unadjusted log odds ratios when added individually. To guard against joint 
confounding, any excluded covariate was added back to the adjusted model and retained 
if the log odds ratios changed by 10%.   Additional adjustment for maternal depression 
and the term for other conditions associated with SSRI use was conducted to control for 
confounding by indication.  To further consider confounding by indication, we also 
examined the SSRI effect in two restricted samples: mothers with a depression history 
and mothers with a history of either depression or other psychiatric conditions potentially 
indicating SSRI use. 
 
Additional Sensitivity Analyses  
A number of other sensitivity analyses were also conducted.   First, we used 
simulation analyses to explore the effects of under-reporting of SSRI use and depression 
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in the register.  For each simulation, a Monte Carlo approach was used simulating 1,000 
datasets to randomly assign an unexposed mother to being exposed from a normal 
distribution.  From each of the 1,000 simulated datasets we obtained the OR and then 
took 1,000 samples from each OR normal distribution.  We then took the median effect 
estimate from these 1,000,000 samples as the OR and the 2.5% and 97.5% percentile to 
estimate the 95% confidence interval.  Models used in the simulations were unconditional 
logistic regressions adjusting for the matching variables as covariates.  
 Because the observed SSRI exposure prevalence (0.7%) was below published 
estimates for other Nordic countries [22] we completed simulations increasing the 
observed prevalence of SSRI exposure from 0.7% to 3%.  We assumed under-reporting 
was non-differential with respect to outcome by keeping sensitivity and specificity equal 
in case and control groups.   Specificity was assumed to be 100%, because it is unlikely a 
prescription for an SSRI would be documented in the register when none was given, and 
sensitivity was assumed to be 26% because that corresponds to a true SSRI use 
prevalence of 3%. 
Simulations also examined the impact of under-ascertainment of maternal 
depression (which would lead to incomplete control for confounding by indication) 
because published estimates of the prevalence of maternal depression during pregnancy 
in Europe range from 3-17% [14, 36-38] - higher than our observed prevalence of 0.6%.   
Simulations were done increasing maternal depression prevalence to 5% and then 15%.  
Maternal depression under-reporting was assumed to be non-differential with respect to 
ASD case status because depression is assessed prior to the birth of the child and, thus, 
could not be influenced by subsequent diagnosis of the offspring.   Specificity was 
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assumed to be 100%; in other words, all mothers truly without a history of depression 
where assumed to be correctly classified as without depression in the register, and 
sensitivity was set to 4.7% to reflect the under-reporting needed where the true 
depression prevalence of 15%.    
In addition, since outpatient data were added to the DCPR in 1993, we wanted to 
ensure that our estimates were not influenced by this change.  Consequently, we re-
analyzed data limited to the birth cohort born between 1998 and 2002 whose outcome 
definitions were based on both inpatient and outpatient data.  Because some time was 
likely needed for any impact of the inclusion of outpatient data to be felt, we chose to 
restrict the birth cohort at 1998 rather than 1993.  Then, finally, we also compared effect 
estimates based on different criteria for considering an individual as exposed during a 
specific window.  In principal analyses, exposure within a window (e.g., first trimester) 
was defined as any SSRI use during that window regardless of whether SSRIs were also 
used in other windows. In our sensitivity analyses we considered an alternate definition 
where only individuals with medication use exclusively during that window were 
considered exposed. 
 
Results 
 
Description of Study Sample 
There are 5215 children diagnosed with ASD and 52150 controls included in the 
study sample for analyses for exposure anytime during pregnancy.  Children with ASD 
were more likely than controls to be male, have older parents, and have a mother with a 
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diagnosis for depression before to the birth of the child (Table 1).  In the source 
population, which consisted of all live births from January 1996 to December 2006 the 
frequency of any ASD was 0.86%.  For each of the exposure periods examined, similar 
patterns in descriptive statistics across case and control groups were observed (Table 1).   
In each exposure period of interest, cases had a higher frequency of SSRI 
exposure compared to controls.  For example, during the entire pregnancy period 1.5% (n 
= 76) of cases compared to 0.7% (n = 356) were exposed to SSRIs in utero.  In addition, 
the highest exposure frequency occurred during the preconception period with 1.7% (n = 
89) cases and 0.8% (n = 413) controls exposed. 
 
Associations of any SSRI use with ASD 
Table 2 presents conditional logistic regression results for dichotomous SSRI 
exposure in various exposure windows.  Inclusion of no additional covariates changed the 
log odds ratios 10% or more in any model.  Consequently, the four models presented for 
each exposure period of interest are a base model that includes only covariates for the 
matching variables (unadjusted Model), a model that adjusts additionally for parental age 
and sex of the child (Adjusted Model 1), a model that includes additional adjustment for 
indication of maternal depression (Adjusted Model 2), and a model that adjusts for 
parental age, sex of the child, and the presence of the broader range of SSRI indicating 
conditions (Adjusted Model 3).  
Table 2 shows results for any SSRI exposure in the various exposure windows of 
interest for any ASD.  Measures of association consistently suggest approximately 
doubling of risk for any ASD regardless of exposure window.   The adjusted odds ratio of 
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any ASD for any SSRI exposure during pregnancy was 2.0 [95% CI, 1.6-2.6]).  Effect 
estimate and confidence interval widths do not change dramatically with adjustment for 
other covariates.  For example, the largest SSRI exposure effect estimates were seen for 
third trimester exposure was 3.1 (95% CI 2.2-4.5) and parental age and child gender-
adjusted effect estimates were 3.1 (95% CI 2.1-4.5).   Further adjustment for maternal 
depression or any SSRI indication reduced OR estimates to 2.7 (95% CI 1.8-4.0) and 2.5 
(95% CI 1.7-3.7), respectively.   Adjustment for the broader range of SSRI indications 
resulted in only slight additional attenuation of effect estimates.   
 
Analyses of SSRI duration and dose of use      
As shown in Table 3, case median duration of use during pregnancy was 119 
days, which was higher than that for controls (75 days).  Table 4 presents logistic 
regression results for exposure duration.  The models presented adjust for the same 
covariates as described above for any exposure since the addition of covariates in these 
models, similarly, did not change duration effect estimates appreciably.   As shown, SSRI 
use longer than 45 days, in each exposure window except for the third trimester, 
regardless of exposure period, resulted in slightly higher odds ratios than exposure of 45 
days or less compared to the unexposed reference group.  In the adjusted model 3 
exposure to SSRIs during the first trimester for less than 45 days resulted in an odds ratio 
of 1.6 (95% CI 1.0-2.6), while exposure greater than or equal to 45 days had an odds ratio 
of 2.4 (95% CI 1.7-3.3) compared to children who were unexposed.  No duration 
response was suggested for third trimester exposure.  In these same models, exposure to 
SSRIs during the third trimester for less than 45 days had an odds ratio of 2.9 (95% CI 
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1.2-6.9), which was similar to exposure for greater than or equal to 45 days (OR 2.9; 95% 
CI 1.9-4.4), both compared to those in the unexposed reference group. 
As shown in Table 5, the median cumulative dose for cases over the entire 
pregnancy period was 2710.0 mg, which was higher than controls (2000.0 mg).  Overall, 
cases had a higher median cumulative dose than controls in each exposure period. Table 
6 show logistic regression results for dose. Adjusted models are parameterized similarly 
to those for any exposure and exposure duration because the introduction of additional 
covariates did not change dose effect estimates.  The highest dose categories tended to 
have slightly higher effect estimates in comparison to the unexposed reference than did 
lower dose categories; the exception being for first trimester exposure.   
To further explore confounding by indication, logistic regression models were 
refit to datasets including, first, only mothers with a diagnosis of depression, and then 
only mothers with depression and other psychiatric conditions associated with SSRI use 
listed above in the methods before the birth of the child.  In both these restricted samples, 
the SSRI effect estimates were close to the null, but had broad confidence intervals 
(Tables 8 and 9).  In the sample of mothers with a history of depression, models adjusting 
for parental age and sex of the child resulted in an odds ratio of 0.9 (95% CI 0.4-1.8) for 
exposure during the pregnancy period compared to those who were unexposed.  Odds 
ratio estimates for the mothers without SSRI indications where close to the estimates 
reported for the full data sets (data not shown).   
 
Additional sensitivity analysis 
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Table 9 shows the results from simulation analyses exploring the influence of 
misclassification.    The first row presents effect estimates and confidence bounds for any 
prenatal SSRI exposure from simulations assuming increased SSRI prevalence and non-
differential misclassification as described above.   Estimates for the full sample were very 
close to the comparable (Model 1) adjusted estimate in Tables 2, suggesting that exposure 
misclassification is unlikely to have strongly influenced results.     The following rows 
show results from simulations investigating the potential effects of non-differential 
under-reporting of maternal depression.   By increasing the assumed depression 
prevalence to 5%, the pooled effect estimate, 2.2 (95% CI 1.9-2.4), is extremely close to 
the comparable (Model 1) estimates shown in Table 2.  At 15% assumed depression 
prevalence, the SSRI effect is only moderately attenuated.   Under the assumed 15% 
depression prevalence scenario we also estimated depression-stratified effects.   A 
positive association was observed in both strata, though the effect was smaller among 
mothers with depression, with median adjusted odds ratios and confidence intervals of 
1.4 (95% CI 0.9-2.4) and 2.1 (1.5-3.0), respectively.   These results suggest that the 
original restriction approach to controlling for confounding by indication may have been 
influenced by depression misclassification. 
 Analysis restricting the birth cohort to those born between 1998 and 2002 yielded 
effect estimates comparable to those observed using our full sample (Table 10).  In the 
sensitivity analysis estimating trimester-specific effects based on considering only those 
with exclusive medication use in the trimester window as exposed results were 
comparable to those shown in Table 2 with similar magnitude effect estimates and 95% 
confidence intervals having substantial overlap (data not shown). 
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Discussion 
In a large population-based case-control study we observed an increased risk of 
ASD associated with in utero exposure to SSRIs.  The effect was present in all exposure 
windows considered and persisted after adjustment for SSRI indications.   Results from 
Croen et al 2011 also observed the same general level of elevated effect estimates in each 
exposure period, which remained even after statistical adjustment for maternal depression 
[15].  They did report the strongest effect associated with exposure during the first 
trimester (adjusted OR, 3.8 [95% CI, 1.8-7.8]), however the confidence intervals of 
trimester-specific estimates overlapped considerably [15].  Unlike Croen et al 2011, we 
were able to also explore prenatal dose and duration of use and risk for ASD and we did 
observe larger effect estimates in the highest dose or duration categories, but these dose 
and duration response effects were not linear, nor particularly strong.  
Adequate control of confounding by indication in treatment effectiveness studies 
is often a concern, and poses a particular challenge in studying the effects of prenatal 
SSRI use on ASD risk.  Due to our large sample, in addition to adjusting for the 
indication, we were also able to conduct analyses stratified by the indication and to 
consider the impact of confounder misclassification.   Analyses adjusting for the 
indication still suggested that there was an independent effect of prenatal SSRI use.  Yet, 
our initial analyses restricted to women with register data indicating a depression 
diagnosis resulted in an attenuation of the prenatal SSRI effect, supporting the idea that 
confounding by indication drives the association.  However, because there were only 55 
cases (just 11 exposed) and 109 exposed controls in this analysis restricted to mothers 
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with a register diagnosis for depression, the effect estimates here were imprecise.   In 
addition, the pooled (adjusted) estimate is dominated by the data in the much larger strata 
without maternal depression indication (where the effect was similar to the unadjusted 
estimate) and the estimate in the strata with maternal depression indication is subject to 
substantive random fluctuation.  
More importantly, these analyses do not consider what may be fairly substantive 
misclassification of maternal depression.  The impact of under-ascertainment of maternal 
depression, would lead to incomplete control for confounding by indication. Published 
literature indicates a higher rate of maternal depression in other Nordic countries 
compared to what we observed in our dataset [14, 22, 36-38] suggesting that depression 
misclassification may be nontrivial.    Our simulation analyses considered the potential 
impact of this misclassification and the results suggested that prenatal SSRI effect might 
indeed persist. independent of indication.  Furthermore, the attenuation observed in the 
initial stratified analysis that did not consider confounder misclassification maybe a result 
of imprecision.   
There are a number of biologically plausible explanations for our findings of an 
association between prenatal SSRI exposure and ASD, which investigate the role of the 
serotoninergic pathways during development [39-42]. Abnormalities in serotonin 
metabolism are one of the few consistent biological observations associated with ASD 
[39] and several lines of evidence suggest that alterations in the serotonergic 
neurotransmitter system might be a mechanistic pathway leading to ASD.  For example, 
serotonin (5-hydroxytryptamine, 5HT) has been shown to play an important role in brain 
development by regulating both serotonergic outgrowth and maturation of target regions 
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[40, 43]. Elevated levels of serotonin in the blood (5-hydroxytryptamine, 5-HT) have 
been reported in patients with ASD [40].  In addition, animal models have suggested 
adverse neurodevelopmental outcomes in the offspring associated with prenatal SSRI 
exposure [44].  Chronic neonatal exposure to SSRIs in male offspring of timed-pregnant 
Long Evans rats resulted in reduced serotonin expression that persists into adulthood, 
which produces changes in the normal maturation of the serotonin system in the brain 
[45].  Rats exposed to SSRIs during the prenatal period had neuroautomic alterations in 
somatosensory structures [44], as well as elevated serotonin levels and receptor binding 
site levels [46].  Together these findings suggest that mechanistically, prenatal exposure 
to SSRIs may operate directly on the brain as it develops. 
Our study had a number of potential limitations related to information bias.  
Register case definition may be imperfect, although recent validation study efforts are 
encouraging [23].  There was also the possibility of exposure and confounder 
misclassification.  In measuring prenatal SSRI use, we had to assume that all the drugs 
from prescriptions were actually taken and we were unable to capture data on any SSRIs 
that may have been prescribed during hospital admissions, though in-hospital prescription 
is infrequent compared to outpatient prescription.  Further, maternal depression, a critical 
SSRI indication appears to be underreported in the register.  However, we were able to 
simulate the impact of misclassification of both the exposure and this important 
confounder and these analyses suggested that the SSRI effect persisted.  
 Our analysis benefited considerably from a large study population and available 
data on pharmacologic exposure reported prospectively to the register.   As the Danish 
registers are population-based, selection bias is not anticipated to be a major limitation in 
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these analyses. The prevalence of prenatal SSRI use in our data is rather low (0.7%) 
which at the observed effect size implies that population attributable risks associated with 
this exposure will be fairly small.  With an exposure prevalence of 0.7% and an odds 
ratio of 1.9, the population attributable risk is only 0.6%.    However, if this effect is real, 
this does suggest that serotonin-mediated biological pathways may be involved in at least 
some cases of ASD and would suggest further exploration of these pathways, which 
might reveal other modifiable factors other than prenatal SSRI exposure.   For example, a 
recent animal model study has suggested that the prenatal stress and certain serotonin 
transporter genotypes may have the combined effect of producing changes in social 
interaction and social interest in the offspring consistent with those observed in 
individuals with ASD [47]. 
The implications of reported associations between prenatal SSRI use and ASD 
risk need to be weighed against the evidence on health consequences of discontinuation 
of SSRI treatment.  Direct associations between depression and developmental 
psychopathology have been hypothesized as operating through mechanisms involving the 
changing intrauterine environment or maternal stress response.  Maternal hypothalamo–
pituitary–adrenal (HPA) activity in response to psychological stress, which can be caused 
by depression, has been linked to reduced birth weight [48] and adverse 
neurodevelopmental effects [49].  There has also been evidence suggesting that 
depressive mood during pregnancy may be associated with restricted fetal growth [50].   
A recent study found that 68% of the women who discontinued antidepressant treatment 
during pregnancy relapsed in depression, with 50% experiencing recurrence of 
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depression in the first trimester of pregnancy and 90% by the end of the second trimester 
[51].  
In light of this, the epidemiologic evidence from this and other studies of SSRI 
and ASD risk should still be cautiously interpreted.  Further epidemiologic investigation 
of the association between prenatal SSRI use and ASD risk is warranted, especially in 
studies capitalizing on large registers or databases and involving more heterogenous 
populations.  These studies must explicitly account for confounding by indication and, as 
demonstrated here, it will likely be important also to consider misclassification of both 
the exposure and the indication. 
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TABLES 
Table 1. Study demographics for SSRI analysis 
 Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls 
 Pregnancy Preconception 1st Trimester 2nd Trimester 3rd Trimester 
No. (%) 5215 (9.1) 52150 (90.9) 5228 (9.1) 52280 (90.9) 5210 (9.1) 52100 (90.9) 5183 (9.1) 51830 (90.9) 5178 (9.1) 51780 (90.9) 
Maternal age           
≤25 years 819 (15.7) 7319 (14.1) 818 (15.6) 7445 (14.2) 817 (15.7) 7312 (14.1) 814 (15.7) 7324 (14.2) 813 (15.7) 7320 (14.1) 
26-30 1754 (33.6) 18802 (36.1) 1757 (33.6) 18713 (35.8) 1751 (33.6) 18897 (36.3) 1744 (33.7) 18731 (36.0) 1744 (33.7) 18732 (36.2) 
31-35 1739 (33.4) 18160 (34.4) 1748 (33.4) 18036 (34.7) 1738 (33.4) 17844 (34.3) 1729 (33.4) 17970 (35.0) 1728 (33.4) 17890 (34.6) 
≥36 903 (17.3) 7869 (15.3) 905 (17.3) 7896 (15.3) 903 (17.3) 8047 (15.6) 896 (17.3) 7805 (15.1) 893 (17.3) 7856 (15.2) 
Paternal age           
≤29 years 1276 (24.5) 12707 (24.4) 1275 (24.4) 12938 (24.8) 1274 (24.5) 12878 (24.7) 1269 (24.5) 12979 (25.0) 1267 (24.5) 12653 (24.4) 
29-39 2672 (51.2) 28464 (54.6) 2684 (51.3) 28293 (54.1) 2670 (51.3) 28100 (53.9) 2658 (51.3) 27848 (53.7) 2656 (51.3) 28133 (54.3) 
40-49 531 (10.2) 4266 (8.2) 532 (10.2) 4279 (8.2) 530 (10.2) 4305 (8.3) 527 (10.2) 4201 (8.1) 526 (10.2) 4330 (8.4) 
50-54 37 (0.7) 263 (0.5) 37 (0.7) 246 (0.5) 37 (0.7) 284 (0.6) 37 (0.7) 243 (0.5) 37 (0.7) 249 (0.5) 
≥ 55  20 (0.4) 116 (0.2) 20 (0.4) 119 (0.2) 20 (0.4) 123 (0.2) 20 (0.4) 147 (0.3) 20 (0.4) 101 (0.2) 
Missing 679 (13.0) 6334 (12.1) 680 (13.0) 6405 (12.2) 679 (13.0) 6410 (12.3) 672 (13.0) 6412 (12.4) 672 (13.0) 6314 (12.1) 
Child sex           
Boys 4278 (82.0) 26522 (50.9) 4288 (82.0) 26523 (50.7) 4273 (82.0) 26524 (50.9) 4254 (82.1) 26689 (51.5) 4250 (82.1) 26325 (50.8) 
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Table 1 (continued). Study demographics for SSRI analysis (continued) 
 Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls 
 Pregnancy Preconception 1st Trimester 2nd Trimester 3rd Trimester 
No. (%) 5215 (9.1) 52150 (90.9) 5228 (9.1) 52280 (90.9) 5210 (9.1) 52100 (90.9) 5183 (9.1) 51830 (90.9) 5178 (9.1) 51780 (90.9) 
Maternal 
Depression 
          
Yes 55 (1.1) 347 (0.7) 53 (1.0) 277 (0.5) 51 (1.0) 298 (0.6) 49 (1.0) 268 (0.5) 51 (1.0) 250 (0.5) 
Other SSRI 
Indications 
          
Yes 108 (2.1) 618 (1.2) 110 (2.1) 633 (1.2) 107 (2.1) 674 (1.3) 103 (2.0) 630 (1.2) 102 (2.0) 565 (1.1) 
Paternal 
history of 
psychiatric 
disorder by 
rank 
          
Rank 1 25 (0.5) 130 (0.3) 25 (0.5) 138 (0.3) 25 (0.5) 157 (0.3) 23 (0.4) 134 (0.3) 23 (0.4) 134 (0.3) 
Rank 2 22 (0.4) 158 (0.3) 22 (0.4) 159 (0.3) 22 (0.4) 167 (0.3) 21 (0.5) 135 (0.3) 21 (0.4) 156 (0.3) 
Rank 3 26 (0.5) 210 (0.3) 26 (0.5) 192 (0.4) 26 (0.5) 227 (0.4) 26 (0.5) 197 (0.4) 26 (0.5) 198 (0.4) 
Rank 4 139 (2.7) 764 (1.6) 143 (2.7) 805 (1.5) 139 (2.7) 777 (1.5) 139 (2.7) 782 (1.5) 139 (2.7) 835 (1.4) 
No disorder 5003 (95.9) 50888 (97.5) 5012 (95.9) 50986 (97.5) 4998 (95.9) 50772 (97.5) 4974 (96.0) 50582 (97.6) 4969 (96.0) 50457 (97.4) 
Maternal 
history of 
psychiatric 
disorder by 
rank 
          
Rank 1 14 (0.3) 84 (0.2) 15 (0.3) 76 (0.2) 14 (0.3) 60 (0.2) 13 (0.3) 80 (0.1) 13 (0.3) 60 (0.1) 
Rank 2 23 (0.4) 108 (0.2) 22 (0.4) 104 (0.2) 22 (0.4) 97 (0.2) 20 (0.4) 84 (0.2) 22 (0.4) 78 (0.2) 
Rank 3 13 (0.3) 72 (0.2) 13 (0.3) 81 (0.2) 13 (0.3) 81 (0.1) 13 (0.3) 61 (0.1) 13 (0.3) 73 (0.1) 
Rank 4 123 (2.4) 716 (1.3) 126 (2.4) 749 (1.4) 123 (2.4) 679 (1.4) 120 (2.3) 697 (1.3) 119 (2.3) 695 (1.3) 
No disorder 5042 (96.7) 51170 (98.1) 5052 (96.6) 51270 (98.1) 5038 (96.7) 51183 (98.2) 5016 (96.8) 50908 (98.2) 5011 (96.7) 50875 (98.2) 
Family SES           
Low 834 (16.0) 6474 (12.5) 835 (16.0) 6539 (12.5) 833 (16.0) 6683 (12.8) 824 (15.9) 6523 (12.6) 821 (15.8) 6690 (12.9) 
Medium 2724 (52.2) 26558 (50.6) 2727 (52.2) 26677 (51.0) 2720 (52.2) 26317 (50.5) 2706 (52.2) 26323 (50.8) 2704 (52.2) 25937 (50.1) 
High 1657 (31.8) 19109 (36.5) 1666 (31.9) 19055 (36.5) 1657 (31.8) 19088 (36.6) 1653 (31.9) 18974 (36.6) 1653 (31.9) 19145 (37.0) 
Missing 0 (0.0) 9 (0.0) 0 (0.0) 9 (0.0) 0 (0.0) 12 (0.0) 0 (0.0) 10 (0.0) 0 (0.0) 8 (0.0) 
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Table 2. Effect estimates for prenatal SSRI exposure and risk for ASD. 
  Exposed No. (%)  
Outcome  # Cases Exposure Period Cases Controls Unadjusted 
ORa 
(95% CI) 
Adjusted 
Model 1 ORb 
(95% CI) 
Adjusted 
Model 2 ORc 
(95% CI) 
Adjusted 
Model 3 OR6 
(95% CI) 
Any ASD         
 5228 Preconception 89 (1.7) 413 (0.8) *2.2 (1.7-2.8) *2.1 (1.6-2.6) *1.9 (1.5-2.4) *1.8 (1.4-2.3) 
 5215 Pregnancy 76 (1.5) 365 (0.7) *2.2 (1.6-2.7) *2.0 (1.6-2.6) *1.9 (1.5-2.5) *1.8 (1.4-2.3) 
 5210 First Trimester 71 (1.4) 309 (0.6) *2.3 (1.8-3.0) *2.2 (1.7-2.9) *2.0 (1.6-2.7)  *2.0 (1.5-2.6) 
 5183 Second Trimester 44  (0.9) 183 (0.4) *2.4 (1.7-3.4) *2.4 (1.7-3.4) *2.3 (1.6-3.2)  *2.1 (1.5-3.0) 
 5178 Third Trimester 39 (0.8) 127 (0.3) *3.1 (2.2-4.5) *3.1 (2.1-4.5) *2.7 (1.8-4.0) *2.5 (1.7-3.7) 
Abbreviations: Autism spectrum disorders (ASD); Odds ratio (OR); Confidence Intervals (CI) 
Reference: No exposure during any exposure period 
a. Controls for matching variables of child year and month of birth through conditioning 
b. Odds ratios adjusted for parental age and sex of the child (and conditions on matching variables of child birth month and year) 
c. Odds ratios adjusted for parental age, sex of the child, history of maternal depression (and conditions on matching variables of child birth month and 
year) 
d. Odds ratios adjusted for parental age, sex of the child, history of maternal depression, other SSRI indications (and conditions on matching variables of 
child birth month and year) 
*P-value < 0.05 
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Table 3. Duration of prenatal exposure to SSRIs. 
Duration of Prenatal Exposure to SSRIs (days) 
 Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls 
 Pregnancy Preconception 1st Trimester 2nd Trimester 3rd Trimester 
Mean 140.1 116.2 63.3 58.5 63.1 56.9 69.6 65.5 75.5 76.1 
Variance 103.8 96.2 29.7 30.0 29.5 25.6 31.1 31.3 30.0 28.6 
Mode 28.0 30.0 90.0 90.0 90.0 90.0 90.0 90.0 82.0 84.0 
Minimum 8.0 1.0 2.0 1.0 4.0 1.0 2.0 2.0 5.0 2.0 
25th percentile 32.5 30.0 36.0 28.0 30.0 28.0 45.2 36.0 49.0 60.0 
Median 119.0 75.0 78.0 65.0 75.0 60.0 90.0 86.0 88.0 84.0 
75th percentile 259.0 200.0 90.0 90.0 90.0 90.0 90.0 90.0 97.0 98.0 
Maximum 296.0 299.0 90.0 90.0 90.0 90.0 90.0 90.0 115.0 114.0 
 
Table 4.  Effect estimates ASD associated with duration of prenatal SSRI use. 
  Models   
Exposure Period Unadjusted ORa (95% CI) Model 1 ORb  
(95% CI) 
Adjusted Model 2 ORc  
(95% CI) 
Adjusted Model 3 ORd  
(95% CI) 
Preconception     
1-45 days *1.8 (1.2-2.7) *1.7 (1.1-2.6) *1.5 (1.0-2.4) *1.6 (1.0-2.5) 
≥ 45 days *2.4 (1.8-3.2) *2.3 (1.7-3.0) *2.1 (1.6-2.8) *2.1 (1.6-2.8) 
First Trimester     
1-45 days     
≥ 45 days *1.8 (1.1-2.8) *1.7 (1.1-2.7) *1.6 (1.0-2.6) *1.6 (1.0-2.6) 
Second Trimester *2.7 (1.9-3.6) *2.6 (1.8-3.5) *2.4 (1.7-3.4) *2.4 (1.7-3.3) 
1-45 days     
≥ 45 days *2.1 (1.1-4.0) *2.2 (1.1-4.2) *2.0 (1.0-4.0) *2.0 (1.0-3.9) 
Third Trimester *2.6 (1.7-3.8) *2.5 (1.7-3.8) *2.3 (1.6-3.5) *2.4 (1.6-3.5) 
1-45 days     
≥ 45 days *3.8 (1.7-8.5) *3.1 (1.3-7.3) *2.8 (1.2-6.7) *2.9 (1.2-6.9) 
 *3.0 (2.0-4.5) *3.1 (2.0-4.7) *2.7 (1.7-4.1) *2.9 (1.9-4.4) 
The reference group is unexposed 
The cut point at 45 days was determined since it was median number of days in each 90-day exposure period for preconception and each trimester.  
a. Controls for matching variables of child year and month of birth through conditioning 
b. Odds ratios adjusted for parental age and sex of the child (and conditions on matching variables of child birth month and year) 
c. Odds ratios adjusted for parental age, sex of the child, history of maternal depression (and conditions on matching variables of child birth month and year) 
d. Odds ratios adjusted for parental age, sex of the child, history of maternal depression, and other SSRI indications (and conditions on matching variables of child birth 
month and year) 
*P-value < 0.05 
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Table 5. Cumulative dose of prenatal exposure to SSRIs. 
Dose of Prenatal Exposure to SSRIs (mg) 
 Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls Any ASD Controls 
 Pregnancy Preconception 1st Trimester 2nd Trimester 3rd Trimester 
Mean 5694.1 3734.7 2397.8 2115.4 2444.7 2127.3 3278.6 2543.7 3323.9 2716.3 
Variance 10732.0 4477.0 2948.9 2456.5 3200.9 2880.7 5432.1 3209.5 4454.8 2274.2 
Mode 560.0 600.0 1620.0 560.0 1800.0 600.0 380.0 1720.0 1760.0 600.00 
Minimum 180.0 40.0 80.0 10.0 80.0 20.0 40.0 80.0 100.0 100.0 
25th percentile 1000.0 860.0 840.0 700.0 900.0 600.0 995.0 860.0 1180.0 1540.0 
Median 2710.0 2000.0 1700.0 1520.0 1640.0 1400.0 2050.0 1820.0 2100.0 2060.0 
75th percentile 6460.0 5240.0 2900.0 2600.0 2720.0 2680.0 3650.0 3020.0 4100.0 3360.0 
Maximum 82900.0 38950.0 23400.0 25300.0 22400.0 34000.0 34900.0 23500.0 26200.0 17450.0 
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Table 6.  Effect estimates for any ASD associated with cumulative dose of prenatal exposure to SSRI. 
Exposure Period Dosea  Unadjusted ORb 
(95% CI) 
Adjusted Model 1 ORc 
(95% CI) 
Adjusted Model 1 ORd 
(95% CI) 
Adjusted Model 1 ORe 
(95% CI) 
Preconception      
 Quartile 1 (≤700 mg) *1.8 (1.1-3.0) 1.6 (0.9-2.7) 1.5 (0.9-2.5) 1.5 (0.9-2.4) 
 Quartile 2 (701-1520 mg) *1.8 (1.1-3.0) 1.6 (0.9-2.7) 1.5 (0.9-2.5) 1.4 (0.8-2.3) 
 Quartile 3 (1521-2600 mg) *2.4 (1.5-3.7) *2.4 (1.5-3.9) *2.3 (1.4-3.6) *2.1 (1.3-3.4) 
 Quartile 4 (>2600 mg) *2.8 (1.8-4.2) *2.6 (1.7-4.1) *2.4 (1.6-3.8) *2.3 (1.5-3.6) 
Pregnancy      
 Quartile 1 (≤860 mg) 1.6 (1.0-2.8) 1.7 (1.0-3.0) 1.6 (0.9-2.9) 1.5 (0.9-2.7) 
 Quartile 2 (861-2000 mg) *2.1 (1.3-3.4) *2.0 (1.2-3.4) *1.9 (1.1-3.2) *1.8 (1.1-3.0) 
 Quartile 3 (2001-5240 mg) *1.9 (1.1-3.2) *1.7 (1.0-3.0) 1.6 (1.0-2.8) 1.5 (0.9-2.6) 
 Quartile 4 (>5240 mg) *2.8 (1.8-4.3) *2.6 (1.6-4.0) *2.4 (1.5-3.9) *2.3 (1.4-3.7) 
First Trimester      
 Quartile 1 (≤600 mg) 1.5 (0.8-2.8) 2.3 (1.1-4.7) 1.4 (0.7-2.5) 1.3 (0.7-2.3) 
 Quartile 2 (601-1400 mg) *2.7 (1.7-4.5) *2.9 (1.7-5.0) 2.8 (1.6-4.7) *2.6 (1.5-4.4) 
 Quartile 3 (1401-2680 mg) *2.6 (1.6-4.3) *2.6 (1.5-4.4) *2.4 (1.4-4.2) *2.3 (1.4-3.9) 
 Quartile 4 (>2680 mg) *2.5 (1.5-4.2) *2.2 (1.3-3.7) *2.1 (1.2-3.5) *2.0 (1.2-3.4) 
Second Trimester      
 Quartile 1 (≤860 mg) *2.1 (1.1-4.2) 2.3 (1.1-4.7) *2.2 (1.1-4.4) *2.0 (1.0-4.1) 
 Quartile 2 (861-1821 mg) 1.9 (0.9-3.9) *1.9 (0.9-3.9) 1.8 (0.8-3.7) 1.6 (0.8-3.4) 
 Quartile 3 (1822-3020 mg) *2.5 (1.3-4.8) 2.3 (1.2-4.6) *2.2 (1.1-4.4) *2.0 (1.0-4.1) 
 Quartile 4 (>3020 mg) *3.2 (1.8-5.9) 3.2 (1.7-6.0) *2.9 (1.5-5.5) *2.7 (1.5-5.2) 
Third Trimester      
 Quartile 1 (≤1540 mg) *3.6 (1.8-7.1) *3.2 (1.5-6.5) *2.8 (1.3-5.8) *2.5 (1.2-5.1) 
 Quartile 2 (1541-2060 mg) *2.5 (1.1-5.3) *2.2 (1.0-4.8) 1.9 (0.9-4.3) 1.8 (0.8-4.0) 
 Quartile 3 (2061-3360 mg) *2.6 (1.2-5.7) *3.0 (1.3-6.7) *2.7 (1.2-6.0) *2.3 (1.0-5.3) 
 Quartile 4 (>3360 mg) *3.9 (2.0-7.7) *4.3 (2.1-8.7) *3.7 (1.8-7.5) *3.5 (1.7-7.1) 
The reference group is unexposed 
a. Dose categories were based on the distribution of cumulative dose of exposed controls in the exposure period of interest. 
b. Controls for matching variables of child year and month of birth through conditioning 
c. Odds ratios adjusted for parental age and sex of the child (and conditions on matching variables of child birth month and year) 
d. Odds ratios adjusted for parental age, sex of the child, history of maternal depression (and conditions on matching variables of child birth month and year) 
e. Odds ratios adjusted for parental age, sex of the child, history of maternal depression, other SSRI indications (and conditions on matching variables of child 
birth month and year) 
*P-value < 0.05 
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Table 7. Effect estimates for SSRIs use with any ASD, restricted to mothers with a history of depression  
 No. (%)   
Exposure Period Cases Controls Unadjusted ORa 
(95% CI) 
Adjusted Model 1 ORb 
(95% CI) 
Preconception (n = 583) 9 (17.0) 96 (18.0) 0.9 (0.4-2.0) 1.0 (0.5-2.3) 
Pregnancy (n = 605) 11 (20.0) 109 (19.8) 1.0 (0.5-2.0) 0.9 (0.4-1.8) 
First Trimester (n = 605) 7 (12.7) 90 (16.4) 0.7 (0.3-1.7) 0.7 (0.3-1.6) 
Second Trimester (n = 605) 5 (9.1) 69 (12.6) 0.7 (0.3-1.8) 0.7 (0.3-1.9) 
Third Trimester (n = 605) 6 (10.9) 68 (12.4) 0.9 (0.4-2.1) 0.7 (0.3-1.9) 
The reference group is unexposed 
a. Controls for matching variables of child year and month of birth through conditioning 
b. Odds ratios adjusted for parental age and sex of the child (matching: child birth month and year) 
 
Table 8. Effect estimates for SSRIs use with any ASD, restricted to mothers with history of depression and other indications 
for SSRIs 
 No. (%)   
Exposure Period Cases Controls Unadjusted ORa 
(95% CI) 
Adjusted Model 1 ORb 
(95% CI) 
Preconception (n = 1628) 21 (14.2) 189 (13.0) 1.1 (0.7-1.8) 1.1 (0.7-1.8) 
Pregnancy (n = 1617) 20 (13.6) 164  (11.2) 1.3 (0.8-2.1) 1.1 (0.7-1.9) 
First Trimester (n = 1573) 16 (11.2) 163 (11.4) 1.0 (0.6-1.7) 1.0 (0.6-1.8) 
Second Trimester (n = 1518) 11 (8.0) 82 (5.9) 1.3 (0.7-2.7) 1.2 (0.6-2.4) 
Third Trimester (n = 1518) 11 (8.0) 94 (6.8) 1.2 (0.6-2.3) 1.0 (0.5-1.9) 
The reference group is unexposed 
a. Controls for matching variables of child year and month of birth through conditioning 
b. Odds ratios adjusted for parental age and sex of the child (matching: child birth month and year) 
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Table 9. Adjusteda OR estimates (median) and confidence bounds (2.5 and 97.5 percentiles) for the effect of any SSRI 
exposure during pregnancyb on risk of any ASD from simulation-basedc sensitivity analysis for nondifferential under-
reporting of SSRI and depression in the register. 
                                               
 Adjusted OR estimates (median) and confidence 
bounds (2.5 and 97.5 percentiles)  
Assumed SSRI Prevalence (3%) 1.9 (1.6-2.6) 
Assumed Depression Prevalence (5%) 2.2 (1.9-2.4) 
Assumed Depression Prevalence (15%) 1.9 (1.5-2.4) 
                 Restricted to those with depression 1.4 (0.9-2.4) 
Restricted to those without depression  2.1 (1.5-3.0) 
a. Unconditional logistic regressions models adjusting for child birth year and month, parental age, sex of 
the child, and maternal history of depression.  
b. Reference group is no exposure during pregnancy  
c. Monte Carlo with simulating 1,000 datasets to obtain the median OR estimates and the 2.5% and 97.5% 
percentile OR estimates as the confidence interval. 
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Table 10. Effect estimates for any ASD associated with prenatal exposure to SSRIs on a restricted birth cohort (1998-2002). 
 
Exposed No. (%)     
ASD Cases  
(N = 3249) 
Controls  
(N = 32490) 
Unadjusted ORa  
(95% CI) 
Adjusted Model 1  
ORa (95% CI) 
Adjusted Model 2  
ORb (95% CI) 
Adjusted Model 3  
ORc (95% CI) 
40 (1.2) 172 (0.5) *2.3 
(1.7-3.3) 
*2.5 
(1.6-3.8) 
*2.1 
(1.5-3.0) 
*2.0 
(1.4-2.8) 
Abbreviations: SSRI, selective serotonin reuptake inhibitors; ASD, autism spectrum disorder; OR, odds ratio; CI, confidence interval. 
a. The reference group had no exposure during any exposure period. 
b. Odds ratios were adjusted for parental age and child sex (matching on child birth month and year) 
c. Odds ratios were adjusted for parental age, child sex, maternal depression (matching on child birth month and year) 
d. Odds ratios were adjusted for parental age, child sex, maternal depression, and other SSRI indicators (matching on birth month and year) 
*P-value < 0.05 
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CHAPTER 5: INTERACTION BETWEEN SPECIFIC CANDIDATE 
GENOTYPES AND IN UTERO B2AR AGONIST EXPOSURE ON THE RISK 
FOR AUTISM SPECTRUM DISORDERS 
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Abstract 
Objective: There has been strong evidence of a heritable component in autism spectrum 
disorder (ASD) etiology, however no definitive gene has been identified.  Similar to the 
complexities in identifying the genetic influence of ASD, environmental risk factors for 
the disorder is also largely unknown.  We explored whether the effects of beta-2 
adrenergic receptor (B2AR) agonists in utero are modified by susceptible genotypes - 
Gly16 and Glu27 polymorphisms in the ADBR2 gene, on the risk for ASD.  
Methods: This gene-environment interaction analysis was based on unmatched case-
control data from the Study to Explore Early Development (SEED).  Genotype 
information came from planned genotyping using the Illumina Infinium HD Assay.     
Unconditional logistic regression was used to estimate adjusted odds ratios and 95% 
confidence intervals.  Two statistical approaches to test for interaction were applied –
multiplicative model and the multiplicative two-degree of freedom joint test. 
Results: In models assessing the interaction between the any B2AR agonist use and 
presence of the Arg16Gly polymorphism we found that compared to children who were 
homozygous for Arg16 and were unexposed to B2AR agonist drugs in utero, children 
who were either heterozygous or homozygous for the Gly16 and exposed to the drug had 
an effect estimate of 1.1 [95% CI, 0.6-2.3]) associated with risk for ASD.  In interaction 
models between exposure and the Gln27Glu genotype we found an unadjusted OR of 1.0 
(95% CI 0.4-2.4) with adjusted models to be slightly higher.  The likelihood ratio test for 
the unadjusted model for the joint effect of Gln27Gly polymorphism was significant 
(p=0.01), with adjusted models reaching marginal significance.   
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Conclusion:  These preliminary results do not confirm a gene-environment interaction 
effect, however it does encourage further exploration to untangle modest risk estimates 
found in exposure to B2AR agonist use during pregnancy.  Results from this study 
encourage further research on maternal pharmacological exposures and the potential for 
interaction with susceptible genotypes.      
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 Introduction 
Autism spectrum disorders (ASD) are a group of developmental disabilities 
characterized by core deficits in three domains: social interaction, communication, and 
repetitive or stereotypic behavior [1].  The disorder is largely of unknown cause, and 
there is variability of impairment among individuals with ASD [2].  Although ASD has 
moderate to high heritability [3], several reviews of autism genetics have suggested the 
possibility for an interaction between genetic mechanisms and environmental exposures 
in autism etiology [4, 5].  Particularly, recent studies have focused on exposures during 
the prenatal period such as hazardous air pollutants [6], other prescription drug exposures 
during pregnancy [7-9], and pesticides [10].  A recent, large population-based twin study 
reported found a dizygotic twin concordance rate that was 0.77 for 45 monozygotic pairs 
(95% CI, 0.65-0.86) and 0.31 for 45 dizygotic pairs [11], which is substantially larger 
than recently reported non-twin sibling recurrence risk (18.7%) [12].  This suggests not 
only that the environmental contribution to autism etiology is substantial but that shared 
environmental factors unique to twins as opposed to other siblings (eg, those occurring 
during prenatal period) may be of particular importance. 
As briefly mentioned, prenatal pharmacologic exposures have been implicated as 
potential risk factors for ASD [7, 9, 13].  In particular, concerns have been expressed that 
exposure to B2AR agonist drugs during pregnancy may increase the risk for 
neurodevelopmental disorders in offspring[14-16].  Terbutaline has been used off-label as 
tocolytic agents since they may delay early contractions[17].  Along with B2AR agonists 
drugs used as a tocolytic, drugs such as salmeterol and formoterol are indicated to reduce 
asthma exacerbations and provide asthma control in adults [18].   For women with certain 
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chronic medical conditions such as asthma the use of drugs is essential.  The prevalence 
of B2AR agonist drug exposure (including both tocolytic and asthma indication) during 
pregnancy in the U.S. is estimated to be 4%-20% [19, 20].  B2ARs within the 
catecholamine system are required for normal nervous system development and for the 
function of both neural and non-neural tissues in the adult.  If used during pregnancy, 
these drugs can impact the fetal brain by crossing the placenta, resulting in the disruption 
of either replication or differentiation of the developing neurons [21]. 
Prior human studies of in utero B2AR agonist exposure have been small but 
suggest an increased risk associated with ASD [22]. Epidemiological findings are limited 
however indicate a moderate risk associated with ASD [22, 23].  Connors et al 2005 
reported an increased concordance for ASD in dizygotic twins exposed to terbutaline 
[22].  In a more recent study, the findings from Croen et al 2011 also suggest a modest 
increased risk associated with ASD, with the highest effect estimated for exposure during 
the first and second trimester of pregnancy[23].  Moreover, Croen et al 2011 also found 
the preconception period to be associated with the highest risk overall, however all their 
estimates had wide confidence intervals.   
 The observed main effects described in the epidemiological studies presented 
above are subtle in pregnancies exposed to B2AR agonists.  It is possible that if a 
subgroup is more susceptible to these exposures, effects in those groups will be more 
pronounced.  The beta 2-adrenergic receptor gene (ADBR2), located on chromosome 
5q31-32, have been shown to influence B2AR receptor sensitivity and consequently may 
enhance susceptibility to the neurodevelopment effects of B2AR exposure [24].  There 
are two common polymorphisms known to influence receptor function [24].  On codon 
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16 (rs1042713), a G for A substitution encodes the amino-acid glycine rather than 
arginine (Arg16Gly), and a G for C substitution at codon 27 (rs1042714) codes for 
glutamic acid rather than glutamine (Gln27Glu) [25].   A study by Cheslack-Postava et al 
2007 investigated these known polymorphisms in this gene and autism risk using 331 
autism case parent trios from the Autism Genetic Resource Exchange (AGRE).   
Cheslack-Postava et al found a Glu27 homozygous genotype to be associate with 
increased autism risk, while Gly16 did not reach statistical significance [26].    If the true 
etiologic mechanism is one of gene-environment interaction, estimated genetic main 
effects, like environmental main effects, may be attenuated. 
 The objective of this study is to directly explore interaction between the ADRB2 
gene and B2AR exposure during pregnancy in a population-based case-control sample.   
 
Methods 
Population 
The Study to Explore Early Development (SEED) is a population-based case-
control study of children born between September 1, 2003-August 31, 2005 (ages 2-5) 
and currently residing in the six study areas (San Francisco Bay area, Denver 
metropolitan area, Philadelphia metropolitan area, northeast Maryland, central North 
Carolina, and the Atlanta metropolitan area).  This analysis includes the first 337 
confirmed cases.   Cases were identified from multiple clinical and educational 
developmental service providers based on a recorded diagnosis of ASD, one or more 
select diagnoses associated with ASD, or an ASD/ASD-related exceptionality from early 
intervention/special education services. All potential cases that were identified through 
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these services were then given the Social Communication Questionnaire (SCQ) and were 
later administered diagnostic evaluation such as the Autism Diagnostic Observation 
Schedule using the new algorithms, and the Autism diagnostic Interview-Revised Cases.  
In addition these potential cases were clinically observed and further divided into several 
sub classifications to characterize them by degree of observed or reported, or both, ASD 
behavioral symptoms based on the standardize diagnostic assessments mentioned above 
[27].  Controls (n = 521) were randomly selected from birth certificates files.    Controls 
were also given the SCQ, and those with negative SCQ scores were assigned the control 
group workflow.  If during their evaluation, a clinician suspected them of having ASD, 
they were then further tested for the disorder [27]. 
 
Genotyping  
DNA was obtained from blood samples collected from study visits completed at 
enrollment. In cases where children were unable or unwilling to give blood, buccal 
samples were collected.  Blood samples are collected by trained phlebotomists, processed 
and packaged for shipment following standardized protocols, and shipped via overnight 
courier to the Central Lab.  Buccal sample kits are mailed to participants, the collection is 
self-administered, and samples are mailed directly to the Central Lab. 
Candidate genotypes of interest were elected from GWAS genotype.  GWAS 
genotyping was carried out by the Johns Hopkins SNP Center (joint effort with the 
Center for Inherited Disease Research) using the Illumina HumanOmni1-Quad panel.  
One ug of genomic DNA was genotyped on the Illumina Omni 1M Quad platform.  This 
is a highly accurate and reproducible platform that measures over 1 million loci in the 
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human genome.  After genotyping, several quality control measures were applied 
including a sample call rate of 98% and SNP call rate threshold of 96%.  SNPs that were 
monomorphic or had a minor allele frequency of <0.01 were removed. Samples with sex 
discrepancies, IBS relatedness pi-hat score that is >0.25, and SNPs deviating from the 
Hardy Weinberg Equilibrium in the control samples (p<10-8 by Fisher exact) were 
removed from the downstream analysis. 
Beginning and end coordinates of the ADBR2 gene were initially identified based 
on the default provided in the UCSC Genome Browser website (genome.ucsc.edu).  We 
then extended the 5’ and 3’ coordinates to include contiguously correlated SNPs that 
were typed in HapMap (hapmap.org), with the rationale being that important regulatory 
regions may exist beyond the traditional known promoter and UTR regions of the gene 
and that these regulatory regions would likely co-travel and therefore be highly correlated 
with the traditional gene coordinates.  After we used HapMap information to revise the 
start and end coordinates of the ADRB2 gene (chr5:148184770-148193699), 13 known 
HapMap SNPs were available within this extended region, seven of which were present 
in the Human Omni-Quad1 Marker genome-wide panel.  However, these seven SNPs 
provide 100% coverage of the ADRB2 gene when comparing to HapMap.   
Indicator variables for candidate genotypes of interest were developed as follows.   
The Arg16Gly polymorphism was one of the seven SNPs available in the Illumina panel.  
So for that SNP, a dichotomous genotype exposure variable was created directly from the 
presence of one or two copies of Gly allele contrasted against homozygous Arg/Arg 
reference.  For the Gln27Glu polymorphism, which was not included in the panel, an 
imputation procedure was performed using the IMPUTE2 software and 1000 Genomes 
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on all individuals [28].  We extended the gene region by 10ks on each end of the gene to 
ensure that we had sufficient information to get the right haplotype phasing from each 
SEED individual.  A dichotomous genotype exposure variable for this SNP was created 
contrasting the presence of one or two copies of the Glu allele.  The reference group was 
homozygous for the Gln allele. 
 
Phenotypic Data and Covariates 
 Pharmacological exposure data was self-reported, and came from the SEED 
Caregiver Interview.  A trained SEED interviewer administered the questionnaire to the 
mother and asked her to recall events during her pregnancy.  They were asked generally 
between three months prior to the estimated date of conception to the time she stopped 
breastfeeding.  Questions regarding exposure to B2ARs medications indicated for asthma 
were separate from those used as a tocolytic.  Questions related to exposure first required 
that the participant recall whether or not they had experienced any of the listed illness.  
Once she had indicated an illness the question then prompted the interviewee to ask what 
medications were used to treat the illness.  Since there could be multiple conditions that 
indicated for B2AR agonist drug use, we reported the existing conditions a mother had 
for those that were taking B2AR agonist drugs.  A single dichotomous variable was 
created as either exposed or unexposed to B2AR agonist drugs anytime during 
pregnancy.  The limited sample size did not permit trimester specific analysis since there 
were very few exposed mothers in each group. 
Covariates included demographic factors that were strongly associated with ASD 
risk (parental age and sex of the child) and self-reported indications for B2AR agonist 
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drug use. They were selected based on prior literature suggesting them as potential risk 
factors for ASD [29-32].  In regards to race and ethnicity, the decision to adjust for these 
covariates were motivated by the idea that common ancestry is related to genotypes and 
perhaps to exposure through culturally mediated mechanisms. Population stratification 
occurs if the gene under study shows marked variation in allele frequency across different 
groups of the population and if the groups also differ in their baseline risk of the disease 
[33]. To ensure that we were correcting for this, the CGI included self-reported data on 
race/ethnicity categorizing subjects into several categories, which enabled participants to 
include mixed races as well, and thus there were several categories a person could 
include.  However, because race and ethnicity were self-reported we suspected problems 
with accuracy, misclassification that is often not at random, and missing data on this 
variable [34].  Therefore using this variable alone could potentially hinder our ability to 
adequately control for population stratification.   
The principal component analysis can be used to account for the different 
proportional contributions from various ancestral lineage due to population structure [35].  
We used the top two principal components values (PCV) as covariates derived using the 
software EIGENSTRAT.  This software detects and corrects for population stratification 
in GWAS, and is based on the principal component analysis that models differences 
between cases and controls along a continuous axes which is specific to a candidate 
markers variation across ethnic differences [36].  By incorporating the values from this 
analysis as covariates into our models we were able to correct for large differences in 
allele frequency across ancestral populations.  It was especially important to use this in 
our analysis since we do not have a homogenous population.  Our population included 
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children with ancestors from East Asia, south Asia, Africa, and the Europeans.  Without 
correcting for this, we could potentially have false positives that are due to the 
differences between cases and control groups that are actually related to ancestral 
background, and not disease status.  Once computed, each sample has values that 
correspond to a position on a coordinate system that effectively clusters samples together 
by ethnic similarity.  This was then used to identify ethnic outliers as well as the structure 
of the genetic data.  These two PCV numbers were used as continuous variables were 
then incorporated in all the models as covariates to see if they changed the log odds ratio 
by 10%, and then retained in the final model. 
 
Statistical Analyses 
 Descriptive analyses compared cases and controls on covariates. Unconditional 
logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals 
(95% CI).  Adjusted models were constructed by individually adding parental age, child 
sex, self-reported race ethnicity, indications for B2ARs agonist, and PCV from the 
principle component analysis to the unadjusted model that included terms for the 
genotype, B2AR agonist drug exposure, and interaction term(s). A covariate was retained 
in the final model if its addition generated a 10% change in any of the beta estimates for 
main or interaction effects.   Models were also fit forcing in the PCV variables to provide 
adjustment for potential population stratification.  Separate models were constructed for 
the Arg16Gly and Gln27Glu polymorphisms. 
We explored gene-environment interaction two ways.  First we used a 
conventional interaction term approach testing for multiplicative scale interaction in the 
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full case control data set.  Next, we used the two-degrees of freedom joint test of 
marginal genetic effects and gene-environment interactions [37].  This approach is not an 
explicit test of gene-environment interaction per se, but can be more efficient than 
conventional approaches for detecting multiplicative interaction when interaction is 
quantitative rather than qualitative.   The test uses the same likelihood ratio test as the test 
of for gene environment interaction but constrains both the beta coefficient for the 
interaction term and the gene under the null so that the degrees of freedom are two. 
 
Results 
We estimated the unadjusted odds ratio from the unconditional logistic regression 
for the marginal effect of the B2AR agonist drug exposure anytime during pregnancy, the 
marginal effect of each genotype separately (Arg16Gly and Gln27Glu), and the 
interaction of the gene and exposure.  There were no covariates that individually resulted 
in a 10% change in the log odds ratios.  The two models presented for exposure to B2AR 
agonist drugs anytime during pregnancy, the genotype, and the interaction form consisted 
of the unadjusted (no additional covariates), and the model adjusted for PCVs. 
 
Description of study sample 
There were a total of 858 children with complete case status.  However for the 
genetic information, there was one child with missing Arg16Gly information, and 61 
children with missing Gln27Gly information.  Only complete case, exposure and genetic 
information were used in all models for interaction (ie Total N for Arg16Gly = 857; Total 
N for Gln27Gly = 797).  Children with ASD (n = 337) were more likely than controls 
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(n=521) to be male (81.9% vs 53.7%) and have mother’s who have reported using a 
B2AR agonist drug during their pregnancy (6.5% vs 4.6%) (Table 1).  The parental age 
of the child in both the case and control groups was similar.  The genotype counts and 
frequencies for both polymorphisms are shown in Table 2 and are similar to population 
frequencies observed in the literature [26].    
 
Associations of any B2AR agonist use, susceptible genotype and their interaction with 
ASD 
Table 3 shows the marginal effects of B2AR agonist use and both susceptibility 
genotypes associated with ASD risk in unadjusted and PCV-adjusted models.  Point 
estimates for B2AR effects are above one while estimated genotype effects are 
protective.  However, all 95% confidence intervals around all adjusted odds ratio 
estimates include 1.0.  
Table 4 displays the B2AR agonist drug effect stratified by candidate 
susceptibility genotype from unconditional logistic regression models including 
interaction terms.  The pattern of the effect estimates suggests qualitative multiplicative 
scale interaction between Arg16Gly and B2AR agonist drug use with unadjusted and 
PCV-adjusted odds ratios below 1.0 among those with the homozygous reference 
genotype and above one among those with either AG or GG genotype.  There does not 
appear to be any qualitative multiplicative scale interaction for the Gln27Gly and B2AR 
with unadjusted and PCV-adjusted odds ratio both being above 1 for both the 
homozygous reference genotype and heterozygous or homozygous variant type.  In both 
the unadjusted and PCV adjusted models, the confidence intervals were wide and the p-
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value on the interaction term was greater than 0.05.  From the two-degree of freedom test, 
the unadjusted and PCV adjusted models had p-values that were consistently smaller than 
the traditional multiplicative models.  The p-value was below 0.05 for the unadjusted 
interaction between B2AR and Gln27Gly only. 
 
Discussion 
 This analysis was completed using genotyping on DNA collected from the first 
331 cases and 551 non-impaired controls in the SEED study population.  While these 
preliminary results do not confirm a gene-environment interaction effect; however, the 
findings encourage further exploration of interaction hypotheses with respect to B2AR 
agonist use during pregnancy.  We did find estimates for the marginal effects of B2AR 
agonist use during pregnancy similar in magnitude to those from an analysis of a large 
Danish register-based sample reported elsewhere in this dissertation (Chapter 3) as well 
to those reported by Croen et al 2011 [23] in a case-control study of Kaiser Permanente 
members.  In regards to the two SNPs of interest, the Arg16Gly and Gln27Glu, the 
marginal effect estimates for carriers suggested a protection – a finding counter to that 
reported by Cheslack-Postava et al 2007 [26].  The marginal estimates we observed in the 
present analysis (0.7 for Arg16Gly and 0.6 for Gln27Glu) were very close to the lower 
bound, but fell outside the confidence limits reported by Cheslack-Postava et al 2007 
(0.85–2.07 and 0.0.97–3.47, respectively).  However our marginal estimates had very 
wide confidence intervals themselves including both protective and risk conferring 
effects.  
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We results suggest that the ASD risk associated with prenatal B2AR exposure 
may be modified by ADRB2 genotype; however, these findings are very preliminary 
given the imprecision of effect estimates. Animal models have suggested the existence of 
a biological mechanism by which the ADRB2 gene polymorphisms and exposure to 
B2AR agonist during pregnancy may interact in a manner that influences 
neurodevelopment.  Experiments have shown that β2- adrenergic receptors (B2AR) in the 
central nervous system are present during gestation, with neurotransmitters acting as 
growth factors [22, 38].  During gestation, overstimulation of the receptors may have 
harmful effects on the development of the brain and the peripheral nervous system [38, 
39].  Mature receptors have mechanisms protecting against over-stimulation; however, 
fetal receptors do not have the ability to regulate imbalances and may in fact become 
sensitized to agonist exposure [40]. B2AR agonist drugs administered to pregnant rats 
during the second trimester of gestation alters neural cell replication and differentiation, 
synaptogenesis, and expression of synaptic proteins involved in neurotransmission [40].  
At the same time, polymorphisms in the β 2-adrenergic receptor gene (ADBR2) have 
been shown to influence fetal B2AR sensitivity and consequently may enhance 
susceptibility to the neurodevelopment effects of B2AR exposure [24]. Cardiovascular 
disease research supports the notion that ADBR2 polymorphisms may influence the 
biologic response to B2AR agonists [41].  The Gly16 substitution has been associated 
with faster activation of the cAMP formation [42, 43] in humans with homozygous Gly16 
have a greater cardiac function and vasodilation in response than those with Arg16 [41, 
44].    The Glu27 allele has been shown to increase resting sympathetic nerve traffic [45].  
Compared to subjects who are homozygous for the Glu27 allele, subjects with the Gln27 
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substitution had a lower baseline blood flow and had significantly attenuated increase in 
the forearm blood flow, especially in veins [46].  Studies investigating the possibility for 
interaction have found that compared to Arg16 homozygotes, Gly16 homozygotes 
demonstrate significantly greater blood flow responses to systemic infusions of beta 2-
agonists [44]. 
Although biologically plausible, the suggestion of interaction here needs to be 
interpreted with a substantial measure of caution.  The direction of the marginal genotype 
effects we observed suggest protection with respect to ASD risk – a finding that is 
counter to expectation but may be a byproduct of the small sample size (as confidence 
limits also included risk conferring estimates).   A previously published study using of 
331 autism case parent trios from the Autism Genetic Resource Exchange (AGRE) found 
Glu27 homozygous genotype to be associated with increased autism risk and, although 
the Gly16 effect did not reach statistical significance, the odds ratio estimate for that 
genotype was also above one [26].   While the marginal genetic effect was not consistent 
with this previous work, we did observe stronger B2AR effects in the strata of individuals 
with these higher activity genotypes.   Though consistent with the a priori interaction 
hypothesis, as has been mentioned, our power to detect interaction in this small sample is 
limited. The p-values for the two-degrees of freedom test were smaller than the p-values 
from the conventional multiplicative interaction models, which is consistent with the 
expected performance of this test [37].  
Other limitations in this study include the possibility of B2AR agonist drug 
exposure misclassification since these data came from a maternal interview.    However, 
retrospective self-report of pharmacologic exposures during pregnancy are most accurate 
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when questions are designed around indications for use, as was done here, and when 
recall periods are not overly long [47].  The SEED study employed a rigorous case 
confirmation approach [48]; consequently, there is unlikely to be misclassification of 
outcome.     Because of the limited sample size we were unable to consider other 
potential confounders of the association between B2AR agonist drug exposure and ASD 
(e.g., indicating diagnosis).     
Nonetheless, this is the first direct exploration of gene-environment interaction 
with respect to a prenatal pharmacologic exposure and ASD risk.  Although there have 
been general concerns raised surrounding the use of B2AR agonist drugs in pregnancy 
and ASD risk [14] the limited epidemiologic evidence is equivocal [23] and the 
investigation of the continued exploration of the existence of geneticly susceptible 
subgroups  appears warranted.   This analysis capitalized on initial genotyping data 
available in the SEED sample and as additional genotyping is completed, this exploration 
of gene-environment interaction should be revisited.     
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TABLES 
Table 1. Descriptive characteristics of cases and controls for gene-environment analysis 
 Cases Controls 
No. (%) 337 (39.3) 521 (60.7) 
Maternal age (median) 32.1 32.9 
≤25 years 44 (13.1) 47 (9.0) 
26-30 83 (24.6) 102 (19.6) 
31-35 115 (34.1) 195 (37.4) 
≥36 19.9) 129 (24.8) 
Missing  28 (8.3) 48 (9.2) 
Paternal age (median) 34.2 34.5 
≤25 years 30 (8.9) 27 (5.2) 
26-30 48 (14.2) 81 (15.6) 
31-35 92 (27.3) 158 (30.3) 
≥36 121 (35.9) 187 (35.9) 
Missing  46 (14.0) 68 (13.1) 
Child sex   
Boys 276 (81.9) 280 (53.7) 
Girls 61 (18.1) 241 (46.3) 
Self-reported Race and Ethnicity   
White 233 (69.1) 426 (81.8) 
Black 60 (17.8) 49 (9.4) 
Hispanic 40 (11.9) 48 (9.2) 
Asian 32 (9.5) 30 (5.8) 
Pacific Islander 0 (0.0) 1 (0.2) 
Native America 9 (2.7) 15 (2.9) 
Alcohol (pregnancy)   
Yes 37 (11.0) 76 (14.6) 
Missing 7 (2.1) 4 (0.8) 
Active Smoking (pregnancy)   
Yes 33 (9.8) 27 (5.2) 
Passive Smoking (pregnancy)   
Yes 25 (7.4) 23 (4.4) 
Maternal Asthma   
Yes 18 (5.3) 33 (6.3) 
Any B2 indications*   
Yes 182 (54.0) 276 (53.0) 
*Includes: Asthma, Cold or Cough, Early Labor, Allergy, Upper Respiratory Infection, Influenza 
or Flu, Pneumonia, and Respiratory conditions.  
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Table 2: Allele frequencies among cases and controls for Arg16Gly and Gln27Glu. 
Arg16Gly Gln27Glu 
 Cases 
N=337 
Controls 
N=521 
 Cases 
N=337 
Controls 
N=521 
Arg/Arg 70 (20.8) 79 (15.2) Gln/Gln 160 (50.5) 190 (36.5) 
Arg/Gly 151 (44.8) 225 (48.9) Gln/Glu 117 (36.9) 210 (43.8) 
Gly/Gly 116 (34.4) 186 (35.7) Gln/Gly 40 (12.6) 80 (16.7) 
Missing 0  1 Missing 20  41  
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Table 3. Marginal effects of genotypes and prenatal B2AR exposure  
 Marginal Effects 
 Unadjusted pvalue PCV* Adjusted pvalue 
B2AR 1.5 (0.8-2.6)  0.22 1.5 (0.8-2.7) 0.20 
Arg16Gly (AG or GG)** 0.7 (0.5-1.0) 0.06 0.8 (0.5-1.1) 0.16 
Gln27Gly (CG or GG)*** 0.6 (0.5-0.9) 0.003 0.8 (0.6-1.1) 0.12 
* PCV=Principle Component Value – the terms that are derived using the software EIGENSTRAT and used to adjust for 
ethnic differences.  
**Compared to homozygous reference genotype AA 
***Compared to homozygous reference genotype CC 
 
 
Table 4.  Heterogeneity of multiplicative effects analysis (unadjusted and PCV adjusted) of B2AR Odds Ratios stratified by 
Arg16Gly and Gln27Glu 
  Arg16Gly  Gln27Glu 
  Unadjusted PCV* Adjusted  Unadjusted PCV* Adjusted 
Homozygous Reference Genotype   0.56 (0.1-3.2) 0.53 (0.2-3.1)  1.22 (0.5-3.0) 1.13 (0.5-2.9) 
Heterozygous or Homozygous Variant   1.71 (0.3-9.9) 1.91 (0.3-11.2)  1.62 (0.7-3.7) 1.79 (0.8-4.1) 
* PCV=Principle Component Value – the terms that are derived from the principle component analyses and used to adjust for 
ethnic differences.  
 
 
Table 5. Summary of test statistics for interaction. 
  Arg16Gly  Gln27Glu 
  Unadjusted PCV* Adjusted 
 
 Unadjusted 
 
PCV* Adjusted 
Multiplicative: parameter estimate for 
interaction term (p-val) 
 1.1 (0.24) 1.20 (0.21)  0.28 (0.65) 0.47 (0.47) 
Multiplicative: 2df χ2 (p-val)  5.249 (0.07) 3.741 (0.15)  8.75 (0.01) 2.86 (0.23) 
* PCV=Principle Component Value – the terms that are derived from the principle component analyses and used to adjust for 
ethnic differences.  
	   	   134 
CHAPTER SIX: DISCUSSION 
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Summary of Findings  
 The objective of this dissertation was to investigate associations between two 
specific classes of drug exposures, beta-2 adrenergic receptor (B2AR) agonists and 
selective serotonin reuptake inhibitors (SSRIs), still commonly used during pregnancy 
that may pose a risk for ASD.  This was accomplished through two specific aims: 1) 
estimate the main effects of these medications commonly used during the prenatal period 
on autism risk in a large population-based cohort; 2) explore whether effects of exposure 
to B2AR agonist drugs are modified by maternal susceptibility genotypes in the ADRB2 
gene.   
 The first aim focused on estimation of exposure main effects capitalizing on the 
large sample constructed from Denmark’s population-registers.  The results from the 
analysis investigating the effect of B2AR agonist drugs and ASD suggest that exposure 
during the preconception (90 days before estimated date of conception) and prenatal 
periods were associated with modest increases in the risk for ASD.  Preconception and 
trimester specific results during the prenatal period resulted in estimates that were similar 
across all models, with the second and third trimester effects being only slightly higher.  
However, since the effect sizes in all of the models had confidence intervals that 
overlapped, it does not provide enough evidence to suggest a particular exposure 
window.  Our findings were consistent with other epidemiological evidence looking at in 
utero exposure to B2AR agonist drugs and the risk associated with ASD in that modest 
effect estimates were also reported [1, 2].   
This is the first study to look at the association of both dose and duration of 
prenatal use of B2AR agonist drugs and risk for ASD.  Epidemiological studies thus far 
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have only looked at duration of use and report the highest risk associated with prolonged 
use (>2 days) [1], which is also consistent with our findings.  There was notable overlap 
between confidence intervals of the observed estimates, which remained elevated 
throughout each dose category.  However, this evidence does not suggest any particular 
cumulative dose range or trimester specific exposure for dose.  These dose and duration 
analyses were able to detect the elevated effect estimates in the second trimester, which is 
also supported by animal models [3, 4]. 
A limitation of these analyses however, was that exposure data were restricted to 
outpatient prescriptions.   Although most prescriptions for B2AR agonist drugs, including 
those used for asthma indications, are obtained in an outpatient setting, they are also 
prescribed as a tocolytic for in-hospital use. B2AR agonist drug exposure due to tocolytic 
use would most likely occur in the third trimester.  Therefore, third trimester exposure 
may have been underestimated since drugs prescribed during hospital admission are not 
included. It would have been interesting to explore the effect of B2AR agonist drugs 
indicated solely as a tocolytic. Another limitation to this study was that diagnostic 
subgroups of ASD were not explored.  It would have been interesting to investigate the 
association between our exposure and various outcome definitions.  These outcome 
definitions include childhood autism alone and those diagnosed with atypical autism, 
Asperger’s syndrome, and pervasive developmental disorder, unspecified.  However, the 
validity of diagnostic subgroup classification other than autistic disorder in the register 
has not been established and the use of an outcome definition that included all ASD 
subtypes is consistent with other register-based studies of autism from Denmark [5, 6]. 
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In the second aim of the dissertation, I investigated the relationship between 
prenatal exposure to SSRIs and ASD, also using the same case-control population used in 
aim one.  Here I also found increased ASD risk associated with in utero exposure to 
SSRIs.   In this analysis, any exposure to SSRIs during pregnancy was associated with 
ASD (odds ratio (OR) 2.0 [95% confidence interval CI, 2.0 [1.6-2.6]) compared to the 
unexposed reference group.  To our knowledge, this is the first study to explore prenatal 
dose and duration of use and the risk associated with ASD.  Our findings suggest that 
compared to children unexposed to SSRIs in utero, children who were exposed to the 
highest cumulative dose had the highest risk associated with ASD. Although I did not 
observe a linear dose response effect, I observed the highest effect estimate in the largest 
dose category.  In regards to duration, I also found prolonged use of SSRIs during the 
prenatal period had a larger measure of association for ASD.   
The limitations of this analysis are similar to those mentioned for the first aim.  
Namely, I only had the ability to investigate SSRIs dispensed in outpatient prescriptions.  
We were unable to capture data on any SSRIs that may have been prescribed during 
hospital admissions, though in-hospital prescription is infrequent compared to outpatient 
prescription.  In addition, I had to assume that all the drugs from prescriptions were 
actually taken by the mother prior to delivery as well as throughout her pregnancy.  It is, 
however, also possible that part of the drugs was left unused or used by others, such that I 
may overestimate the exposure and thus underestimate the drug effect.  Lastly, I was not 
able to observe effects estimates from other diagnostic subgroups, which may shed light 
on how exposure may affect severity of ASD.   
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Since confounding by indication is a major concern in pharmacoepidemiology, 
the use of Denmark’s national registers provided a large sample size sufficient to perform 
several statistical analyses to control for possible independent effects of the indicating 
condition on ASD.  In the analyses for B2AR agonist drugs, statistical adjustment for the 
indication and a restriction analysis on a subset of the study sample with maternal asthma 
resulted in estimates that remained robust regardless of the various sensitivity analyses 
implemented. However, in our SSRI analyses, understanding the potential impact of 
confounding by indication proved to be more complicated.  I observed attenuated effect 
estimates when I restricted to only mothers with a diagnosis for depression, however after 
I had first corrected for misclassification of depression and then restricted the sample to 
only mothers with a depression, I observed a risky effect estimate in the strata with 
maternal depression.  This suggests that under-reporting of the confounder, maternal 
depression, may be a limitation in approaches previously used to consider the influence 
of confounding by indication.   We were also able to explore the potential effect of 
exposure misclassification in our analysis and found that exposure misclassification did 
not appear to have a substantial impact on the effect estimates in both the B2AR agonist 
drug and SSRI analyses.    
 Given that the effect sizes observed were modest, in the last aim I explored the 
extent to which prenatal medication exposure effects might be larger among a genetically 
susceptible subgroup.  For this candidate gene-environment interaction analysis the 
register-based data from Denmark was not used, but instead I capitalized on the 
availability of exposure and genotype data in a large ongoing US autism case-control 
study, the Study to Explore Early Development (SEED).  This analysis was limited to the 
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possible interaction between B2AR agonist drugs and candidate genotypes only.  
Although it is also of interest to consider genetic susceptibility with respect to SSRI 
effects, the single-nucleotide polymorphisms (SNPs) of interest for the best candidate 
gene (the serotonin transporter gene, SLC6A4) were not included on the Illumina 
genotyping panel used in the SEED study. There are two specific SNPs of interest within 
this gene, and although both were present in the imputed data, there were high rates of 
missing data (~50-70%). Tag SNPs could not be used because these two particular SNPs 
were untaggable (using r2 > 0.8 threshold) due to the mixed ancestral populations in the 
dataset (African decent, European decent, and African-European admixed). I considered 
tagging SNPs within each of these three ancestral populations, however the same tag SNP 
could be used for the European decent and admixed populations, but not for the African 
decent population.  It would have been possible to complete the analysis using different 
tag SNPs per population, which could then be followed by a meta analysis to assess the 
effect across ancestral populations. Another option considered was to analyze the whole 
SLC6A4 gene, which would involve pruning SNPs.  Although these methods would have 
yielded informative results, I was not comfortable with the amount of missing genetic 
information for this SNP given the small sample size.  Perhaps it would be beneficial for 
the larger SEED sample to explore these various methods using a meta analysis for tag 
SNPs, but for the purposes of this dissertation I decided to focus my efforts on the genetic 
influence of B2AR agonist drug exposure.  Thus, I concentrated our analysis on 
exploring whether effects of B2AR agonists used during pregnancy are modified by 
polymorphisms in the beta 2-adrenergic receptor gene (ADRB2).   
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I investigated whether the effect estimates associated with B2AR agonist drug 
exposure in utero on the risk for ASD was modified by two candidate susceptibility 
genotypes – the Gly16 and Glu27 polymorphisms in the ADRB2 gene.  The ADBR2 
gene, located on chromosome 5q31-32, encodes the beta-2 adrenergic receptor and has 
been shown to influence receptor sensitivity and consequently may enhance susceptibility 
to the neurodevelopment effects of B2AR exposure [7].  There are two common 
polymorphisms known to influence receptor function [7].  On codon 16 (rs1042713), a G 
for A substitution encodes the amino-acid glycine rather than arginine (Arg16Gly), and a 
G for C substitution at codon 27 (rs1042714) codes for glutamic acid rather than 
glutamine (Gln27Glu) [8].  Unconditional logistic regression was used to estimate 
adjusted odds ratios and 95% confidence intervals and two different approaches to test 
for interaction were applied –multiplicative model and 2-degree of freedom joint test.   
These preliminary results do not confirm a gene-environment interaction effect 
however they do encourage the further exploration of gene-environment interaction in 
order determine if subgroups more susceptible to prenatal B2AR exposure do exist.  We 
did find similar in magnitude marginal effects for B2AR agonist use during pregnancy in 
the SEED sample that were similar to those found in the Denmark sample reported in 
Chapter Three of this dissertation and to those reported by Croen et al 2011 [1].  In 
regards to the two SNPs of interest, the Arg16Gly and Gln27Glu, the marginal effects of 
these genes alone indicated a protective effect which differed from the one previous 
report [9]; however, our estimates had very wide confidence intervals.  The pattern of the 
effect estimates suggests qualitative multiplicative scale interaction between Arg16Gly 
and B2AR agonist drug use, however there does not appear to be any qualitative 
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multiplicative scale interaction for the Gln27Gly and B2AR.  While the marginal genetic 
effect was not consistent with this previous work, we did observe stronger B2AR effects 
in the strata of individuals with these higher activity genotypes.  However, the results 
from the two-degrees of freedom joint test suggest no interaction on the multiplicative 
scale, but the unadjusted model for the Gln27Gly analyses was significant.  This may be 
a symptom of the imprecision of the effect estimates. As expected the, p-values for the 
two-degrees of freedom joint test for all models were less than the p-values from the 
conventional multiplicative interaction models, which is consistent with literature [10].  It 
has been shown that the two-degrees of freedom test has more power to detect genetic 
influences of gene-environment interaction, and is therefore known to be more sensitive 
to these effects when compared to traditional multiplicative interaction tests [10].  
  The interaction assessments were complicated due to this marginal genotype 
effect, which was against expectation, and were also impacted by the limits of power due 
to the small sample size.  However, since this study took advantage of the first round of 
genotyping in the SEED populations, our results when used in conjunction with those 
from the larger SEED analysis, can lead to insight into other possible mechanisms for 
gene environment interaction.  More importantly, this is the first direct exploration of 
gene-environment interaction with respect to a prenatal pharmacologic exposure and 
ASD risk and will encourage further research endeavors in this area. 
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Future Directions  
To date, in addition to the work reported here, there have been only two 
epidemiological studies that have investigated prenatal exposure to B2AR agonist and 
risk for ASD [2, 11], and one observational study on SSRIs and risk for ASD [12].  
Although these studies were all population based, they had relatively small sample sizes. 
Further research is needed to replicate these few epidemiological findings and, as has 
been noted, these approaches need to address potential confounding by indication.  
Randomized study designs are not an option when a treatment has already diffused or 
may not be applied to certain subpopulations (i.e., children, pregnant women) commonly 
excluded from trials.   Therefore, employing statistical adjustment and a restriction 
analysis in observational studies should continue to be used in efforts to control for 
confounding by indication when randomized trials cannot be used.  Moreover, future 
studies should also consider matching on the propensity score, which would be similar to 
the expected balance achieved through a randomized trial [13].  In conjunction with 
controlling for confounding by indication, investigations moving forward should consider 
methods to account for potential misclassification of the indication.  This would include 
Monte Carlo simulations such as those used throughout this dissertation and Bayesian 
approaches which have significant advantages [14].  The impact of under-ascertainment 
of indication, would lead to incomplete control for confounding. 
The indicating conditions for these pharmacologic exposures, consisting of 
maternal asthma and depression, have also been suggested as autism risk factors [15, 16].  
Since these associations have not been themselves firmly established, continued 
investigation of alternative pathways by which these exposures could influence ASD risk 
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should also continue to be explored. This is a complicated challenge in itself and involves 
a range of factors to be considered, such as genetic susceptibility and physiologic changes 
related to maternal stress, especially during the pregnancy period.  Recent animal models 
have suggested that the prenatal stress and certain serotonin transporter genotypes may 
have the combined effect of producing changes in social interaction.  Associations 
between maternal depression and developmental psychopathology in children have been 
suggested as potentially operating through mechanisms involving the changing 
intrauterine environment or maternal stress response.  Maternal hypothalamo–pituitary–
adrenal (HPA) activity in response to psychological stress, which can be caused by 
depression, has been linked to adverse neurodevelopmental effects.  Maternal stress can 
lead to in utero glucocorticoid exposure and reduced birth weight.  The resulting 
gestational stress and poor fetal growth has been linked to the development of emotional 
problems in children [17].    
As mentioned previously, there is a possible association between the indication 
and ASD, especially if these indications are uncontrolled during the pregnancy period.  
Understanding the mechanisms behind drug exposure and risk for ASD is just as 
important.  It has been shown that during gestation, overstimulation of the beta-2- 
adrenergic receptors from B2AR agonist drugs has harmful effects on the development of 
the brain and the peripheral nervous system, especially when the fetus does not have the 
ability to regulate any imbalance [4, 18, 19].  Research using animal models has revealed 
abnormalities within the central and peripheral nervous system and a decrease in the cell 
numbers in the fetal brain and liver of rats that were exposed to B2AR agonist drugs 
prenatally[18].   These findings were also gender selective with males experiencing more 
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abnormalities, similar to what is observed in male predominance of autism in humans 
[18].  Abnormalities in serotonin metabolism are one of the few consistent biological 
observations associated with ASD [20] and several lines of evidence suggest that 
alterations in the serotonergic neurotransmitter system might be a mechanistic pathway 
leading to ASD.  In addition, animal models have suggested adverse neurodevelopmental 
outcomes in the offspring associated with prenatal SSRI exposure [21].  The few 
epidemiological studies on prenatal exposure to B2AR agonist drugs and SSRIs in 
conjunction with insight from research using animal models suggest that mechanistically, 
prenatal exposure to these drugs may operate directly on the brain as it develops leading 
to ASD.   
Since there is increasing need to understand the etiology and mechanisms 
underlying the medication exposure and non-medication exposure pathways potentially 
connecting prenatal maternal asthma and depression to offspring ASD risk in order to 
make informed decisions regarding treatment during pregnancy.  Furthermore, efforts 
should be made to include in-patient prescription data particularly in analysis focusing on 
B2AR agonist drugs solely indicated as a tocolytic.  If terbutaline administered as a 
tocolytic does in fact increase ASD risk as previously reported [1] there may be other 
opportunities to focus on preterm birth and the consequence of this medication used off-
label.    This information should be coupled with identifying critical time periods of 
development for the fetus, and adequately balance the risks and benefits of medication 
use during pregnancy.       
The observed main effects described in this dissertation as well as in other 
epidemiological studies are subtle in pregnancies exposed to these medications, which 
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indicate the possibility for gene-environment interaction effects. This suggests that the 
combined effect of exposure during pregnancy with a fetus that carries a genetically 
susceptible genotype may have an increased risk of ASD.  Without fully understanding 
the casual pathway of these exposures, it is also possible that the uncontrolled indication 
could also be a risk factor in this gene environment interplay.   To explore possible gene-
environment interaction effects, I recommend a large sample size to be adequately 
powered to observe an association.  Moreover, investigators exploring gene-environment 
interactions should be cognizant of the idea that common ancestry is related to genotypes 
and perhaps to exposure through culturally mediated mechanisms. Population 
stratification occurs if the gene under study shows marked variation in allele frequency 
across different groups of the population and if these groups also differ in their baseline 
risk of the disease [22]. Studies exploring the genetic effects on ASD should be 
correcting for this using a principle component analysis (PCA), as was done in this 
dissertation, to summarize large scale genomic surveys through covariates that correct for 
population structure in GWAS analyses, and therefore enable us to further explain the 
structure of genetic variation in large samples [23].  In addition employing various 
statistical approaches to test for interaction provides several benefits (ie multiplicative 
model, additive model, case-only multiplicative model, and the multiplicative 2-degree of 
freedom joint test).  The value of applying different statistical methods comes from 
understanding the strengths of each test.  For example, the traditional conventional 
multiplicative interaction test can be easily interpreted and are conventionally reported 
throughout the gene-environment literature.  Having additive interaction does not ensure 
multiplicative interaction, so using the additive interaction will allow one to explore 
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expected joint effects based on the sum of the different measures. The two-degrees of 
freedom test has been shown to be more sensitive to the genetic effects in the presence of 
an exposure when compared to the traditional multiplicative interaction.  Lastly, the case-
only approach has more power to detect interaction effects.  Taken together, these 
methods can yield informative results, especially when faced a small sample size such as 
in this dissertation.   
 
Public Health Significance 
Prenatal pharmacologic exposures are one of the few known environmental risks 
factors for ASD [24] although the few drugs linked to ASD are no longer prescribed in 
pregnancy.  However, as the teratogenic potential of most drugs with respect to 
neurodevelopmental outcomes is generally understudied, it is important to consider 
further prescription drug use as ASD risk factors.  For women with a number of common 
chronic medical conditions, including epilepsy, diabetes, depression, inflammatory bowel 
disease and asthma, the use of prescription drugs in pregnancy is still the recommended 
standard of care.  In addition, since clinical trials during drug development commonly 
exclude pregnant women due to ethical reasons, there have been many questions 
regarding the effects of the drug on the developing human fetus.    
The combination of low exposure prevalence during pregnancy and modest effect 
size implies that population attributable risks associated with both exposures, B2AR 
agonist drugs and SSRIs, will be fairly small.   Our Denmark data suggest a prevalence of 
SSRIs used during pregnancy of 0.7% and an effect estimate of 1.9, which imply that the 
population attributable ASD risk associated with this exposure is only 0.6%. Prevalence 
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of asthma drugs used during pregnancy in our study was 2.9% and I observed a1.3 odds 
ratio associated with exposure and outcome - consequently, the population attributable 
risk here was 0.9%.  If these effects are in fact real, this still suggests that even a small 
proportion of autism cases in the population could be prevented if they were not exposed 
to either of these medications during pregnancy. However, decisions to avoid these 
medication exposures prenatally because of concerns over ASD must be balanced against 
reports of the health effects on the developing fetus and the mother posed by uncontrolled 
indications during pregnancy.  Further consideration of the biological mechanisms 
underlying these exposure effects could also lead to an improved understanding of 
common etiologic pathways in ASD that, in turn, might then inform potential prevention 
or treatment strategies that would affect larger number of ASD cases.  
There is still a need to continue to carefully explore prenatal prescription drug use 
as ASD risk factors.  At the same time, while it is important to detect any such 
associations and consider their etiologic implications, the public health implications may 
not be straightforward.   With respect to maternal B2AR agonist drug use, uncontrolled 
asthma in pregnancy has been associated with poor birth outcomes [25, 26].   During an 
asthma exacerbation in pregnancy, the prenatal maternal stress response may be elevated, 
which would be harmful during a time when the fetal limbic system is considered to be 
the most vulnerable to such a stress response, especially before 32 weeks of gestation 
[27].   Consequently, any ASD risk associated with maternal B2AR agonist drug use 
needs to be balanced against the benefits of indicated medication use by pregnant 
mothers.  Additional studies need to replicate the present study before the implications of 
prenatal B2AR agonist drug exposure through maternal use of these agents for asthma 
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control on ASD risk be considered when making individual decisions about asthma 
control in pregnancy. 
Similarly, it would be potentially dangerous for both the fetus and mother to 
recommend avoidance of medications such as antidepressants during pregnancy.  The 
implications for these findings on prenatal SSRI exposure and risk of ASD reported in 
this dissertation should be tempered with those reports of uncontrolled depression during 
pregnancy and the growing concern over the potential risk for relapsed depression after 
discontinuing antidepressant medication during pregnancy.  A recent study found that 
68% of the women who discontinued antidepressant treatment during pregnancy relapsed 
in depression, with 50% experiencing recurrence of depression in the first trimester of 
pregnancy and 90% by the end of the second trimester [28]. Associations between 
maternal depression and developmental psychopathology in children have been suggested 
as potentially operating through mechanisms involving the changing intrauterine 
environment or maternal stress response.  It should also be noted that postnatal 
depression are often preceded by antenatal depression; similarly, postnatal anxiety is 
most like preceded by antenatal anxiety [29].  Furthermore, antenatal anxiety occurs 
frequently, overlaps with depression, and also increases the likelihood of postnatal 
depression [29].  The consequences of depression during pregnancy and its transference 
into postpartum depression could have dangerous repercussions for infants.  This can 
manifest itself physically and behaviorally, including less optimal interaction behaviors 
and developmental delays [30, 31].  In addition, women who were depressed during their 
pregnancy were more likely to experience increased life stress, decreased social support, 
poor weight gain, and the use of harmful substances such as cigarettes, alcohol, and 
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cocaine [32].  The impact of this undoubtedly has adverse effect on infant outcome and 
their development. Interventions to change health behaviors during pregnancy in light of 
the finding from this dissertation should consider a woman's affective state, social 
context, and mental health.  More importantly, appropriate judgment for treatment for 
indications, maternal asthma and depression, should include communication regarding 
risks and benefits of treatment, and any adverse consequences to their well-being and 
their infants. 
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INTRODUCTION 
 In this chapter several tables, figures, and more detailed information on analyses 
presented in the dissertation are described.  It provides more in-depth explanation of 
aspects of the study design and analyses discussed in the previous chapters and also 
include some additional analyses not shown elsewhere.   
 
DENMARK’S NATIONAL REGISTERS 
The Fertility Database 
The Fertility Database, formally known as the Statistical Register for Fertility 
Research, relates to births (both live and stillbirths) and is used primarily for analyses of 
fertility trends, birth patterns, and number of children in specific population groups.  The 
Danish Social Science Research Council and Statistics Denmark maintain this database.  
Currently it has become a statistical register that is now on par with other registers 
operated by Statistical Denmark.  It contains information on both women and men, 
including parental and familial relationships such as mother-child, father-child, and 
parents of the same child.  A range of information, which is collected annually, covers the 
education and employment of the parents, as well as family and housing conditions. 
Information within this register contains data from 1996 that is updated annually. The 
female population of Denmark comprises approximately 1.3 million women.   
 
Danish Civil Registration System 
The Danish Civil Registration System (CRS) was established in 1968 and 
includes all live persons living in Denmark.  It includes a unique personal identification 
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number, name, gender, date of birth, place of birth, citizenship, and identity of parents.  
This register is updated continuously to include all information regarding vital status, 
place of residence and martial information.  All Danish citizens are assigned a unique 
personally identification number (CPR number) enabling accurate linkage between all 
national registers.  This registration system was established for administrative purposes, 
and it is generally accepted that the information recorded is of very high quality.  It is 
continuously updated and corrects for errors as they are encountered.  It is required by 
law that residents register for this system.  For persons born in Denmark in 1960 or later 
the register contains complete information on maternal identity, and for women born in 
April of 1935 or later there is complete information on all children.  In regards to 
immigration and emigrations, there is complete information from 1969 and onward, 
permanent residence in a Danish municipality from 1971 onward, and a full address in 
Demark from 1977 and onward. 
 
Register of Medicinal Products Statistics 
The Danish Medicines Agency owns and is responsible for the Register of 
Medicinal Product Statistics.  The Statistics and Analysis Department in the 
Pharmacoeconomic Division is responsible for the day-to-day operations of the register.  
It was established in order to obtain statistics and price indices as well as monitor the 
consumption of medicinal products in order to aid in the decision making of the central 
health authorities.  It is unique on a global scale because it is the only register that 
contains information regarding consumption of the medicinal products over the entire 
population of a country over several years, since 1994.  Danish pharmacies, hospital 
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pharmacies, the National Central Laboratory of the Danish Health System (Statens Serum 
Institut) and the Danish Institute for Food and Veterinary Research report information to 
this register every month.  Over the counter medication has been included since 2001 
including their monthly sales. This encompasses 8 million reports per month and around 
96 million a year. Aside from the personal identification number, additional information 
include the identification number of the prescriber, information about the individual 
packet of medicine distributed, time and place of the sale, the doctor’s recommendations 
regarding substitutions, reiteration number on the prescription, price, and reimbursement.  
In regards to over-the counter sales, the information reported includes the individual 
packet of medication and the number of packets sold.  Hospital registers only their 
consumption of the medication used under ward codes and not under the personal 
identification number of person. Therefore, only medication dispensed in pharmacies for 
outpatient use is only recorded. 
 
Danish Medical Birth Register 
The Danish Medical Birth Register was established in 1968 and has been 
computerized since 1973.  The information in this register includes records from all live 
and stillbirths of women living in Denmark.  In addition, it also includes socio-
demographic information of the newborn and parents, data on parity, complications and 
procedures during pregnancy and delivery, date of perinatal death and cause of death.  
The purpose of this register is to monitor the health of newborns, and assess the quality of 
obstetric care.  Gestational age, a common variable of interest in perinatal studies, is 
included in this register, extracted from birth records completed by midwives.  
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Gestational age is recorded as completed weeks since the self-reported last menstrual 
period, and corrected using an ultrasound if the last menstrual period is uncertain.   
 
Danish National Hospital Register 
The Danish National Hospital Register was initiated in 1977 and includes 
information on all hospital admissions for all Danish residents.  The initiation of 
information regarding outpatient care was included into this register in 1995.  The Danish 
version of the International Classification of Diseases (ICD-8) was used from 1977-1993, 
and ICD-10 codes since 1993.  Nearly complete registration of somatic hospital events is 
included in this register.  The National Board of Health validates this registrar by double 
entry of each administrative and clinical data and it is generally regarded as having a high 
reliability.   
 
Danish Psychiatric Central Register 
A nationwide collection of data from mental hospitals was initiated in 1938 from 
the eight psychiatric hospitals available.  It was not until April of 1969 that the 
Psychiatric Central Register became an electronic database, which contained information 
on every psychiatric admission since 1969 and onwards.  From then on, all mental 
hospitals and psychiatric wards reported information to this register.  It was not until 
1995 that data on outpatient treatment and emergency room contacts was included.  This 
register then became integrated as part of the Danish National Hospital Register in 1977, 
and each month, the psychiatric data is passed on to the Psychiatric Central Register at 
the Centre for Psychiatric Research, Aarhus University Hospital, Risskov in Denmark 
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(http://psykiatriskforskning.dk/registre/1/). The National Board of Health is the authority 
responsible for the data.  
 
PHARACOLOGIC INFORMATION FROM THE REGISTER OF MEDICINAL 
PRODUCTS STATISTICS 
Pharmacologic information used in analyses included in Chapter 3 and 4 was 
drawn from the Register of Medicinal Products Statistics. For dispatches of prescribed 
medicine from any pharmacy, except hospitals’ dispensaries, in Denmark this register 
captures the unique individual patient identification number, date of dispatch, name of 
drug, amount of drug, code from the WHO Anatomical Therapeutic Chemical (ATC) 
classification system, and the coded defined daily dosage (DDD).  
The WHO Anatomical Therapeutic Chemical classification system (ATC) and the 
defined daily dosage (DDD) were designed to enable drug utilization research in order to 
improve the quality of drug use [1].  The DDD is defined as the assumed average 
maintenance dose per day for a drug used for its main indication in adults [2].  It was 
developed in response to the need to convert and standardize readily available volume 
data from pharmaceutical inventory data into medically meaningful units, to make crude 
estimates of the number of persons exposed to a particular medicine or class of 
medication [1].  Drug consumption data presented in DDDs only give a rough estimate of 
consumption and not an exact description of actual use.  The DDD provide a fixed unit of 
measurement independent of price and dosage form (e.g. tablet strength) enabling the 
researcher to assess trends in drug consumption and to perform comparisons between 
population groups.  It should be noted that the DDD is not a recommended or prescribed 
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dose, but a technical unit of comparison, and usually the result of literature review.  Thus 
DDDs may be high or low relative to actual prescribed doses.  However, a recent study 
evaluating the DDDs system found that it is a reliable tool for standardizing antipsychotic 
doses in drug-utilization research [3].    
ATC codes were used to identify B2AR agonists and SSRIs in the analyses 
included in Chapters 2 and 3.  The table below displays the codes used. The DDD 
information was used to create dose and duration variables as described in the Chapters. 
 The table below describes the medication codes used in Chapter 3 and 4.   
Table A: Medication 
Medication Class Medication Abbreviation Medication Code 
β2-adrenergic receptor agonists B2AR agonists R03AC02, R03AC03, 
R03AC04, R03AC05, 
R03AC12, R03AC13, 
R03CC02, R03CC03, 
R03CC12 
Selective serotonin reuptake inhibitors SSRI N06AB03, N06AB04, 
N06AB05, N06AB06, 
N06AB08, N06AB10 
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THE INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASE AND 
RELATIED HEALTH PROBLEMS, 10TH REVISION (ICD-10) 
 The Danish version of the International Classification of Diseases (ICD-8) was 
used from 1977-1993, and ICD-10 codes since 1993.  The table below lists all ICD-8 and 
ICD-10 codes to construct individual covariates and the outcome, ASD utilized in 
analyses described in Chapters 3 and 4 of the dissertation.  These individual covariates 
and outcome definitions are only relevant for data from Denmark, and not utilized in the 
gene-environment interaction analyses. 
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Table B:  International Statistical Classification of Disease Codes 10th Revision 
Variable ICD-8 Code ICD-10 Code 
Parental psychiatric disorder ranked as follows 
(in order of most to least severe) 
  
Rank 1: schizophrenia-like psychosis  295, 297, 298.39, 301.83 F20–F25, F28–F29 
Rank 2: affective disorder  296, 298.09, 298.19, 300.4  F30–F39 
Rank 3: substance abuse  303, 304 F10–F19.9 excluding F1x.0 
Rank 4: Any other psychiatric disorder   
Maternal depression   
Bipolar disorders  296.19 and 296.39 F31 
Unipolar disorders  296.09, 296.29, 296.89, 
296.99, 298.09, 300.49, 
and 301.19  
F32, F33, F34, F38 
 
Maternal asthma 493.00, 493.01, 493.02, 
493.08, 493.09 
J45, J45.0, J45.1, J45.8, 
J45.9, J46, J46.9  
Parental autoimmune disease   
T1D 249 E10 
Thyrotoxicosis 242.00 E05.0 
Autoimmune thyroiditis 245.03 E06.3 
Primary adrenocortical insufficiency 255.1 E27.1 
RA 712.19, 712.39, 712.59 M05, M06 
Juvenile arthritis 712.09 M08 
Dermatopolymyositis 716 M33 
Polymyalgia rheumatica/temporal arteritis 446.3 M31.5, M31.6, M35.3 
Scleroderma 734.0 M34 (except M34.2) 
Systemic lupus erythematosus 734.19 M32.1, M32.9 
Sjögren syndrome 734.90 M35.0 
Ankylosing spondylitis 712.49 M45.9 
Wegener granulomatosis 446.29 M31.3 
Celiac disease 269.00 K90.0 
Crohn disease 563.01 K50 
Ulcerative colitis 563.19 K51 
Pernicious anemia 281.0 D51.0 
Autoimmune hemolytic anemia 283.90, 283.91 D59.1 
Idiopathic thrombocytopenic purpura 446.49 D69.3 
Multiple sclerosis 340 G35 
Guillain-Barré syndrome 354 G61.0 
Myasthenia gravis 733.09 G70.0 
Pemphigus 694 L10 (except L10.5) 
Psoriasis vulgaris 696.09, 696.10, 696.19 L40 (except L40.4) 
Alopecia areata 704.00 L63 
Vitiligo 709.01 L80.9 
   
Maternal infection   
Any infection 000–136, 780.21, 788.89 
and all listed below 
 A00–B99, G00–G09, 
R50.9, R56.0 and all listed 
below 
Virus infection 008.8–008.9, 040–079, 
381.00, 470–474, 480 
 A08, A80–A99, B00–B34, 
B97, G02.0, G05.1, H67.1, 
J10–J12, J17.1, J20.3–
J20.7, J21.0, M01.4–M01. 
Bacterial infection  000–005, 008.0–008.3, 
010–039, 079.84, 090–
104, 320–324, 381.01, 
390–391, 464.03, 481–
482, 501, 508.00–508.03, 
510, 513, 540–542, 590, 
595, 599.00, 599.06, 612–
614, 616.0, 620, 622, 630, 
A00–A05, A15–A59, A65–
A79, B95–B96, G00, G01, 
G04.2, G05.0, G06–G09, 
H66, H67.0, I00–I01, J13–
J15, J17.0, J20.0–J20.2, 
J36, J39.0–J39.1, J85–
J86, K35–K37, L00–L08, 
M00, M01.0–M01.3, N10–
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635, 680–686, 710 N12, N30, N34.0, N39.0, 
N70–N77, O23 
Respiratory infection 032–034, 460–474, 480–
486 491.01, 501, 503, 506, 
508.00–508.05, 510–511, 
513 
A36–A38, J00–J22, J32, 
J36–J37, J39.0–J39.1, 
J85–J86 
Infectious enteritis  001–009  A01–A09 
Skin infection 680–686  L00–L08 
Urinary tract infection 590, 595, 599.00, 599.06, 
635 
N10–N12, N30, N34.0, 
N39.0, O23.0–O23.4 
Genital infection including STDs 054.02, 079.84, 090–099, 
131, 612–614, 616.0, 620, 
622, 630 
A50–A64, N70–N77, 
O23.5–O23.9 
Appendicitis  540–542 K35–K37 
Birth complications   
Breeched presentation   
Cesarean section   
Assisted labor   
Postpartum hemorrhage   
Childhood autism  F840 
 
Atypical autism  F841 
Asperger’s syndrome   F845 
Pervasive developmental disorder, unspecified 
(PDD-NOS) 
 F848, F849 
Indications for SSRIs   
Anxiety and Phobia 300.0, 300.2 F40, F41 
Obsessive-compulsive disorder 300.3 F42 
Adjustment disorders  F43.2 
Schizophrenia 295 F20, F29 
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DERIVED VARIABLES FROM THE DANISH REGISTRY USED IN CHAPTERS 
3 and 4.  
Family Socioeconomic Status (SES) 
Family SES was measured as a standardized sum of father’s educational level, 
mother’s educational level, father income, and mother income. Education for each parent 
was scored from 1-3 and income from 1-4. Then a parent’s SES was a summation of 
income and education. Then to obtain family SES both the mother and father SES were 
added to obtain a scale from 1-14. 
 
Parental Psychiatric History 
Parental psychiatric history was categorized using an algorithm from a recent 
paper that explored the association between perinatal factors, parental psychiatric history, 
socioeconomic status, and risk of ASD [4].  A parent was defined as having a psychiatric 
history if a psychiatric diagnosis had been recorded before the date that autism was 
diagnosed in the child.  Parental psychiatric history was categorized as either absent or 
falling into one of four severity categories following the algorithm of a prior study [4] 
developed by Larrson et al in 2005.  A parent was defined as having a psychiatric history 
if a psychiatric diagnosis had been recorded before the date of birth of the child.  
Diagnosis considered in the severity score included schizophrenia-like psychosis 
followed by affective disorder in the second most severe category.   Diagnoses were 
ranked by Larrson et al 2005 according to severity and each parent with a psychiatric 
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history received a score equal to the highest ranked condition.  The score of the parent 
with the highest-ranking diagnosis determined the specific category assigned. 
 A ranking of psychiatric diagnosis will determine how the parents were 
categorized; the parent with the highest-ranking diagnosis will determine the specific 
category 
 
CONFOUNDING BY INDICATION 
This section provides an in depth review of the concept of confounding by 
indication.  Since this was issue is frequently encountered in studies involving drug 
exposures and a range of outcomes, special attention to the methodology was explored.  
In addition, this overview demonstrates how confounding by indication can affect the 
findings of pharmacoepidemiologic studies if not properly accounted for in the analyses. 
Due to the strong association between the indications described in the dissertation 
and exposures of interests and documented association between the indications and 
autism risk, special attention was paid to address potential confounding by indication.  In 
observational studies of medical treatment, confounding by indication is a term used 
when confounding is introduced because a known or perceived indication (or 
contraindication) for the treatment under study and is also a risk factor for an outcome.  It 
occurs when a variable is a risk factor for a disease and is associated with the exposure of 
interest in the population from which the cases derive, without being an intermediate step 
in the causal pathway between the exposure and the disease.  The Dictionary of 
Epidemiology gives the following definition:  “A distortion of the effect of the treatment 
on the outcome that is caused by the presence of a sign or symptom that is associated 
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with both with the treatment and with the outcome; or a distortion of the effect of 
treatment that is caused by the presence of an indication or a contraindication for the 
treatment that is associated with the outcome” [5].   Meittien describes confounding by 
indication as “a commonly used term that refers to an extraneous determinant of the 
outcome parameter that is present if a perceived high risk or poor prognosis is an 
indication for intervention” [6].   
Confounding by indication can occur in treatment studies when outcomes of 
interest are measures of effectiveness (eg, cure, symptom amelioration, longer survival 
etc.) or when outcomes of interest are near-term adverse events or side effects.   In 
treatment studies confounding by indication is typically introduced by disease severity or 
other prognostic factors (e.g., comorbidity).   An example comes from a recent study of 
combined antiretroviral therapy (cART) on AIDS-free survival [7].  cART is more likely 
to be initiated in individuals with low CD4 cell count, an indicator of greater HIV 
severity.  Consequently, in this example, low CD4 cell count is expected to be both 
associated with the outcome, AIDS-free survival, and the exposure without being on the 
causal pathway.    
Adequate control of confounding by indication in treatment effectiveness studies 
is often a challenge.  As with other confounding challenges, randomized designs can 
offer distinct advantages.   However randomized designs are not always an option when a 
treatment has already diffused or may not be applied to certain subpopulations (i.e., 
children, pregnant women) commonly excluded from trials.   Further, randomized trials 
may not be adequately powered to study rare side effects.   In observational studies, most 
commonly, statistical adjustment is used in attempts to control for confounding by 
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indication.   In the Philips et al HIV treatment study, the authors adjusted for CD4 cell 
count.   Because this was a prospective study where CD4 count was affected by prior 
cART use (time-varying confounding), it was important that the authors appropriately 
adjusted for the time-dependent confounding by indication variables (e.g., due to CD4 
cell count); in this case by using inverse probability weighting of marginal structural 
models.  Each patient in the logistic models had received a time- varying weight 
inversely proportional to the estimated probability of having his/her own observed history 
of cART initiation.     
Propensity score approaches are another analytic method that has more recently 
gained popularity as a way to control confounding by indication in observational designs 
[8, 9].  The propensity score approach uses a statistical model to estimate the conditional 
probability of exposure to a treatment given a range of predictor variables [10].  
Propensity is then defined as an individual's predicted probability of being treated with 
the intervention of interest given the complete set of all information about that individual 
and provides a single metric that summarizes all the information from variables 
predicting treatment, typically including measures of disease severity [11].   Matching on 
the propensity score has been promoted as superior to conventional adjustment since the 
balance achieved between the exposed and unexposed groups has been viewed as being 
similar to the expected balance achieved through a randomized trial [12].   A limitation of 
matching on propensity scores is that there may be unmatched subjects which will then 
be excluded from analysis, leading to a loss of information and a decrease in the precision 
of the estimate association between the drug and the outcome [11].   Of course, if 
	   	   169 
propensity scores omit important confounders, propensity score approaches like other 
analytic strategies can be subject to residual confounding. 
Residual confounding occurs when a confounder control approach does not 
completely remove the confounding effect.  This can occur when confounders are 
omitted or when a confounder is measured with error.  In the study discussed above 
focused on cART treatment and AIDS free survival, there was concern that using CD4 
cell counts alone was and inadequate measure of disease severity and would result in 
residual confounding.  The investigators chose to adjust for both CD4 cell count and viral 
load as a more complete measure of HIV severity.  Misclassification of a confounding 
variable is another means by which confounder control may be incomplete and residual 
confounding introduced.      
An alternative method of confounder control not yet discussed is restriction.   In 
confronting confounding by indication in treatment studies where the confounder is 
indicating condition severity, restriction would involve limiting the analysis to a 
particular indicating condition severity level.   The principal drawback to restriction 
approaches is the reduced number of subjects available for analysis.   However, 
restriction can sometimes be used as a means to avoid residual confounding due to 
measurement error if there is one level of severity less subject to measurement error (e.g., 
if it is easier to identify those without comorbid disease than to distinguish between mild, 
moderate and severe comorbid disease).  
Thus far, the discussion here has been about confounding by indication in its most 
common context, observational studies of treatment effectiveness.  However confounding 
by indication can also be a challenge in risk factor investigations when an established 
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treatment for a particular indication is being investigated as a risk factor for another 
outcome.  Here the temporal period between the exposure (the established treatment) and 
outcome is usually much longer than that seen in traditional treatment effectiveness 
studies.   Another important feature distinguishing these studies from observational 
studies of treatment effectiveness is that confounding by indication can also be 
introduced in these investigations by the presence of an indicating condition, because the 
study population includes subjects with and without the indication, whereas in the typical 
observational study of treatment all subjects are affected (Salas et al; 1999).   Salas et al 
(1999) offered the example of an investigation of antidepressant drugs and an increased 
risk of infertility.  A large case control study (597 cases and 3,833 controls) reported a 3-
fold increased risk of infertility in women self-reporting use of an antidepressant at least 
6 months prior [13].   However, at the same time, a case-control study of 428 women 
nested in a prospective cohort of nearly 3,000 subjects found history of depression was 
associated with subsequent infertility; the hypothesized mechanism being elevated 
prolactin levels among women with depression [14].  Consequently, in the example 
provided by Salas (1999), the presence of the indication, depression, may be a 
confounder.   
As illustrated in this example, the presence of an indicating condition can be a 
potential confounder when studying downstream effects of pharmacologic treatment.   
This was the case in this dissertation.  The indicating conditions for the pharmacologic 
exposures, maternal asthma and depression, have also themselves been suggested as 
autism risk factors [15, 16].  While the association is not firmly established and 
mechanisms have not been well specified, should these indicating conditions be 
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associated with ASD risk through some way other than a direct pathway going through 
pharmacologic exposure, confounding by indication would be a concern.  Associations 
between maternal depression and developmental psychopathology in children have been 
suggested as potentially operating through mechanisms involving the changing 
intrauterine environment or maternal stress response.  Maternal hypothalamo–pituitary–
adrenal (HPA) activity in response to psychological stress, which can be caused by 
depression, has been linked to adverse neurodevelopmental effects.  Maternal stress can 
lead to in utero glucocorticoid exposure and reduced birth weight.  The resulting 
gestational stress and poor fetal growth has been linked to the development of emotional 
problems in children [17].  It has also been hypothesized that the presence of maternal 
asthma, could affect 
neurodevelopmental outcomes via 
altered levels of circulating 
inflammatory cytokine interleukin 6 
(IL-6), which can cross the placenta 
and cause dysregulation of IL-6 during 
critical periods of development for the fetus [18].  In the dissertation, subjects in both 
case and control children groups have mothers with and without history of both these 
indicating conditions.    
The directed acyclic graph (DAG) in Figure 1 was be used to guide exploration of 
confounding by indication in analyses of SSRI exposure and autism risk in the full study 
sample. It shows that controlling for the presence of maternal depression through 
statistical adjustment will remove confounding by indication as well as block the path 
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between any antecedent genetic liability associated with both maternal depression and 
autism risk.   In addition, controlling for the presence maternal depression does not 
appear to open any additional paths and introduce unexpected biases. There is however 
one major assumption made in this DAG – that there is no association between other 
maternal SSRI indicators and ASD, including a backdoor path going through a shared 
genetic liability with autism risk.  Other known indications for SSRI use in this 
population include premenstrual syndrome and anxiety, neither of which to-date, has 
been associated with ASD.  However, studies have reported family history of psychiatric 
conditions (including anxiety disorder) to be associated with autism risk [16, 19, 20], thus 
suggesting that there could be shared genetic determinants of maternal anxiety disorders 
and autism.   
As discussed above, residual confounding is also a concern when adjustment does 
not completely remove the confounding effect.   In my investigation, the presence of 
maternal depression is measured through ICD-10 codes (F32 to F34: depressive episode, 
recurrent depressive disorder, persistent mood [affective] disorders) as reported from 
episodes of both inpatient and outpatient care from psychiatric hospitals and psychiatric 
wards in Denmark.  If these codes as captured during outpatient and inpatient visits are an 
imperfect measure of the presence of maternal depression, confounding by indication 
may not be removed.  Consequently, I incorporated a sensitivity analysis to quantify 
likely effects of misclassification of depression (partial knowledge of exposure 
misclassification probabilities). 
Confounding by indication can also be introduced in my study by depression 
severity.  An example of this would be if only more serious depression lead to prescribed 
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doses or durations of SSRIs sufficient to increase risk of having a child with ASD.  To 
approach this, analysis was conducted separately in women with and without indicators 
of depression. Here this stratification can be viewed as removing confounding by 
indication associated with the presence of the indicating condition.   However, SSRI 
exposure prevalence in the group of women without depression will be fairly rare and 
effect estimates may have limited precision.  In the group of women with depression, 
statistical adjustment for measures of depression can then be used to address what can be 
now thought of as residual confounding due to severity.  Measures of depression severity 
will be constructed from available data on depression including:  presence of an inpatient 
hospitalization for depression, recurrent mention of depressive disorder in outpatient 
claims; mention of only persistent mood [affective] disorders or dysthymia diagnoses 
without depression diagnoses.   
The DAG shown in Figure 2 
illustrates the approach in the restricted 
sample where all included women now 
have the indicating condition.   Similar to 
that seen in Figure 1 in the full sample 
analysis, statistical adjustment will remove confounding by severity and block any path 
between a genetic variant associated with both depression severity and autism risk while 
not appearing to open any additional pathways in which maternal SSRI use may be 
associated with ASD.   The depression severity measures available are also potentially 
susceptible to measurement error.   The misclassification correction analyses mentioned 
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previously can also be used to quantify likely effects of misclassification of each 
depression subtype.   
Confounding by indication is often found in epidemiological treatment studies focused on 
measures of treatment effectiveness and can also be found in studies of treatments as risk 
factors for more downstream health events.   The presence or absence of an indicating (or 
contraindicating) condition or the severity of the indicating (contraindicating) condition 
can introduce this type of confounding.  Unless treatment is assigned across subjects 
through a randomization process, treatment allocation will be based on indications – this 
is in fact what is desired in the thoughtful medical treatment of individual patients.  For 
observational studies where treatments are risk factors, this poses real analytic 
challenges.  Statistical adjustment, propensity scores, and restriction are techniques that 
can be utilized to control for confounding by indication in these types of studies.  The 
potential for unmeasured or erroneously measured indicators leading to residual 
confounding is also a common concern.   The investigator in observational studies of 
medical treatment must clearly be attentive to confounding by indication.      
Understanding the impact of confounding by indication and extent to which it may or 
may not be controlled is vital in the proper interpretation of pharmacoepidemiologic 
research findings. 
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ADDITIONAL ANALYSIS  
Imputation of Depression Severity ICD-10 Codes as a means of predicting ICD-10 
Codes for mothers with only ICD-8 codes for depression in Chapter 4, that would 
have otherwise been dropped. 
Severity measures for depression were explored in order to control for 
confounding by indication.  The Danish version of the International Classification of 
Diseases (ICD-8) was used from 1977-1993, and ICD-10 codes since 1993.  ICD-10 
codes categorize depression as severe, moderate or high.  For women who only had an 
ICD-8 code, we imputed ICD-10 codes using a regression model with maternal age and 
family SES as predictors and ICD-10 case the outcome.  Below is the effect estimate for 
imputed ICD-10 severity codes and risk for ASD.  This imputation analysis was not used 
in any of the Chapters since I did not explore the effect of depression severity on drug 
exposure and outcome.  This was mainly due to the small numbers that resulted from 
stratifying by depression severity based solely on ICD-10 codes.  In addition there were 
other definitions for depression that were not included in the severity measure (ie: major 
depressive episode) that would have been eliminated if I had only used ICD-10 
depression severity scores. 
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Table C: Results from Imputation of Depression Severity Analysis in Chapter 4 
 No. (%)   
SSRI Exposure Period Cases  
n= 53 
Controls 
n=4326 
Crude OR 
(95% CI) 
Adjusted OR 
(95% CI)a 
Preconception  6 619 0.8 (0.3-1.9) 0.8 (0.3-1.9) 
Pregnancy  7 730 0.9 (0.4-2.0) 0.9 (0.4-2.0) 
First Trimester  4 524 0.7 (0.3-2.0) 0.7 (0.2-2.0) 
Second Trimester 3 415 0.8 (0.2-2.5) 0.7 (0.2-2.4) 
Third Trimester  3 444 0.6 (0.2-2.1) 0.6 (0.2-2.0) 
Abbreviations: SSRI, Selective serotonin reuptake inhibitors; ASD, autism spectrum 
disorder; OR, odds ratio; CI, confidence interval. 
The reference group had no exposure during the exposure period of interest. 
a. Odds ratios were adjusted for month and year of birth of child and severity (reference 
is most severe) 
Maternal Depression Severity 
Mild: F32.0, 33.0, 32.8, 32.9, 33.4, 33.8, 33.9, 34.0, 34.1, 34.8, 34.9 
Moderate: F32.1, 33.1 
Severe: F32.2, 32.3, 33.2, 33.3 
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Multiplicative case-only approach in Chapter 5 
The case-only approach to test for multiplicative interaction was also considered 
in the Chapter 5 analyses.   This approach is more statistically efficient than conventional 
approaches of multiplicative interaction but requires a strong assumptions of 
independence between the exposure and genotype [1].  In implementing these analyses 
logistic regression models were limited to the ASD cases with predictors including 
exposure, the genotype alone, and their joint effects.  In the models, only observations 
where ASD is equal to 1 were used (ie: cases only).  The models were constructed by 
modeling the genotype of interested as the outcome, and the B2AR agonist exposure 
during pregnancy as the outcome, thus achieving the assumption that genotype and 
exposure are independent.   
 The odds ratio for this is a function of the odds ratios for the exposure alone, the 
genotype alone, and their joint effects in a standard case-control study: 
ORfrom case-only = [ORfrom standard case-control /(ORe X ORg)] x OR from controls only 
Under the null hypothesis of no multiplicative effects the case-only odds ratio will be 
one.  The results of this analysis are presented below.   
The tables below summarize the results of these analyses.   As can be seen, the 
case-only interaction odds ratio for the Arg16Gly genotype and B2AR agonist use during 
pregnancy was 2.7 (95% CI: 0.6-11.9) with adjusted odds ratios increasing after 
adjustment for potential indications and principle component values to adjust for ethnic 
differences (OR: 3.7; 95%CI 3.7 (0.8-16.6), Similarly, for associations for any B2AR 
agonist use, Gln27Gly, and their interaction we found a crude case-only interaction OR 
of 1.1 (95% CI 0.5-2.7) with little subsequent impact of adjustment.  Possible indications 
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were adjusted in these models, but not elsewhere in the dissertation.  The reason for this 
was that although it would have been interesting to see how these indications would 
effect the estimates, these variables were constructed based on all possible illnesses the 
mother mentioned while taking B2AR agonist drugs.  Since there could be multiple 
conditions that indicated for B2AR agonist drug use, we reported the existing conditions 
a mother had for those that were taking B2AR agonist drugs.   
Though the magnitudes of the case-only interaction odds ratio for Arg16Gly were 
above two, the confidence intervals were still quite wide and none of these estimates, nor 
those for Gln27Gly, were significantly different from the null at a conventional alpha 
error tolerance of 0.05.   These estimates were not included in Chapter 5 since they did 
not add any addition information that was already presented in the traditional 
multiplicative interaction models and the two-degrees of freedom test.  Furthermore, the 
confidence intervals for these estimates were rather wide due to the imprecision resulting 
form a small sample size. 
 
1. Khoury, M.J. and W.D. Flanders, Nontraditional epidemiologic approaches in the 
analysis of gene-environment interaction: case-control studies with no controls! 
Am J Epidemiol, 1996. 144(3): p. 207-13. 
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Table D: Multiplicative effects analysis (unadjusted and PCV adjusted) of B2AR odds ratios from Arg16Gly case only models 
Arg16Gly Crude OR (95% CI) P value 
Adjusted ORa 
(95% CI) P value 
Adjusted ORb 
(95% CI) P value 
Pregnancy 2.7 (0.6-11.9) 0.1868 2.7 (0.6-11.9) 0.1901 3.7 (0.8-16.6) 0.0887 
a. Adjusted for principle component values 
b. Adjusted for principle component values and B2AR agonist drug indications (Indications: Asthma, Cold or Cough, Early Labor, Allergy, Upper Respiratory 
Infection, Influenza or Flu, Pneumonia, and Respiratory conditions. 
 
Crude ORcontrols= 0.84 (0.3-2.5) 
Table E: Multiplicative effects analysis (unadjusted and PCV adjusted) of B2AR odds ratios from Gln27Glucase only models 
Gln27Glu Crude OR (95% CI) P value 
Adjusted ORa 
(95% CI) P value 
Adjusted ORb 
(95% CI) P value 
Pregnancy 1.1 (0.5-2.7) 0.8093 1.1 (0.4-3.0) 0.7878 1.3 (0.5-3.5) 0.5790 
a. Adjusted for principle component values 
b. Adjusted for principle component values and B2AR agonist drug indications (Indications: Asthma, Cold or Cough, Early Labor, Allergy, Upper Respiratory 
Infection, Influenza or Flu, Pneumonia, and Respiratory conditions. 
 
Crude ORcontrols= 0.84 (0.4-2.0) 
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ADDITIONAL NOTES ON SENSITIVITY ANALYSES USED IN CHAPTER 3 
and 4 
Below are additional notes that were used to formulate the results from the 
sensitivity analysis from Chapters 3 and 4.  It provides additional calculations that were 
used to conceptualize the sensitivity analysis in these Chapters.  To briefly summarize, 
misclassification was a potential challenge in this study since we were relying on 
registers data.   The proportion of non-diseased or unexposed that is correctly classified 
can be assumed to be high.  In other words, a person is less likely to be in the register if 
they do not have the disease or can be considered unexposed.  While using Monte Carlo 
analysis we assumed a specificity of 100%.  To correct for the misclassification of 
exposure and the confounder a Monte Carlo analysis was used to produce 1,000 
simulated datasets, reclassifying exposure and indication status.  For each simulation we 
present median OR estimates and the 2.5% and 97.5% percentile OR estimates as the 
confidence interval.  Models using observed data are from conditional logistic regressions 
conditioning on the matching variables (child birth year and month) and adjusting for 
maternal depression while models using simulation were from unconditional logistic 
regressions models adjusting for the same variables as covariates.      
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Exposure to SSRIs during pregnancy and risk for ASD 
Non-differential exposure misclassification with respect to outcome (equal sensitivity and 
(specificity = 1) of exposure among cases and controls) 
• Increase overall p(SSRI) from 0.8% to 3%  
Observed 
 ASD+ ASD- Total 
SSRI+ 76 365 441 
SSRI- 5139 51785 56924 
Total 5210 52150 57365 
 
Truth 
 ASD+ ASD- Total 
SSRI+ 297 = x 1424 = y 1721 
SSRI- 4918 50726 55644 
Total 5210 52150 57365 
• (76/x) = (365/y) 
• x + y = 1721 
• 76y = 365x 
• y = 365x/76 
• x + 365x/76 = 1721 
• 5.8x = 1721 
• x = 297 
• Overall sensitivity = 0.26 
• Sensitivity cases = 0.26 
• Sensitivity controls = 0.26 
• Reclassify 4.3% unexposed cases and 2.0% unexposed controls to exposed to 
SSRIs during pregnancy. 
 
	   	   184 
Differential exposure misclassification with respect to outcome (unequal sensitivity and 
(specificity = 1) of exposure among cases and controls) 
• Increase overall p(SSRI) from 0.8% to 3%  
Observed 
 ASD+ ASD- Total 
SSRI+ 76 365 441 
SSRI- 5139 51785 56924 
Total 5210 52150 57365 
 
Truth 
 ASD+ ASD- Total 
SSRI+ 194 1556 1750 
SSRI- 5021 50594 55615 
Total 5210 52150 57365 
• 3% of 57365 = 1721 
• 1721 – 441 = 1280 needs to be reclassified 
• Overall sensitivity = 0.26 
• Sensitivity cases = 0.39 
• Sensitivity controls = 0.23 
• Reclassify 2.3% unexposed cases and 2.3% unexposed controls to exposed to 
SSRIs during pregnancy 
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Non-differential misclassification of depression with respect to outcome (equal 
sensitivity and (specificity = 1) of maternal depression among cases and controls) 
• Increase overall p(depression) from 0.7% to 15%  
Observed 
 ASD+ ASD- Total 
Depression+ 55 347 402 
Depression- 5160 51803 56963 
Total 5210 52150 57365 
 
Truth 
 ASD+ ASD- Total 
Depression+ 1177 = x 7428 = y 8605 
Depression- 4038 44722 48760 
Total 5210 52150 57365 
• (55/x) = (347/y) 
• x + y = 8605 
• 76y = 365x 
• y = 347x/55 
• x + 347x/55 = 8605 
• 7.3x = 8605 
• x = 1177 
• Overall sensitivity = 0.047 
• Sensitivity cases = 0.047 
• Sensitivity controls = 0.047 
• Reclassify 21.7% cases and 13.7% controls who did not have a mother with a 
history of depression as now having a diagnosis 
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Differential misclassification of depression with respect to outcome (unequal sensitivity 
and (specificity = 1) of maternal depression among cases and controls) 
• Increase overall p(depression) from 0.7% to 15%  
Observed 
 ASD+ ASD- Total 
Depression+ 55 347 402 
Depression- 5160 51803 56963 
Total 5210 52150 57365 
 
Truth 
 ASD+ ASD- Total 
Depression+ 803 7858 8661 
Depression- 4407 44292 48699 
Total 5210 52150 57365 
• 15% of 57365 = 8605 
• 8605 – 402 = 8203 needs to be reclassified 
• Overall sensitivity = 0.047 
• Sensitivity cases = 0.068 
• Sensitivity controls = 0.044 
• Reclassify 14.5% cases and 14.5% controls who did not have a mother with a 
history of depression as now having a diagnosis 
 
 
 
 
	   	   187 
Exposure to B2ARs during pregnancy and risk for ASD 
Correcting for non-differential exposure misclassification with respect to outcome (equal 
sensitivity and (specificity = 1) of exposure among cases and controls) 
• Increase overall p(B2AR) from 3% to 4%  
Observed 
 ASD+ ASD- Total 
B2AR+ 190 1489 1679 
B2AR- 5010 50511 55521 
Total 5200 52000 57200 
 
Truth 
 ASD+ ASD- Total 
B2AR+ 259 = x 1424 = y 2288 
B2AR- 4941 49971 54912 
Total 5200 52000 57200 
• (190/x) = (1489/y) 
• x + y = 2288 
• 190y = 1489x 
• y = 1489x/190 
• x + 1489x/190 = 2288 
• 8.8x = 2288 
• x = 259 
• Overall sensitivity = 0.73 
• Sensitivity cases = 0.73 
• Sensitivity controls = 0.73 
• Reclassify 1.38% unexposed cases and 1.07% unexposed controls to exposed to 
B2AR agonist drugs during pregnancy 
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Correcting for non-differential misclassification of maternal asthma with respect to 
outcome (equal sensitivity and (specificity = 1) asthma among cases and controls) 
• Increase overall p(asthma) from 1.3% to 2%  
Observed 
 ASD+ ASD- Total 
Asthma+ 83 673 756 
Asthma- 5117 51327 56444 
Total 5200 52000 57200 
 
Truth 
 ASD+ ASD- Total 
Asthma+ 126 = x 1018 = y 1144 
Asthma- 5074 50982 56056 
Total 5200 52000 57200 
• (83/x) = (673/y) 
• x + y = 1144 
• 83y = 673x 
• y = 673x/83 
• x + 673x/83= 1144 
• 9.1x = 1144 
• x = 126 
• Overall sensitivity = 0.66 
• Sensitivity cases = 0.66 
• Sensitivity controls = 0.66 
• Reclassify .84% cases and .67% controls that did not have a mother with an 
asthma diagnosis in the register to having asthma. 
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